書籍詳細

A. 総論 Cancer immunoediting

P.5 掲載の参考文献

• 1) Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 13: 1-27, 1970.
  pubmed

• 2) Dunn GP, Bruce AT, Ikeda H, et al: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998, 2002.
  pubmed

• 3) Dunn GP, Old J, Schreiber RD, et al: The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360, 2004.

• 4) Kim R, Emi M, Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology 121: 1-14, 2007.
  pubmed

• 5) Swann JB, Smyth MJ: Immune surveillance of tumors. J Clin Invest 117: 1137-1146, 2007.
  pubmed

• 6) Bhardwaj N: Harnessing the immune system to treat cancer. J Clin Invest 117: 1130-1136, 2007.

• 7) Sjoblom T, Jones S, Wood LD, et al: The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274, 2006.
  pubmed

• 8) Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
  pubmed

• 9) Bishop SC, Burlison JA, Blagg BS: Hsp 90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets 7: 369-388, 2007.
  pubmed

• 10) Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045, 1994.
  pubmed

• 11) Kohl J: Self, non-self, and danger: a complementary view. Adv Exp Med Biol 586: 71-94, 2006.
  pubmed

• 12) Hayakawa Y, Smyth MJ: NKG2D and cytotoxic effector function in tumor immune surveillance. Semin Immunol 18: 176-185, 2006.
  pubmed

• 13) Prterson AC, Harlin H, Gajewski TF: Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21: 2342-2348, 2003.

• 14) Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004.
  pubmed

P.8 掲載の参考文献

• 1) Swann JB, Smyth MJ: Immune surveillance of tumors. J Clin Invest 117:1137-1146, 2007.
  pubmed

• 2) Haanen JB, Baars A, Gomez R, et al: Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer J Immunol Immunother 55: 451-458, 2006.
  pubmed

• 3) Lee KH, Wang E, Nielsen MB, et al: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163: 6292-6300, 1999.

• 4) Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyomd current vaccines. Nat Med 10: 909-915, 2004.
  pubmed

• 5) Han LY, Fletcher MS, Urbauer DL, et al: HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 14: 3372-3379, 2008.
  pubmed

• 6) Van Oijen M, Bins A, Elias S, et al: On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res 10: 4754-4760, 2004.
  pubmed

• 7) Gajewski TF, Meng Y, Harlin H: Immune suppression in the tumor microenvironment. J Immunother 29: 233-240, 2006.
  pubmed

• 8) Rosenberg SA, Sherry RM, Morton KE, et al: Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175: 6169-6176, 2005.
  pubmed

• 9) Berger TG, Haendle I, Schrama D, et al: Circulation and homing of melanoma-reactive T cells to both cutaneous and viseral metastases after vacctination with monocyte-derived dendritic cells. Int J Cancer 20: 229-237, 2004.

• 10) Zippelius A, Batard P, Rubio-Godoy V, et al: Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64: 2865-2873, 2004.
  pubmed

• 11) Chaput N, Darrasse-Jeze G, Bergot AS, et al: Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol 179: 4969-4978, 2007.

• 12) Filaci G, Fenoglio D, Fravega M, et al: CD8+CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 179: 4323-4334, 2007.
  pubmed

• 13) Perrot I, Blanchard D, Freymond N, et al: Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178: 2763-2769, 2007.

• 14) Janicki CN, Jenkinson SR, Williams NA, et al: Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 68: 2993-3000, 2008.
  pubmed

• 15) Bai A, Higham E, Eisen HN, et al: Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci USA 105: 13003-13008, 2008.
  pubmed

• 16) Shafer-Weaver KA, Anderson MJ, Stagliano K, et al: Cutting edge: tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 183: 4848-4852, 2009.

• 17) Gajewski TF: Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13: 5256-5261, 2007.
  pubmed

• 18) Soria G, Ben-Baruch A: The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267: 271-285, 2008.
  pubmed

• 19) Albert ML, Darnell JC, Bender A, et al: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 4: 1321-1324, 1998.
  pubmed

• 20) Mathew RM, Cohen AB, Galetta SL, et al: Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci 250: 153-155, 2006.

• 21) Radoja S, Rao TD, Hillman D, et al: Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J Immunol 164: 2619-2628, 2000.
  pubmed

• 22) Liakou CI, Narayanan S, Ng Tang D, et al: Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 7: 10, 2007.
  pubmed

• 23) Monu N, Frey AB: Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumorinfiltrating T cells. Cancer Res 67: 11447-11454, 2007.
  pubmed

• 24) Sheu BC, Lin RH, Lien HC, et al: Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 167: 2972-2978, 2001.
  pubmed

P.15 掲載の参考文献

• 1) Pamer E, Cresswell P: Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 16: 323-358, 1998.
  pubmed

• 2) Hicklin DJ, Marincola FM, Ferrone S: HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5: 178-186, 1999.
  pubmed

• 3) Rammensee HG, Friede T, Stevanovich S: MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228, 1995.

• 4) Aptsiauri N, Cabrera T, Garcia-Lora A, et al: MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 256: 139-189, 2007.
  pubmed

• 5) Demanet C, Mulder A, Deneys V, et al: Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 103: 3122-3130, 2004.

• 6) Kageshita T, Ishihara T, Campoli M, et al: Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65: 419-428, 2005.

• 7) Chang CC, Ogino T, Mullins DW, et al: Defective human leukocyte antigen class I-associated antigen presentation caused by a novel β2-microglobulin loss-of-function in melanoma cells. J Biol Chem 281: 18763-18773, 2006.

• 8) van den Elsen PJ, Holling TM, Kuipers HF, et al: Transcriptional regulation of antigen presentation. Curr Opin Immunol 16: 67-75, 2004.
  pubmed

• 9) Nie Y, Yang G, Song Y, et al: DNA hypermethylation is a mechanism for loss of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22: 1615-1623, 2001.
  pubmed

• 10) Coral S, Sigalotti L, Gasparollo A, et al: Prolonged upregulation of the expression of HLA class-I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2-deoxycytidine (5-AZA-CdR). J Immunother 22: 16-24, 1999.
  pubmed

• 11) Rivoltini L, Carrabba M, Huber V, et al: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 188: 97-113, 2002.

• 12) Spiotto MT, Rowley DA, Schreiber H: Bystander elimination of antigen loss variants in established tumors. Nat Med 10: 294-298, 2004.
  pubmed

• 13) Sanchez-Perez L, Kottke T, Diaz RM, et al: Potent selection of antigen loss variants of B16 melanoma followig inflammatory killing of melanocytes in vivo. Cancer Res 65: 2009-2017, 2005.

• 14) Kurnick JT, Ramirez-Montagut T, Boyle LA, et al: A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J Immunol 167: 1204-1211, 2001.
  pubmed

• 15) Rosenberg SA: Progress im human tumor immunology and immunotherapy. Nature 411: 380-384, 2001.
  pubmed

• 16) Durda PJ, Dunn IS, Rose LB, et al: Induction of "antigen silencing" in melanomas by oncostatin M: downmodulation of melanocyte antigen expression. Mol Cancer Res 1: 411-419, 2003.
  pubmed

• 17) Bai XF, Liu J, Li O, et al: Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 111: 1487-1496, 2003.

• 18) Barrow C, Browning J, MacGregor D, et al: Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12: 764-771, 2006.
  pubmed

• 19) Pandha H, Rigg A, John J, et al: Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cell lines. Clin Exp Immunol 148: 127-135, 2007.
  pubmed

• 20) Lopez-Albaitero A, Nayak JV, Ogino T, et al: Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176: 3402-3409, 2006.
  pubmed

• 21) Tao J, Li Y, Liu YQ, et al: Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity. J Invest Dermatol 128: 1991-1996, 2008.

• 22) Zhang L, Conejo-Garcia JR, Katsaros D, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003.
  pubmed

• 23) Han LY, Fletcher MS, Urbauer DL, et al: HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrates as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 14: 3372-3379, 2008.
  pubmed

• 24) Silacci P, Mottet A, Steimle V, et al: Development extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene C II TA. J Exp Med 180: 1329-1336, 1994.

• 25) Murpfy SP, Holtz R, Lewandowski N, et al: DNA alkylaing agents alleviates silencing of class II transactivator gene expression in L1210 lymphoma cells. J Immunol 169: 3085-3093, 2002.

• 26) Pulaski BA, Ostrand-Rosenberg S: Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7. 1 cell-based tumor vaccines. Cancer Res 58: 1486-1493, 1998.
  pubmed

• 27) Concha A, Esteban F, Cabrera T, et al: Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 2: 47-54, 1991.
  pubmed

• 28) Esteban F, Ruiz-Cabello F, Concha A, et al: HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Exp Metastasis 8: 319-328, 1990.
  pubmed

• 29) Gutierrez J, Lopez-Nevot MA, Cabrera T, et al: Class I and II HLA antigen distribution in normal mucosa, adenoma, and colon carcinoma: Relation with malignancy and invasiveness. Exp Clin Immunogenet 4: 144-152, 1987.

• 30) Lovig T, Andersen SN, Thorstensen L, et al: Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer 87: 756-762, 2002.
  pubmed

• 31) Lopez-Nevot MA, Garcia E, Romero C, et al: Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 5: 203-212, 1988.

• 32) de Bruin EC, van de Velde CJ, van Krieken JH, et al: Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients. Clin Cancer Res 15: 1073-1079, 2008.
  pubmed

• 33) Pages F, Berger A, Camus M, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666, 2005.
  pubmed

• 34) Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006.
  pubmed

• 35) Walsh MD, Dent OF, Young JP, et al: HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers. Int J Cancer 125: 1231-1237, 2009.

• 36) Muhlethaler-Mottet A, Di Berardino W, Otten LA, et al: Activation of the MHC class II transactivator C II TA by interferon-γ requires cooperative interaction between Stat1 and USF-1. Immunity 8: 157-166, 1998.

• 37) Sato A, Toyota M, Ikeda H, et al: Epigenetic inactivation of class II transactivator (C II TA) is associated with the absence of interferon-γ-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23: 8876-8886, 2004.

• 38) Kanasaki T, Ikeda H, Takamura Y, et al: Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J Immunol 170: 4980-4985, 2003.

• 39) Magner WJ, Kazim AL, Stewart C, et al: Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165: 7017-7024, 2000.
  pubmed

• 40) Vo DD, Prins RM, Begley JL, et al: Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 69: 8693-8699, 2009.
  pubmed

• 41) Carosella ED, Favier B, Rouas-Freiss N, et al: Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 111: 4862-4870, 2008.
  pubmed

• 42) Urosevic M, Dummer R: Human leukocyte antigen-G and cancer immunoediting, Cancer Res 68: 627-630, 2008.
  pubmed

• 43) Hunt JS, Petroff MG, McIntire RH, et al: HLA-G and immune tolerance in pregnancy. FASEB J 19: 681-693, 2005.

• 44) Contini P, Ghio M, Poggi A, et al: Soluble HLA-A, -B, -C and-G molecules induce apoptosis in T and NKCD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 33: 125-134, 2003.

• 45) LeMaoult J, Zafaranloo K, Le Danff C, et al: HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19: 662-664, 2005.

• 46) Liang S, Zhang W, Horuzsko A: Human ILT2 receptor associates with murine MHC class I molecules invitro and impairs T cell function. Eur J Immunol 36: 2457-2471, 2006.

• 47) Naji A, Durrbach A, Carosella ED, et al: Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. Hum Immunol 68: 233-239, 2007.
  pubmed

• 48) Pistoia V, Morandi F, Wang X, et al: Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol 17: 469-479, 2007.
  pubmed

• 49) Morandi F, Levreri I, Bocca P, et al: Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 67: 6433-6441, 2007.
  pubmed

• 50) Mouillot G, Marcou C, Zidi I, et al: Hypoxia modulates HLA-G gene expression in tumor cells, Hum Immunol 68: 277-285, 2007.
  pubmed

• 51) Zidi I, Guillard C, Marcou C, et al: Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-κB inducers. Cell Mol Life Sci 63: 2669-2681, 2006.

• 52) Yie SM, Yang H, Ye SR, et al: Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol 128: 1002-1009, 2007.

• 53) Yie SM, Yang H, Ye SR, et al: Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 58: 267-274, 2007.

• 54) Davidson B, Elstrand MB, McMaster MT, et al: HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 96: 42-47, 2005.
  pubmed

• 55) Rouas-Freiss N, Moreau P, Menier C, et al: Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 17: 413-421, 2007.
  pubmed

• 56) Caumartin J, Favier B, Daouya M, et al: Trogocytosis-based generation of suppressive NK cells. EMBO J 26: 1423-1433, 2007.
  pubmed

• 57) Diepstra A, Poppema S, Boot M, et al: HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigen 71: 219-226, 2008.
  pubmed

• 58) Maki G, Hayes GM, Naji A, et al: NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 22: 998-1006, 2008.
  pubmed

• 59) Komohara Y, Harada M, Ishihara Y, et al: HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep 18: 1463-1468, 2007.
  pubmed

• 60) Braud VM, Allan DS, O'Callaghan CA, et al: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391: 795-799, 1998.

• 61) Lee N, Llano M, Carretero M, et al: HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 95: 5199-5204, 1998.

• 62) Marin R, Ruiz-Cabello F, Pedrinaci S, et al: Analysis of HLA-E expression in human tumors. Immunogenetics 54: 767-775, 2003.

• 63) Derre L, Corvaisier M, Charreau B, et al: Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 177: 3100-3107, 2006.

• 64) Levy EM, Bianchini M, Von Euw EM, et al: Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol 32: 633-641, 2008.
  pubmed

• 65) Wischhusen J, Friese MA, Mittelbronn M, et al: HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol 64: 523-528, 2005.

• 66) Ebert LM, Tan BS, Browning J, et al: The regulatory T cell-associated transcription factor Foxp3 is expressed by tumor cells. Cancer Res 68: 3001-3009, 2008.
  pubmed

• 67) Hinz S, Pagerols-Raluy L, Oberg HH, et al: Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67: 8344-8350, 2007.
  pubmed

• 68) Baltz KM, Krusch M, Bringmann A, et al: Cancer immunoediting by GITR (glucocorticoid-induced TNF- related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 21: 2442-2454, 2007.
  pubmed

• 69) Colovai AI, Tsao L, Wang S, et al: Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia. Cytometry B Clin Cytom 72: 354-362, 2007.
  pubmed

P.22 掲載の参考文献

• 1) Uyttenhove C, Pilotte L, Theate I, et al: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3- dioxygenase. Nat Med 9: 1269-1274, 2003.
  pubmed

• 2) Brandacher G, Perathoner A, Ladurner R, et al: Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12: 1144-1151, 2006.
  pubmed

• 3) Chang MY, Boulden J, Sutanto-Ward E, et al: Bin 1 ablation in mammary gland delays tissue remodeling and drives cancer progrssion. Cancer Res 67: 100-107, 2007.

• 4) Muller AJ, DuHadaway JB, Donover PS, et al: Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin 1, potentiates cancer chemotherapy. Nat Med 11: 312-319, 2005.

• 5) Lind DS: Arginine and cancer. J Nutr 134: 2837s-2841s, 2004.

• 6) Gerner EW, Meyskens FL Jr: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4: 781-792, 2004.
  pubmed

• 7) Porembska Z, Luboihski G, Chrzanowska A, et al: Arginase in patients with breast cancer. Clin Chim Acta 338: 171-172, 2003.

• 8) Wu CW, Chung WW, Chi CW, et al: Immunohistochemical study of arginase in cancer of the stomach. Virchows Arch 428: 325-331, 1996.
  pubmed

• 9)Porembska Z, Zabek J, Grabon W, et al: Arginase isoforms in human colorectal cancer. Clin Chim Acta 305: 157-165, 2001.
  pubmed

• 10) Bronte V, Kasic T, Gri G, et al: Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201: 1257-1268, 2005.
  pubmed

• 11) Smyth MJ, Swann J, Cretney E, et al: NKG2D function protects the host from tumor initiation. J Exp Med 202: 583-588, 2005.
  pubmed

• 12) Wrobel P, Shojaei H, Schittek B, et al: Lysis of a broad range of epithelial tumour cells by human γδ T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition. Scand J Immunol 66: 320-328, 2007.

• 13) Elsner L, Muppala V, Gehrmann M, et al: The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol 179: 5523-5533, 2007.
  pubmed

• 14) Groh V, Wu J, Yee C, et al: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738, 2002.

• 15) Wu JD, Higgins LM, Steinle A, et al: Prevalent expression of the immunostimulatory MHC class I chainrelated molecule is counteracted by shedding in prostate cancer. J Clin Invest 114: 560-568, 2004.
  pubmed

• 16) Holdenrieder S, Stieber P, Peterfi A, et al: Soluble MICA in malignant diseases. Int J Cancer 118: 684-687, 2006.
  pubmed

• 17) Marten A, von Lilienfeld-Toal M, Buhler MW, et al: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Intl Cancer 119: 2359-2365, 2006.

• 18) Boissel N, Rea D, Tieng V, et al: BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 176: 5108-5116, 2006.
  pubmed

• 19) Baltz KM, Krusch M, Bringmann A, et al: Cancer immunoediting by GITR (glucocorticoid-induced TNFrelated protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 21: 2442-2454, 2007.
  pubmed

• 20) Baltz KM, Krusch M, Baessler T, et al: Neutralization of tumor-derived soluble glucocorticouid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood 112: 3735-3743, 2008.
  pubmed

• 21) Biswas K, Richmond A, Rayman P, et al: GM2 expression in renal cell carcinoma: potential role in tumorinduced T-cell dysfunction. Cancer Res 66: 6816-6825, 2006.
  pubmed

• 22) Peguet-Navarro J, Sportouch M, Popa I, et al: Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 170: 3488-3494, 2003.
  pubmed

• 23) Shen W, Stone K, Jales A, et al: Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J Immunol 180: 4425-4432, 2008.
  pubmed

• 24) Nakahara S, Raz A: Biological modulation by lectins and their ligands in tumor progression and metastasis. Anticancer Agents Med Chem 8: 22-36, 2008.
  pubmed

• 25) van den Brule F, Califice S, Castronovo V: Expression of galectins in cancer: a critical review. Glycoconj J 19: 537-542, 2004.

• 26) Grassadonia A, Tinari N, Iurisci I, et al: 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 19: 551-556, 2004.

• 27) Marchetti A, Tinari N, Buttitta F, et al: Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 62: 2535-2539, 2002.

• 28) Song YK, Billiar TR, Lee YJ: Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 160: 1069-1075, 2002.
  pubmed

• 29) Rabinovich GA, Cumashi A, Bianco GA, et al: Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 16: 210-220, 2006.
  pubmed

• 30) Peng W, Wang HY, Miyahara Y, et al: Tumor-associated galectin-3 modulates the function of tumorreactive T cells. Cancer Res 68: 7228-7236, 2008.
  pubmed

• 31) Chung CD, Patel VP, Moran M, et al: Galectin-1 induces partial TCRζ-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 165: 3722-3729, 2000.

• 32) Matarrese P, Tinari A, Mormone E, et al: Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95) -mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem 280: 6969-6985, 2005.

• 33) Garin MI, Chu CC, Golshayan D, et al: Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 109: 2058-2065, 2007.
  pubmed

• 34) Rubinstein N, Alvarez M, Zwirner NW, et al: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: A potential mechanism of tumor-immune privilege. Cancer Cell 5: 241-251, 2004.
  pubmed

• 35) Thijssen VL, Hulsmans S, Griffioen AW: The galectin profile of the endothelium: altered expession and localization in activated and tumor endothelial cells. Am J Pathol 172: 545-553, 2008.

• 36) Thijssen VL, Poirier F, Baum LG, et al: Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 110: 2819-2827, 2007.
  pubmed

• 37) Bennett MW, O'Connell J, O'Sullivan GC, et al: The Fas counterattack in vivo: apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.J Immunol 160: 5669-5675, 1998.

• 38) Okada K, Komuta K, Hashimoto S, et al: Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 6: 3560-3564, 2000.
  pubmed

• 39) Ryan AE, Shanahan F, O'Connell J, et al: Addressing the "Fas counterattack"controversy: blocking Fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 65: 9817-9823, 2005.
  pubmed

• 40) Andreola G, Rivoltini L, Castelli C, et al: Induction of lymphocyte apoptosis by tumor cell secretion of FasLbearing microvesicles. J Exp Med 195: 1303-1316, 2002.
  pubmed

• 41) Huber V, Fais S, Iero M, et al: Human colorectal cancer cells induce T-cell death through release ofproapoptotic microvesicles: role in immune escape. Gastroenterology 128: 1796-1804, 2005.

• 42) Kim JW, Wieckowski E, Taylor DD, et al: Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11: 1010-1020, 2005.
  pubmed

• 43) Abrahams VM, Straszewski SL, Kamsteeg M, et al: Epithelial ovarian cancer secrete functionl Fas ligand. Cancer Res 63: 5573-5581, 2003.

• 44) Houston AM, Michael-Robinson JM, Walsh MD, et al: The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. Hum Pathol 39: 243-250, 2008.

• 45) Miwa K, Asano M, Horai R, et al: Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 4: 1287-1292, 1998.

• 46) Chen JJ, Sun Y, Nabel GJ: Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282: 1714-1717, 1998.
  pubmed

• 47) Kang SM, Schneider DB, Lin Z, et al: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 3: 738-743, 1997.
  pubmed

• 48) Umemura M, Kawabe T, Shudo K, et al: Involvement of IL-17 in Fas ligand-induced inflammation. Int Immunol 16: 1099-1108, 2004.
  pubmed

• 49) Kidoya H, Umemura M, Kawabe T, et al: Fas ligand induces cell-autonomous IL-23 production in dendritic cells, a mechanism for Fas ligand-induced IL-17 production. J Immunol 175: 8024-8031, 2005.
  pubmed

• 50) Koyama S, Koike N, Adachi S: Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol 128: 73-79, 2002.
  pubmed

• 51) Kawasaki BT, Farrar WL: Cancer stem cells, CD200 and immunoevasion. Trends Immunol 29: 464-468, 2008.
  pubmed

• 52) Kawasaki BT, Mistree T, Hurt EM, et al: Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 364: 778-782, 2007.

• 53) Gorczynski RM, Chen Z, Kai Y, et al: Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 77: 1138-1144, 2004.
  pubmed

• 54) Gorczynski R, Khatri I, Lee L, et al: An interaction between CD200 and monoclonal antibody agonists to CD200R2 in development of dendritic cells that preferentially induce populations of CD4+CD25+ T regulatory cells. J Immunol 180: 5946-5955, 2008.

• 55) Boman BM, Wicha MS: Cancer stem cells: a step toward the cure. J Clin Oncol 26: 2795-2799, 2008.

• 56) Kretz-Rommel A, Qin F, Dakappagari N, et al: CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 178: 5595-5605, 2007.
  pubmed

P.26 掲載の参考文献

• 1) Agata Y, Kawasaki A, Nishimura H, et al: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8: 765-772, 1996.

• 2) Iwai Y, Okazaki T, Nishimura H, et al: Microanatomical localization of PD-1 in human tonsils. Immunol Lett 83: 215-220, 2002.
  pubmed

• 3) Dong H, Zhu G, Tamada K, et al: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleikin-10 secretion. Nat Med 5: 1365-1369, 1999.

• 4) Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-HI promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800, 2002.

• 5) Yamazaki T, Akiba H, Iwai H, et al: Expression of programmed death 1ligands by murine T cells and APC. J Immunol 169: 5538-5545, 2002.

• 6) Zhang X, Schwartz JC, Guo X, et al: Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20: 337-347, 2004.
  pubmed

• 7) Tsuruta H, Kishimoto H, Sasaki T, et al: Hyperplasia and carcinoma in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 66: 8389-8396, 2006.
  pubmed

• 8) Parsa AT, Waldron JS, Panner A, et al: Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13: 84-88, 2007.
  pubmed

• 9) Azuma T, Yao S, Zhu G, et al: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111: 3635-3643, 2008.
  pubmed

• 10) Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034, 2000.
  pubmed

• 11) Okazaki T, Maeda A, Nishimura H, et al: PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98: 13866-13871, 2001.
  pubmed

• 12) Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293-12297, 2002.
  pubmed

• 13) Strome SE, Dong H, Tamura H, et al: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63: 6501-6505, 2003.
  pubmed

• 14) Webster WS, Thompson RH, Harris KJ, et al: Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol 179: 2860-2869, 2007.
  pubmed

• 15) Curiel TJ, Wei S, Dong H, et al: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9: 562-567, 2003.
  pubmed

• 16) Thompson RH, Kuntz SM, Leibovich BC, et al: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66: 3381-3385, 2006.
  pubmed

• 17) Wong RM, Scotland RR, Lau RL, et al: Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 19: 1223-1234, 2007.

• 18) Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol 23: 515-548, 2005.
  pubmed

• 19) Mahajan S, Cervera A, MacLeod M, et al: The role of ICOS in the development of CD4 T cell help and the reactivation of memory T cells. Eur J Immunol 37: 1796-1808, 2007.
  pubmed

• 20) Tamura H, Dan K Tamada K, et al: Expression of functional B7-H2 and B7. 2costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 11: 5708-5717, 2005.
  pubmed

• 21) Tran CN, Thacker SG, Louie DM, et al: Interactions of T cells with fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3. J Immunol 180: 2989-2998, 2008.
  pubmed

• 22) Wu CP, Jiang JT, Tan M, et al: Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 12: 457-459, 2006.
  pubmed

• 23) Roth TJ, Sheinin Y, Lohse CM, et al: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 67: 7893-7900, 2007.
  pubmed

• 24) Watanabe N, Gavrieli M, Sedy JR, et al: BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4: 670-679, 2003.
  pubmed

• 25) Sica GL, Choi IH, Zhu G, et al: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18: 849-861, 2003.
  pubmed

• 26) Tringler B, Zhuo S, Pilkington G, et al: B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11: 1842-1848, 2005.
  pubmed

• 27) Salceda S, Tang T, Kmet M, et al: The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 306: 128-141, 2005.
  pubmed

• 28) Tringler B, Liu W, Corral L, et al: B7-H4 overexpression in ovarian tumors. Gynecol Oncol 100: 44-52, 2006.
  pubmed

• 29) Sun Y, Wang Y, Zhao J, et al: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53: 143-151, 2006.

• 30) Zang X, Thompson RH, Al-Ahmadie HA, et al: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104: 19458-19463, 2007.
  pubmed

P.34 掲載の参考文献

• 1) Moore K W, de Waal Malefyt R, Coffman RL, et al: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765, 2001.

• 2) Kawamura K, Bahar R, Natsume W, et al: Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther 9: 109-115, 2002.
  pubmed

• 3) Mocellin S, Marincola FM, Young HA: Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78: 1043-1051, 2005.

• 4) Montuenga LM, Pio R: Tumour-associated macrophages in non small cell lung cancer: the role of interleukin-10. Eur Res Respir J 30: 608-610, 2007.

• 5) Beckebaum S, Zhang X, Chen X, et al: Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 10: 7260-7269, 2004.

• 6) Kurte M, Lopez M, Aguirre A, et al: A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol 173: 1731-1737, 2004.

• 7) Herbeuval JP, Lelievre E, Lambert C, et al: Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol 172: 4630-4636, 2004.
  pubmed

• 8) Zeni E, Mazzetti L, Miotto D, et al: Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30: 627-632, 2007.
  pubmed

• 9) Urosevic M, Dummer R: HLA-G and IL-10 expression in human cancer--different stories with the same message. Semin Cancer Biol 13: 337-342, 2003.
  pubmed

• 10) Gerlini G, Tun-Kyi A, Dudli C, et al: Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions, Am J Pathol 165: 1853-1863, 2004.
  pubmed

• 11) Jovasevic VM, Gorelik L, Bluestone JA, et al: Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. J Immnol 172: 1449-1454, 2004.
  pubmed

• 12) Ye Z, Huang H, Hao S, et al: IL-10 has a distinct immunoregulatory effect on ｎａｉｖｅ and active T cell subsets. J Interferon Cytokine Res 27: 1031-1038, 2007.

• 13) Sun J, Schiffman J, Raghunath A, et al: Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8: 9, 2008.

• 14) Chen YX, Man K, Ling GS, et al: A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DCdevoid of IL-10. J Immunol 179: 6009-6015, 2007.
  pubmed

• 15) Fujii SI, Shimizu K, Shimizu T, et al: Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ. Blood 98: 2143-2151, 2001.

• 16) Elliott RL, Blobe GC: Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078-2093, 2005.

• 17) Levy L, Hill CS: Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58, 2006.

• 18) Wrzesinski SH, Wan YY, Flavell RA: Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin Cancer Res 13: 5262-5270, 2007.

• 19) Teicher BA: Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 20: 133-143, 2001.
  pubmed

• 20) Dong M, Blobe GC: Role of transforming growth factor-β in hematologic malignancies. Blood 107: 4589-4596, 2006.

• 21) Saunier EF, Akhurst RJ: TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6: 565-578, 2006.
  pubmed

• 22) Teicher BA: Transforming growth factor-β and the immune response to malignant disease. Clin Cancer Res 13: 6247-6251, 2007.

• 23) Song B-C, Chung Y-H, Kim JA, et al: Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 94: 175-180, 2002.

• 24) Xu WQ, Jiang XC, Zheng L, et al: Expression of TGF-β1, TβR II and Smad4 in colorectal carcinoma. Exp Mol Pathol 82: 284-291, 2007.

• 25) Arteaga CL: Inhibition of TGFβ signaling in cancer therapy. Curr Opin Genet Dev 16: 30-37, 2006.

• 26) Galliher AJ, Schiemann WP: β3 integrin and Src facilitate transforming growth factor-β mediated inductionof epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 8:R42, 2006.

• 27) McKarns SC, Schwartz RH, Kaminski NE: Smad3 is essential for TGF-β1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol 172: 4275-4284, 2004.

• 28) Mempel TR, Pittet MJ, Khazaie K, et al: Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25: 129-141, 2006.
  pubmed

• 29) Shull MM, Ormsby I, Kier AB, et al: Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359: 693-699, 1992.

• 30) Kulkarni AB, Huh CG, Becker D, et al: Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90: 770-774, 1993.

• 31) Gorelik L, Flavell RA: Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12: 171-181, 2000.

• 32) Lucas P, Kim J-S, Melby SJ, et al: Disruption of T cell homeostasis in mice expressing a T cell-specificdominant negative transforming growth factor β II receptor. J Exp Med 191: 1187-1196, 2000.

• 33) Classen S, Zander T, Eggle D, et al: Human resting CD4+ T cells are constitutively inhibited by TGFβ under steady-state conditions. J Immunol 178: 6931-6940, 2007.

• 34) Eisele G, Wischhusen J, Mittelbronn M, et al: TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 129: 2416-2425, 2006.

• 35) Castriconi R, Cantoni C, Della Chiesa M, et al: Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100: 4120-4125, 2003.

• 36) Lee JC, Lee KM, Kim DW, et al: Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172: 7335-7340, 2004.

• 37) Geissmann F, Revy P, Regnault A, et al: TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 162: 4567-4575, 1999.

• 38) Liu VC, Wong LY, Jang T, et al: Tumor evasion of the immune system by converting CD4+CD25+ T cells into CD4+CD25- T regulatory cells: role of tumor-derived TGF-β. J Immunol 178: 2883-2892, 2007.

• 39) Pyzik M, Piccirillo CA: TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol 82: 335-346, 2007.

• 40) Nam JS, Terabe M, Kang MJ, et al: Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68: 3915-3923, 2008.

• 41) Nam JS, Terabe M, Mamura M, et al: An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68: 3835-3843, 2008.

• 42) Morris JC, Shapiro GI, Tan AR, et al: Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). 2008 ASCO Annual Meeting Proccedings: 489s.

• 43) Uhl M, Aulwurm S, Wischhusen J, et al: SD-208, a novel transforming growth factor β receptor I kinaseinhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961, 2004.

• 44) Ge R, Rajeev V, Ray P, et al: Inhibition of growth and metastasis of mouse mammary carcinoma by selective nhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res 12: 4315-3430, 2006.

• 45) Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al: SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3: 737-745, 2004.

• 46) Suzuki E, Kim S, Cheung HK, et al: A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67: 2351-2359, 2007.

• 47) Bogdahn U, Hau P, Olyushin V, et al: Targeted therapy with AP 12009 in recurrent or refractoryglioblastoma patients: results of a phase I ib study. 2008 ASCO Annual Meeting Proceedings: 93s.

• 48) Fakhrai H, Mantil JC, Liu L, et al: Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine inpatients with advanced glioma. Cancer Gene Ther 13: 1052-1060, 2006.

• 49) Moore LD, Isayeva T, Siegal GP, et al: Silencing of transforming growth factor-β1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clin Cancer Res 14: 4961-4970, 2008.

• 50) Soslow RA, Dannenberg AJ, Rush D, et al: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645, 2000.
  pubmed

• 51) Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
  pubmed

• 52) Schmitz KJ, Callies R, Wohlschlaeger J: Overexpression of cyclo-oxygenase-2 is an independent predictorof unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signaling pathways. J Clin Pathol 59: 685-691, 2006.
  pubmed

• 53) Sinha P, Clements VK, Fulton AM, et al: Prostaglandin E2 promotes tumor progression by inducingmyeloid-derived suppressor cells. Cancer Res 67: 4507-4513, 2007.
  pubmed

• 54) Jung YJ, Isaacs JS, Lee S, et al: IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17: 2115-2117, 2003.

• 55) Liu XH, Kirschenbaum A, Lu M, et al: Prostaglandin E2 induces hypoxia-inducible factor-la stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277: 50081-50086, 2002.

• 56) Yiu GK, Toker A: NFAT induces breast cancer cell invasion by promotig the induction of cyclooxygenase-2. J Biol Chem 281: 12210-12217, 2006.
  pubmed

• 57) Shibata Y, Honda I, Justice JP, et al: Th1 adjuvant N-acety1-D-glucosamine polymer up-regulates Th1 immunity but down-regulates Th2 immunity against a mycobacterial protein (MPB-59) in interleukin-10-knockout and wild-type mice. Infect Immun 69: 6123-6130, 2001.

• 58) Stolina M, Sharma S, Lin Y, et al: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity byaltering balance of IL-10 and IL-12 synthesis. J Immunol 164: 361-370, 2000.
  pubmed

• 59) Yang L, Yamagata N, Yadav R, et al: Cancer-associated immunodeficiency and dendritic cell abnormalitiesmediated by the prostaglandin EP2 receptor. J Clin Invest 111: 727-735, 2003.

• 60) Pockaji BA, Basu GD, Pathangey LB, et al: Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 11: 328-339, 2004.

• 61) Haas AR, Sun J, Vachani A, et al: Cyclooxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12: 214-222, 2006.
  pubmed

• 62) Rodriguez PC, Hernandez CP, Quiceno D, et al: Arginase 1 in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202: 931-939, 2005.
  pubmed

• 63) Baratelli F, Lin Y, Zhu L, et al: Prostaglandin E2 induces FOXIP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175: 1483-1490, 2005.

• 64) Sharma S, Yang SC, Zhu L, et al: Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res 65: 5211-5220, 2005.
  pubmed

• 65) Akasaki Y, Liu G, Chung NHC, et al: Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 173: 4352-4359, 2004.
  pubmed

• 66) Bergmalln C, Strauss L, Zeidler R, et al: Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67: 8865-8873, 2007.

• 67) Braun D, Longman RS, Albert ML: A two-step induction of indoleamine 2, 3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106: 2375-2381, 2005.
  pubmed

• 68) von Bergwelt-Baildon MS, Popov A, Saric T, et al: CD25 and indoleamine 2, 3-dioxygenase are upregulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108: 228-237, 2006.
  pubmed

• 69) Lonnroth C, Andersson M, Arvidsson A, et al: Preoperative treatment with a non-steroidal antiinflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 8: 5, 2008.
  pubmed

• 70) Hahn T, Alvarez I, Kobie JJ, et al: Short-term dietary administration of celecoxib enhances the efficacy oftumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer 118: 2220-2231, 2006.

• 71) Basu GD, Tinder TL, Bradley JM, et al: Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177: 2391-2402, 2006.

• 72) Shinohara N, Harabayashi T, Sazawa A, et al: Combination therapy of meloxicam, a selective COX-2 inhibitor, and interferon alfa in metasatatic renal cell carcinoma: A phase II study on efficacy and toxicity. 2007 ASCO Annual Meeting Proccedings: 261s.

• 73) Bottaro DP, Liotta LA: Cancer: Out of air is not out of action. Nature 423: 593-595, 2003.

• 74) Pennacchietti S, Michieli P, Galluzzo M, et al: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361, 2003.
  pubmed

• 75) Gabrilovich DI, Chen HL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functinal maturation of dendritic cells. Nat Med 2: 1096-1103, 1996.

• 76) Oyama T, Ran S, Ishida T, et al: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J Immunol 160: 1224-1232, 1998.

• 77) George DJ, Kaelin WG Jr: The von Hipple-Lindau protein, vascular endothelial growth factor, and kidneycancer. N Engl J Med 349: 419-421, 2003.

• 78) Kusmartsev S, Eruslanov E, Kubler H, et al: Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 181: 346-353, 2008.
  pubmed

• 79) Belotti D, Paganoni P, Manenti L, et al: Matrix metalloproteinase (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63: 5224-5229, 2003.
  pubmed

• 80) Osada T, Chong G, Tansik R, et al: The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 57: 1115-1124, 2008.

• 81) Santos LL, Morand EF: Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis Clin Chim Acta 399: 1-7, 2009.
  pubmed

• 82) Leech M, Lacey D, Xue JR, et al: Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 48: 1881-1889, 2003.
  pubmed

• 83) Powell ND, Papenfuss TL, McClain MA, et al: Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J Immunol 175: 5611-5614, 2005.
  pubmed

• 84) Petrenko O, Fingerle-Rowson G, Peng T, et al: Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J Biol Chem 278: 11078-11085, 2003.
  pubmed

• 85) Repp AC, Mayhew ES, Apte S, et al: Human uveal melanoma cells produce macrophage migrationinhibitory factor to prevent lysis by NK cells. J Immunol 165: 710-715, 2000.
  pubmed

• 86) Yan X, Orentas RJ, Johnson BD, et al: Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine 33: 188-198, 2006.
  pubmed

• 87) Bifulco C, McDaniel K, Leng L, et al: Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des 14: 3790-3801, 2008.
  pubmed

• 88) Krockenberger M, Dombrowski Y, Weilder C, et al: Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 180: 7338-7348, 2008.

P.42 掲載の参考文献

• 1) Yakirevich E, Resnick MB: Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol 25: 2506-2508, 2007.
  pubmed

• 2) Schreiber TH: The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors. Cancer Epidemiol Biomarkers Prev 16: 1931-1934, 2007.
  pubmed

• 3) Ghebeh H, Barhoush E, Tulbah A, et al: FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 8: 57, 2008.
  pubmed

• 4) Yano H, lshida T, Inagaki A, et al: Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 120: 2052-2057, 2007.

• 5) Yang ZZ, Novak AJ, Ziesmer SC, et al: CD70+ non-Hodgikin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25- T cells. Blood 110: 2537-2544, 2007.

• 6) Kono K, Kawaida H, Takahashi A, et al: CD4(+) CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55: 1064-1071, 2006.
  pubmed

• 7) Kawaida H, Kono K, Takahashi A, et al: Distribution of CD4(+) CD25high regulatory T-cells in tumordraining lymph nodes in patients with gastric cancer. J Surg Res 124: 151-157, 2005.
  pubmed

• 8) Peng L, Kjaergaard J, Plautz GE, et al: Tumor-induced L-selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 169: 4811-4821, 2002.
  pubmed

• 9) Turk MJ, Guevara-Patino JA, Rizzuto GA, et al: Concomitant tumor immunity to a poorly immunogenic melanoma is prevellted by regulatory T cells. J Exp Med 200: 771-782, 2004.
  pubmed

• 10) Chen ML, Pittet MJ, Gorelik L, et al: Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA 102: 419-424, 2005.

• 11) Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
  pubmed

• 12) Strauss L, Bergmann C, Gooding W, et al: The frequency and suppressor function of CD4+CD25high Foxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13: 6301-6311, 2007.
  pubmed

• 13) Strauss L, Bergmann C, Szczepanski M, et al: A unique subset of CD4+CD25high Foxp3+ T cells secreting interleukin-10 and transforming growth factor β1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13: 4345-4354, 2007.

• 14) Miller AM, Lundberg K Ozenci V, et al: CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177: 7398-7405, 2006.
  pubmed

• 15) Strauss L, Bergmann C, Szczepanski MJ, et al: Expression of ICOS on human melanoma-infiltrating CD4+ CD25high Foxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 180: 2967-2980, 2008.
  pubmed

• 16) Vence L, Palucka AK, Fay JW, et al: Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci USA 104: 20884-20889, 2007.
  pubmed

• 17) Wang HY, Lee DA, Peng G, et al: Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118, 2004.
  pubmed

• 18) Wang HY, Peng G, Guo Z, et al: Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol 174: 2661-2670, 2005.
  pubmed

• 19) Lehe C, Ghebeh H, Al-Sulaiman A, et al: The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res 68: 6350-6359, 2008.
  pubmed

• 20) van der Burg SH, Piersma SJ, de Jong A, et al: Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigen. Proc Natl Acad Sci US 4104:12087-12092, 2007.

• 21) Voo KS, Peng G, Guo Z, et al: Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res 65: 1577-1586, 2005.
  pubmed

• 22) Nair RE, Kilinc MO, Jones SA, et al: Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neutransgenic mice bearing advanced spontaneous tumors. J Immunol 176: 7325-7334, 2006.

• 23) Zhou G, Drake CG, Levitsky HI: Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107: 628-636, 2006.
  pubmed

• 24) Nishikawa H, Kato T, Tawara I, et al: Definition of target antigens for naturally occurring CD4+CD25+ regulatory T cells. J Exp. Med 201: 681-686, 2005.
  pubmed

• 25) Webster WS, Thompson RH, Harris KJ, et al: Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol 179: 2860-2869, 2007.
  pubmed

• 26) Han Y, Guo Q, Zhang M, et al: CD69+CD4+CD25- T cell, a new subset of regulatory T cell, suppress T cells proliferation through membrane-bound TGF-β1. J Immunol 182: 111-120, 2009.

• 27) Alvaro T, Lejeune M, Salvado MT, et al: Outcome in Hodgikin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11: 1467-1473, 2005.

• 28) Carreras J, Lopez-Guillermo A, Fox BC, et al: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108: 2957-2964, 2006.
  pubmed

• 29) Tzankov A, Meier C, Hirschmann P, et al: Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgikin's lymphoma. Haematologica 93: 193-200, 2008.

• 30) Zhao DM, Thornton AM, DiPaolo RJ, et al: Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107: 3925-3932, 2006.

• 31) Leffers N, Gooden MJ, de Jong RA, et al: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58: 449-459, 2009.
  pubmed

• 32) Salama P, Phillips M, Grieu F, et al: Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27: 186-192, 2009.
  pubmed

• 33) Hillen F, Baeten CI, van de Winkel A, et al: Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother 57: 97-106, 2008.
  pubmed

• 34) Milne K, Kobel M, Kalloger SE, et al: Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4: e6412, 2009.
  pubmed

• 35) Roncarolo MG, Gregori S, Battaglia M, et al: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212: 28-50, 2006.
  pubmed

• 36) Marshall NA, Christie LE, Munro LR, et al: Immunosuppressive regulatory T cells are abundant in the eactive lymphocytes of Hodgikin lymphoma. Blood 103: 1755-1762, 2004.

• 37) Levings MK, Gregori S, Tresoldi E, et al: Differentiation of Trl cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 105: 1162-1169, 2005.

• 38) Fiore F, Nuschak B, Peola NB, et al: Exposure to myeloma cells lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur J Immunol 35: 1155-1163, 2005.

• 39) Akasaki Y, Liu G, Chung NHC, et al: Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 173: 4352-4359, 2004.
  pubmed

• 40) Bergmann C, Strauss L, Zeidler R, et al: Expansion of human T regulatory type l cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67: 8865-8873, 2007.

• 41) Bergmann C, Strauss L, Wang Y, et al: Tregulatory type l cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14: 3706-3715, 2008.

• 42) Wei S, Kryczek I, Zou L, et al: Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 65: 5020-5026, 2005.
  pubmed

• 43) Filaci G, Fenoglio D, Fravega M, et al: CD8+CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 179: 4323-4334, 2007.
  pubmed

• 44) Ahmadi M, Emery DC, Morgan DJ: Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res 68: 7520-7529, 2008.
  pubmed

• 45) Kiniwa Y, Miyahara Y, Wang HY, et al: CD8+Foxp3+regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13: 6947-6958, 2007.
  pubmed

• 46) Chaput N, Louafi S, Bardier A, et al: Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58: 520-529, 2009.
  pubmed

• 47) Xia ZW, Zhong WW, Meyrowitz JS, et al: The role of heme oxygenase-1 in T cell-mediated immunity: the all encompassing enzyme. Curr Pharm Des 14: 454-464, 2008.

• 48) Jozkowicz A, Was H, Dulak J, et al: Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 9: 2099-2117, 2007.
  pubmed

• 49) Andersen MH, Sorensen RB, Brimnes MK, et al: Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest 119: 2245-2256, 2009,
  pubmed

• 50) Peng G, Wang HY, Peng W, et al: Tumor-infiltrating yδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27: 334-348, 2007.

P.54 掲載の参考文献

• 1) Gabrilovich DI, Bronte V, Chen SH, et al: The terminology issue for myeloid-derived suppressor cells. Cancer Res 67: 425-426, 2007.
  pubmed

• 2) Gallina G, Dolcetti L, Serafini P, et al: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 166: 2777-2790, 2006.

• 3) Gabrilovich DI, Velders MP, Sotomayor EM, et al: Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166: 5398-5406, 2001.
  pubmed

• 4) Kusmartsev S, Gabrilovich DI: Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55: 237-245, 2006.
  pubmed

• 5) Almand B, Clark JI, Nikitina E, et al: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678-689, 2001.

• 6) Pak AS, Wright MA, Matthews JP, et al: Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34 (+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1: 95-103, 1995.
  pubmed

• 7) Almand B, Resser J, Lindman B, et al: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766, 2000.
  pubmed

• 8) Young MRI, Petruzzelli GJ, Kolesiak K, et al: Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34+ progenitor cells. Hum Immunol 62: 332-341, 2001.

• 9) Zea AH, Rodriguez PC, Atkins MB, et al: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65: 3044-3048, 2005.
  pubmed

• 10) Salvadori S, Martinelli G, Zier K: Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164: 2214-2220, 2000.
  pubmed

• 11) Yu S, Liu C, Su K, et al: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 178: 6867-6875, 2007.

• 12) Bharadwaj U, Li M, Zhang R, et al: Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 67: 5479-5488, 2007.

• 13) Beckebaum S, Zhang X, Chen X, et al: Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets, Clin Cancer Res 10: 7260-7269, 2004.

• 14) Nefedova Y, Huang M, Kusmartsev S, et al: Hyperactivation of STAT3 is involeved in abnormal differentiation of dendritic cells in cancer. J Immunol 172: 464-474, 2004.

• 15) Nefedova Y, Nagaraj S, Rosenbauer A, et al: Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 65: 9525-9535, 2005.
  pubmed

• 16) Gerlini G, Tun-Kyi A, Dudli C, et al: Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 165: 1853-1863, 2004.
  pubmed

• 17) Witte MB, Barbul A, Schick MA, et al: Upregulation of arginase expression in wound-derived fibroblasts. J Surg Res 105: 35-42, 2002.
  pubmed

• 18) Barksdale AR, Bernard AC, Maley ME, et al: Regulation of arginase expression by T-helper II cytokines and isoproternol. Surgery 135: 527-535, 2004.

• 19) Bellamy WT, Richter L, Sirjani D, et al: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97: 1427-1434, 2001.
  pubmed

• 20) Gabrilovich D: Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nat Rev Immunol 4: 941-952, 2004.
  pubmed

• 21) Melani C, Chiodoni C, Forni G, et al: Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102: 2138-2145, 2003.

• 22) Storozynsky E, Woodward JG, Frelinger JG, et al: Interleukin-3 and granulocyte-macrophage colonystimulating factor enhance the generation and function of dendritic cells. Immunology 97: 138-149, 1999.
  pubmed

• 23) Zou W, Machelon V, Coulomb-L'Hermin A, et al: Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7: 1339-1346, 2001.
  pubmed

• 24) Huang B, Lei Z, Zhao J, et al: CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252: 86-92, 2007.
  pubmed

• 25) Sawanobori Y, Ueha S, Kurachi M, et al: Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111: 5457-5466, 2008.
  pubmed

• 26) Frey AB: Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest 116: 2587-2590, 2006.

• 27) Gallina G, Dolcetti L, Serafini P, et al: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116: 2777-2790, 2006.
  pubmed

• 28) Serafini P, Carbley R, Noonan KA, et al: High-dose granulocyte-macrophage colony-stimulating factorproducing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64: 6337-6343, 2004.
  pubmed

• 29) Yamamoto Y, Ishigaki H, Ishida H, et al: Analysis of splenic Gr-lint immature myeloid cells in tumorbearing mice. Microbiol Immunol 52: 47-53, 2008.

• 30) Filipazzi P, Valenti R, Huber V, et al: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factorbased antitumor vaccine. J Clin Oncol 25: 2546-2553, 2007.
  pubmed

• 31) Pan PY, Wang GX, Yin B, et al: Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111: 219-228, 2008.
  pubmed

• 32) Sinha P, Clements VK, Fulton AM, et al: Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67: 4507-4513, 2007.
  pubmed

• 33) Rughetti A, Pellicciotta I, Biffoni M, et al: Recombinant tumor-associated MUCI glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 174: 7764-7772, 2005.

• 34) Terabe M, Matsui S, Park JM, et al: Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198: 1741-1752, 2003

• 35) Li H, Han Y, Guo Q, et al: Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol 182: 240-249, 2009.

• 36) Bronte V, Serafini P, De Santo C, et al: IL-4-induced arginase l suppresses alloreactive T cells in tumorbearing mice. J Immunol 170: 270-278, 2003.
  pubmed

• 37) Liu Y, Van Ginderachter JA, Brys L, et al: Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol 170: 5064-5074, 2003.
  pubmed

• 38) Ochoa AC, Zea AH, Hernandez C, et al: Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13: 721s-726s, 2007.
  pubmed

• 39) Polat MF, Taysi S, Polat S, et al: Elevated serum arginase activity levels in patients with breast cancer. Surg Today 33: 655-661, 2003.
  pubmed

• 40) Polembska Z, Skwarek A, Mielczarek M, et al: Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma. Cancer 94: 2930-2934, 2002.

• 41) Grizzle WE, Xu X, Zhang S, et al: Age-related increase of tumor susceptibility is associated with myeloidderived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev 128: 672-680, 2007.
  pubmed

• 42) Rodriguez PC, Zea AH, DeSalvo J, et al: L-arginine consumption by macrophages modulates the expression of CD3ζ chain in T lymphocytes. J Immunol 171: 1232-1239, 2003.

• 43) Popovic PJ, Zeh HJ 3rd, Ochoa JB: Arginine and immunity. J Nutr 137: 1681s-1686s, 2007.
  pubmed

• 44) Sinha P, Clements VK, Ostrand-Rosenberg S: Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65: 11743-11751, 2005.
  pubmed

• 45) Rodriguez PC, Quiceno DG, Zabaleta J, et al: Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64: 5839-5849, 2004.
  pubmed

• 46) Rodriguez PC, Quiceno DG, Ochoa AC: L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109: 1568-1573, 2007.
  pubmed

• 47) Rodriguez PC, Hernandez CP, Quiceno D, et al: Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202: 931-939, 2005.
  pubmed

• 48) Bronte V, Zanovello P: Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654, 2005.
  pubmed

• 49) Mocellin S, Bronte V, Nitti D: Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 27: 317-352, 2007.
  pubmed

• 50) Yanagisawa K, Exley MA, Jiang X, et al: Hyporesponsiveness to natural killer T-cell ligand α-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitoric oxide. Cancer Res 66: 11441-11446, 2006.

• 51) Mazzoni A, Bronte V, Visintin A, et al: Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 168: 689-695, 2002.
  pubmed

• 52) Movahedi K, Guillams M, Van den Bossche J, et al: Identification of discrete tumor-induced myeloidderived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244, 2008

• 53) Shhreck R, Albermann K, Baeuerle PA: Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 17: 221-237, 1992.

• 54) Sauer H, Wartenberg M, Hescheler J: Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 11: 173-186, 2001.
  pubmed

• 55) Kusmartsev S, Gabrilovich DI: Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 74: 186-196, 2003.
  pubmed

• 56) Kusmartsev S, Nefedova Y, Yoder D, et al: Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172: 989-999, 2004.
  pubmed

• 57) Wu G, Morris SM Jr: Arginine metabolism: nitoric oxide and beyond. Biochem J 336: 1-17, 1998.
  pubmed

• 58) Nagaraj S, Gupta K, Pisarev V, et al: Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13: 828-835, 2007.
  pubmed

• 59) Alvarez B, Radi R: Peroxynitrite reactivity with amino acids and proteins. Amino Acids 25: 295-311, 2003.
  pubmed

• 60) Bronte V, Kasic T, Gri G, et al: Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201: 1257-1268, 2005.
  pubmed

• 61) Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007.
  pubmed

• 62) Huang B, Pan PY, Li Q. et al: Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131, 2006.

• 63) Hoechst B, Ormandy LA, Ballmaier M, et al: Anew population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology 135: 234-243, 2008.

• 64) Liu C, Yu S, KapPes J, et al: Expansion of spleen myeloid supPressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109: 4336-4342, 2007.

• 65) Yang L, DeBusk LM, Fukuda K, et al: Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421, 2004.
  pubmed

• 66) Vieweg J, Su Z, Dahm P, et al: Reversal of tumor-mediated immunosuppression. Clin Cancer Res 13: 727s-732s, 2007.
  pubmed

• 67) Sinha P, Clements VK, Bunt SK, et al: Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179: 977-983, 2007.

• 68) Leite-de-Moraes MC, Lisbonne M, Arnould A, et al: Ligand-activated natural killer T lymphocytes promptly produce IL-13 and GM-CSF in vivo: relevance to peripheral myeloid recruitment. Eur J Immunol 32: 1897-1904, 2002.

• 69) Terabe M, Matsui S, Noben-Trauth N, et al: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1: 515-520, 2000.
  pubmed

• 70) Ko HJ, Lee JM, Kim YJ, et al: Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 182: 1818-1828, 2009.
  pubmed

• 71) Yang R, Cai Z, Zhang Y, et al: CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 66: 6807-6815, 2006.
  pubmed

• 72) Serafini P, Mgebroff S, Noonan K, et al: Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68: 5439-5449, 2008.

• 73) Serafini P, Borrello I, Bronte V: Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65, 2006
  pubmed

• 74) Seung LP, Rowley DA, Dubey P, et al: Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 92: 6254-6258, 1995.
  pubmed

• 75) Zhang B, Zhang Y, Bowerman NA, et al: Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 68: 1563-1571, 2008.
  pubmed

• 76) Suzuki E, Kapoor V, Jassar AS, et al: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11: 6713-6721, 2005.
  pubmed

• 77) Kusmartsev S, Cheng F, Yu B, et al: All-trans-retinoic acid eliminates immature myeloid cells from tumorbearing mice and improves the effect of vaccination. Cancer Res 63: 4441-4449, 2003.

• 78) Mirza N, Fishman M, Fricke I, et al: All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66: 9299-9307, 2006.
  pubmed

• 79) Nefedova Y, Fishman M, Sherman S, et al: Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 67: 11021-11028, 2007.
  pubmed

• 80) Pak AS, Ip G, Wright MA, et al: Treating tumor-bearing mice with low-dose γ-interferon plus tumor necrosis factor α to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res 55: 885-890, 1995.

• 81) Young MRI, Lozano Y, Ihm J, et al: Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett 104: 153-161, 1996.

• 82) Lathers DMR, Clark JI, Achille NJ, et al: Phase IB study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother 53: 422-430, 2004.
  pubmed

• 83) Young MR, Lathers DMR: Combination docetaxel plus vitamin D3 as an immune therapy in animals bearing squamous cell carcinomas. Otolaryngol Head Neck Surg 133: 611-618, 2005.
  pubmed

• 84) De Santo C, Serafini P, Marigo I, et al: Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 102: 4185-4190, 2005.
  pubmed

• 85) Serafini P, Meckel K, Kelso M, et al: Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203: 2691-2702, 2006.
  pubmed

• 86) Melani C, Sangaletti S, Barazzetta FM, et al: Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 67: 11438-11446, 2007.
  pubmed

• 87) Gamero AM, Young HA, Wiltrout RH, et al: Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 5: 111-112, 2004.
  pubmed

• 88) Wang T, Niu G, Kortylewski M, et al: Regulation of the innate and immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54, 2004.
  pubmed

• 89) Cheng F, Wang HW, Cuenca A, et al: Acritical role for Stat3 signaling in immune tolerance. Immunity 19: 425-436, 2003.

• 90) Cheng P, Corzo CA, Luetteke N, et al: Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppessor cells in cancer is regulated by S100A9 protein. J Exp Med 205: 2235-2249, 2008.

• 91) Xin H, Zhang C, Herrmann A, et al: Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69: 2506-2513, 2009.

• 92) Bromberg J: Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142, 2002.
  pubmed

• 93) Calo V, Migliavacca M, Bazan V, et al: STAT proteins: from normal cotrol of cellular events to tumorigenesis. J Cell Physiol 197: 157-168, 2003.

• 94) Kusmartsev S, Gabrilovich DI: STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174: 4880-4891, 2005.
  pubmed

• 95) Sinha P, Clements VK, Ostrand-Rosenberg S: Reduction of myeloid-derived suppressor cells and induction of MI macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636-645, 2005.

• 96) Van Ginderachter JA, Meerschaut S, Liu Y, et al: Peroxisome proliferator-activated receptor γ (PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 108: 525-535, 2006.

P.60 掲載の参考文献

• 1) Mosmann TR, Cherwinski H, Bond MW, et al: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
  pubmed

• 2) Mills CD, Kincaid K, Alt JM, et al: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164: 6166-6173, 2000.

• 3) Mantovani A, Sozzani S, Locati M, et al: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002.
  pubmed

• 4) Martinez FO, Sica A, Mantovani A, et al: Macrophage activation and polarization. Front Biosci 13: 453-461, 2008.
  pubmed

• 5) Duluc D, Delneste Y, Tan F, et al: Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110: 4319-4330, 2007.
  pubmed

• 6) Allavena P, Sica A, Garlanda C, et al: The Yin-Yang of tumor-associated macrophages in neoplastic progresslon and immune surveillance. Immunol Rev 222: 155-161, 2008.
  pubmed

• 7) Nardin A, Abastado JP: Macrophages and cancer. Front Biosci 13: 3494-3505, 2008.
  pubmed

• 8) Forssell J, Oberg A, Henriksson ML, et al: High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13: 1472-1479, 2007.
  pubmed

• 9) Welsh TJ, Green RH, Richardson D, et al: Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23: 8959-8967, 2005.
  pubmed

• 10) Murata Y, Shimamura T, Hamuro J: The polarization of Th1/Th2 balance is depenent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Int Immunol 14: 201-212, 2002.

• 11) Murata Y, Ohteki T, Koyasu S, et al: IFN-? and pro-inflammatory cytokine production by antigenpresenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. Eur J Immunol 32: 2866-2873, 2002.
  pubmed

• 12) Duff MD, Mestre J, Maddali S, et al: Analysis of gene expression in the tumor-associated macrophage. J Surg Res 142: 119-128, 2007.
  pubmed

• 13) Murdoch C, Giannoudis A, Lewis CE: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and ischemic tissues. Blood 104: 2224-2234, 2004.
  pubmed

• 14) Murdoch C, Lewis CE: Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer 117: 701-708, 2005.
  pubmed

• 15) Murdoch C, Tazzyman S, Webster S, et al: Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 178: 7405-7411, 2007.
  pubmed

• 16) Lewis CE, De Palma M, Naldini L: Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67: 8429-8432, 2007.
  pubmed

• 17) Kuang DM, Wu Y, Chen N, et al: Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 110: 587-595, 2007.

• 18) Tsan MF, Gao B: Endogenous ligands of Toll-like receptors. J Leukoc Biol 76: 514-519, 2004.
  pubmed

• 19) Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612, 2006.
  pubmed

• 20) Kusmartsev S, Gabrilovich DI: STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174: 4880-4891, 2005.
  pubmed

• 21) Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007.
  pubmed

• 22) Umemura N, Saio M, Suwa T, et al: Tumor-infiltrating myeloid-derived suppressor cells are pleiotropicinflamed monocytes/macrophages that bear M1-and M2-type characteristics. J Leukoc Biol 83: 1136-1144, 2008.
  pubmed

• 23) Lin EY, Nguyen AV, Russell RG, et al: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727-740, 2001.
  pubmed

• 24) Aharinejad S, Paulus P, Sioud M, et al: Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 64: 5378-5384, 2004.
  pubmed

• 25) Takahashi A, Kono K, Ichihara F, et al: Macrophages in tumor-draining lymph node with different characteristics induce T-cell apoptosis in patients with advanced stage-gastric cancer. Int J Cancer 104: 393-399, 2003.
  pubmed

• 26) Kryczek I, Zou L, Rodriguez P, et al: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp 203: 871-881, 2006.
  pubmed

• 27) Kryczek I, Wei S, Zhu G, et al: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67: 8900-8905, 2007.
  pubmed

• 28) Cortesini R: Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3).JOP 8: 697-703, 2007.
  pubmed

P.63 掲載の参考文献

• 1) Inaba T, Sano H, Kawahito Y, et al: Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci USA 100: 2736-2741, 2003.
  pubmed

• 2) Biswas SK, Gangi L, Paul S, et al: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation). Blood 107: 2112-2122, 2006.

• 3) Gabrilovich DL, Bronte V, Chen SH, et al: The terminology issue for myeloid-derived suppressor cells. Cancer Res 67: 425, 2007.

• 4) Gallina G, Dolcetti L, Serafini P, et al: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116: 2777-2790, 2006.
  pubmed

• 5) Leon B, Lopez-Bravo M, Ardavin C: Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26: 519-531, 2007.
  pubmed

• 6) Strauss-Ayali D, Conrad SM, Mosser DM: Monocyte subpopulation and their differentiation patterns during infection. J Leukoc Biol 82: 244-252, 2007.
  pubmed

• 7) Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007.
  pubmed

• 8) Umemura N, Saio M, Suwa T, et al: Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics. J Leukoc Biol 83: 1136-1144, 2008.
  pubmed

P.64 掲載の参考文献

• 1) Perrot I, Blanchard D, Freymond N, et al: Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178: 2763-2769, 2007.

• 2) Liu Y, Bi X, Xu S, et al: Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses. Cancer Res 65 :4955-4962, 2005.

• 3) Vicari AP, Chiodoni C, Vaure C, et al: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 196: 541-549, 2002.
  pubmed

• 4) Guiducci C, Vicari AP, Sangaletti S, et al: Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65: 3437-3446, 2005.
  pubmed

• 5) Hartmann E, Wollenberg B, Rothenfusser S, et al: Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63: 6478-6487, 2003.
  pubmed

• 6) Zou W, Machelon V, Coulomb-L'Hermin A, et al: Stromal-derived factor-1 in human tumors recuits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7: 1339-1346, 2001.

• 7) Preynat-Seauve O, Schuler P, Contassot E, et al: Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor relection. J Immunol 176: 61-67, 2006.

• 8) McCarter M, Baumgartner J, Escobar GA, et al: Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 14: 2854-2860, 2007.
  pubmed

• 9) Battaglia A, Buzzonetti A, Baranello C, et al: Metastatic tumor cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother 58: 1363-1373, 2009.

• 10) Munn DH, Sharma MD, Hou D, et al: Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114: 280-290, 2004.
  pubmed

• 11) Munn DH, Mellor AL: Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154, 2007.
  pubmed

• 12) Sharma MD, Baban B, Chandler P, et al: Plasmacytoid dendritic cells from mouse tumor-draining Iymphnodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J Clin Invest 117: 2570-2582, 2007
  pubmed

P.66 掲載の参考文献

• 1) Silzle T, Randolph GJ, Kreutz M, et al: The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer 108: 173-180, 2004.
  pubmed

• 2) Nazareth M, Broderick L, Simpson-Abelson MR, et al: Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 178: 5552-5562, 2007.
  pubmed

• 3) Maeda T, Alexander CM, Friedl A: Induction of syndecan-1 expression in stromal firoblasts promotes proliferation of human breast cancer cells. Cancer Res 64: 612-621, 2004.
  pubmed

• 4) Maeda T, Desouky J, Friedl A: Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 25: 1408-1412, 2006.
  pubmed

C. 手術と免疫

P.70 掲載の参考文献

• 1) Shakhar G, Ben-Eliyahu S: Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10: 972-992, 2003.

• 2) Shakhar G, Abudarham N, Melamed R, et al: Amelioration of operation-induced suppression of marginating pulmonary NK activity using poly IC: a potential approach to reduce postoperative metastasis. Ann Surg Oncol 14: 841-852, 2007.
  pubmed

• 3) Yardeni IZ, Beilin B, Mayburd E, et al: The effect of perioperative intravenous lidocaine on postoperative pain and immune function. Anesth Analog 109: 1464-1469, 2009.
  pubmed

• 4) Page GG, Bllakely WP, Ben-Eliyahu S, et al: Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 90: 191-199, 2001.

• 5) Bar-Yosef S, Melamed R, Page GG, et al: Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 94: 1066-1073, 2001.
  pubmed

• 6) Melamed R, Bar-Yosef S, Shakhar G, et al: Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analog 97: 1331-1339, 2003.
  pubmed

• 7) Lissoni P, Brivio F, Fumagalli L, et al: Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res 29: 1847-1852, 2009.
  pubmed

• 8) Exadaktylos AK Buggy DJ, Moriarty DC, et al: Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis. Anesthesiology 105: 660-664, 2006.
  pubmed

P.75 掲載の参考文献

• 1) North RJ, Bursuker I: Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 159: 1295-1311, 1984.

• 2) Bursuker I, North RJ: Generation and decay of the immune response to a progressive fibrosarcoma. H. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 159: 1312-1321, 1984.

• 3) Salvadori S, Martinelli G, Zier K: Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164: 2214-2220, 2000.
  pubmed

• 4) Turk MJ, Guevara-Patino JA, Rizzuto GA, et al: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200: 771-782, 2004.
  pubmed

• 5) Zhang P, Cote AL, de Vries VC, et al: Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res 67: 6468-6476, 2007.

• 6) Cote AL, Usherwood EJ, Turk MJ: Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res 68: 1614-1617, 2008.
  pubmed

• 7) Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al: Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102: 9571-9576, 2005.
  pubmed

• 8) Danna EA, Sinha P, Gilbert M, et al: Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64: 2205-2211, 2004.
  pubmed

• 9) Suzuki E, Kim S, Cheung H-K, et al: A novel small-molecule inhibitor of transforming growth factorβ type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67: 2351-2359, 2007.

• 10) Lee CC, Faries MB, Wanek LA, et al: Improved survival after lymphadenectomy for nodal metastasis from an unkown primary melanoma. J Clin Oncol 26: 535-541, 2008.

• 11) Mullins DW, Sheasley SL, Ream RM, et al: Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 198: 1023-1034, 2003.
  pubmed

• 12) Fatouros M, Roukos DH, Lorenz M, et al: Impact of spleen preservation in patients with gastric cancer. Anticancer Res 25: 3023-3030, 2005.
  pubmed

D. 免疫療法

P.79 掲載の参考文献

• 1) Nagorsen D, Thiel E: Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12: 3064-3069, 2006.
  pubmed

• 2) Engell-Noerregaard L, Hansen TH, Andersen MH, et al: Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58: 1-14, 2009.
  pubmed

• 3) Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004.
  pubmed

• 4) Schadendorf D, Ugurel S, Schuler-Thurner B, et al: Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients wih metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17: 563-570, 2006.

• 5) Barve M, Bender J, Senzer N, et al: Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 26: 4418-4425, 2008.

• 6) Lotem M, Machlenkin A, Hamburger T, et al: Autologous melanoma vaccine induces antitumor and self-reactive immune response that affect patient survival and depend on MHC class II expression on vaccine cells. Clin Cancer Res 15: 4968-4977, 2009.
  pubmed

• 7) Harris JE, Ryan L, Hoover HC Jr, et al: Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18: 148-157, 2000

• 8) Mosolits S, Ullenhag G, Mellstedt H: Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 16: 847-862, 2005.
  pubmed

• 9) Kuang M, Peng BG, Lu MD, et al: Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10: 1574-1579, 2004.
  pubmed

• 10) Liang W, Wang H, Sun TM, et al: Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol 15: 495-498, 2003.

• 11) Tuettenberg A, Becker C, Huter E, et al: Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer 118: 2617-2627, 2006.
  pubmed

• 12) Roseberg SA, Sherry RM, Morton KE, et al: Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175: 6169-6176, 2005.

• 13) Germeau C, Ma W, Schiavetti F, et al: High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201: 241-248, 2005.
  pubmed

• 14) Lurquin C, Lethe B, De Plaen E, et al: Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201: 249-257, 2005.
  pubmed

• 15) Carrasco J, Van Pel A, Neyns B, et al: Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 180: 3585-3593, 2008.

• 16) Leon K, Garcia K, Carneiro J, et al: How regulatory CD25+CD4+ T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors. J Theor Biol 247: 122-137, 2007.
  pubmed

• 17) Leon K, Garcia K, Carneiro J, et al: How regulatory CD25+D4+ T cells impinge on tumor immunobiology: the differential response of tumors to therapies. J Immunol 179: 5659-5668, 2007.

• 18) Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, et al: Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206: 849-866, 2009.
  pubmed

P.87 掲載の参考文献

• 1) Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307, 2006.
  pubmed

• 2) Shimizu J, Yamazaki S, Sakaguhi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.

• 3) Turk MJ, Guevara-Patino JA, Rizzuto GA, et al: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200: 771-782, 2004.
  pubmed

• 4) Antony PA, Piccirillo CA, Akpinarli A, et al: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper Cells and hindered by naturally occurring T regulatory Cells. J Immunol 174: 2591-2601, 2005.

• 5) Fecci PE, Sweeney AE, Grossi PM, et al: Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12: 4294-4305, 2006.
  pubmed

• 6) Barnett B, Kryczek I, Cheng P, et al: Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54: 369-377, 2005.
  pubmed

• 7) Litzinger MT, Fernando R, Curiel TJ, et al: IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110: 3192-3201, 2007.
  pubmed

• 8) Dannull J, Su Z, Rizzieri D, et al: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633, 2005.
  pubmed

• 9) Morse MA, Hobeika AC, Osada T, et al: Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112: 610-618, 2008.
  pubmed

• 10) Powell DJ Jr, Felipe-Silva A, Merino MJ, et al: Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 179: 4919-4928, 2007.
  pubmed

• 11) Wei S, Kryczek I, Edwards RP, et al: Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 67: 7487-7494, 2007.
  pubmed

• 12) Cesana GC, DeRaffele G, Cohen S, et al: Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24: 1169-1177, 2006.
  pubmed

• 13) O'Mahony D, Morris JC, Quinn C, et al: A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13: 958-964, 2007.

• 14) Egen JG, Kuhns MS, Allison Jp: CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3: 611-618, 2002.
  pubmed

• 15) Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377, 2003.
  pubmed

• 16) Phan GQ, Weber JS, Sondak VK: CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol 15: 3014-3021, 2008.
  pubmed

• 17) Klein O, Ebert LM, Nicholaou T, et al: Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 15: 2507-2513, 2009.
  pubmed

• 18) Thompson JA: Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma. Am Soc Clin Oncol: abstr 9055, 2008.

• 19) Ribas A, Camacho LH, Lopez-Berestein G, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 23: 8968-8977, 2005.

• 20) van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF) -producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355-366, 1999.
  pubmed

• 21) Sutmuller RPM, van Duivenvoorde LM, van Elsas A, et al: Synergism of cytotoxic T lymphocyte associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194: 823-832, 2001.

• 22) Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100: 4712-4717, 2003.
  pubmed

• 23) Gerritsen W, Van Den Eertwegh A, De Gruijl T, et al: A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibogy (MDX-010, Ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC). Am Soc Clin Oncol: abstr 2500, 2006.

• 24) Quezada SA, Peggs KS, Curran MA, et al: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116: 1935-1945, 2006.
  pubmed

• 25) Hodi FS, Butler M, Oble DA, et al: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105: 3005-3010, 2008.
  pubmed

• 26) Hamid O, Urba WJ, Yellin MJ, et al: Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. Eur J Cancer 43: 396 (suppl 5, abstr 7005) , 2007.

• 27) Fong L, Small EJ: Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26: 5275-5283, 2008.

• 28) Ferretti G, Felici A, Pino MS, et al: Does CTLA4 influence the suppressive effect of CD25+CD4+ regulatory T cells? J Clin Oncol 24: 5469-5470, 2006.
  pubmed

• 29) Kavanagh B, O'Brien S, Lee D, et al: CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fasion. Blood 112: 1175-1183, 2008.

• 30) Menard C, Ghiringhelli F, Roux S, et al: Ctla-4 blockade confers lympocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 14: 5242-5249, 2008.

• 31) Fecci PE, Ochiai H, Mitchell DA, et al: Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13: 2158-2167, 2007.

• 32) Quezada SA, Peggs KS, Simpson TR, et al: Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 205: 2125-2138, 2008.
  pubmed

• 33) Sato E, Olson SH, Ahn J, et al: Intraepithelial CD8+ Tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543, 2005.

• 34) Shimizu J, Yamazaki S, Takahashi T, et al: Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 135-142, 2002.
  pubmed

• 35) Ji HB, Liao G, Faubion WA, et al: Cutting edge: The natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol 172: 5823-5827, 2004.
  pubmed

• 36) Ronchetti S, Zollo O, Bruscoli S, et al: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulation. Eur J Immunol 34: 613-622, 2004.

• 37) Kanamaru E Youngnak P, Hashiguchi M, et al: Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol 172: 7306-7314, 2004.

• 38) Hanabuchi S, Watanabe N, Wang YH, et al: Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 107: 3617-3623, 2006.
  pubmed

• 39) Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, et al: Glucocorticoid-induced TNF receptorfamily related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 176: 6434-6442, 2006.

• 40) Zhou P, L'italien L, Hodges D, et al: Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 179: 7365-7375, 2007.

• 41) Nishikawa H, Kato T, Hirayama M, et al: Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 68: 5948-5954, 2008.
  pubmed

• 42) Tuyaerts S, Van Meirvenne S, Bonehill A, et al: Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol 82: 93-105, 2007.

• 43) Gough MJ, Ruby CE, Redmond WL, et al: OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 68: 5206-5215, 2008.
  pubmed

• 44) Redmond WL, Gough MJ, Weinberg AD: Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol 39: 2184-2194, 2009.
  pubmed

• 45) Kitamura N, Murata S, Ueki T, et al: OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. Int J Cancer 125: 630-638, 2009.
  pubmed

• 46) Piconese S, Valzasina B, Colombo MP: OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205: 825-839, 2008.
  pubmed

• 47) Zhou D: OX40 signaling directly triggers the antitumor effects of NKT cells. J Clin Invest 117: 3169-3172, 2007.
  pubmed

• 48) Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, et al: OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 206: 1103-1116, 2009.
  pubmed

• 49) Nair S, Boczkowski D, Fassnacht M, et al: Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 67: 371-380, 2007.
  pubmed

• 50) Valencia X, Stephens G, Goldbach-Mansky R, et al: TNF down modulates the function of human CD4+CD25hi T-regulatory cells. Blood 108: 253-261, 2006.

• 51) Larmonier N, Janikashvili N, LaCasse CJ, et al: Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL tumors. J Immunol 181: 6955-6963, 2008.
  pubmed

• 52) Hipp MM, Hilf N, Walter S, et al: Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111: 5610-5620, 2008.

• 53) Finke JH, Rini B, Ireland J, et al: Sunitinib reverses type-1 immune suppression and decreases T regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14: 6674-6682, 2008.
  pubmed

• 54) Chen A, Liu S, Park D, et al: Depleting intratumoral CD4+CD25+ T regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res 67: 1291-1298, 2007.
  pubmed

• 55) Pan PY, Wang GX, Yin B, et al: Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor-cell development by blockade of stem-cell factor function. Blood 111: 219-228, 2008.
  pubmed

• 56) Ozao-Choy J, Ma G, Kao J, et al: The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immne-based cancer therapies. Cancer Res 69: 2514-2522, 2009.

• 57) Ko JS, Zea AH, Rini BI, et al: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulationin renal cell carcinoma patients. Clin Cancer Res 15: 2148-2157, 2009.

• 58) Xin H, Zhang C, Herrmann A, et al: Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69: 2506-2513, 2009.

P.99 掲載の参考文献

• 1) June CH: Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476, 2007.
  pubmed

• 2) Waldmann TA: The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595-601, 2006.
  pubmed

• 3) Boyman O, Purton JF, Surh CD, et al: Cytokines and T-cell homeostasis. Curr Opin Immunol 19: 320-326, 2007.

• 4) Hinrichs CS, Spolski R, Paulos CM, et al: IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111: 5326-5333, 2008.
  pubmed

• 5) Klebanoff CA, Gattinoni L Torabi-Parizi P, et al: Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102: 9571-9576, 2005.
  pubmed

• 6) Robbins PF, Dudley ME, Wunderlich J, et al: Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell trnasfer therapy. J Immunol 173: 7125-7130, 2004.

• 7) Zhou J, Dudley ME, Rosenberg SA, et al: Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28: 53-62, 2005.

• 8) Huang J, Khong HT, Dudley ME, et al: Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28: 258-267, 2005.
  pubmed

• 9) Sallusto F, Lenig D, Forster R, et al: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712, 1999.

• 10) Monteiro J, Batliwalla F, Ostrer H, et al: Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 156: 3587-3590, 1996.
  pubmed

• 11) van den Hove LE, Van Gool SW, Vandenberghe, P, et al: CD57+/CD28- T cells in untreated hemato oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. Leukemia 12: 1573-1582, 1998.
  pubmed

• 12) Gattioni L, Klebanoff CA, Palmer DC, et al: Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626, 2005.

• 13) Becker TC, Wherry EJ, Boone D, et al: Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 195: 1541-1548, 2002.
  pubmed

• 14) Klebanoff CA, Finkelstein SE, Surman DR, et al: IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101: 1969-1974, 2004.
  pubmed

• 15) Chin CS, Miller CHT, Graham L, et al: Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Int Immunol 16: 1283-1294, 2004.

• 16) Le HK, Graham L, Miller CHT, et al: Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1+ionomycin in IL-7+IL-15 increases yield of cells capable of inducing regression of melanomatastases compared to culture in IL-2. Cancer Immunol Immunother 58: 1565-1576, 2009.
  pubmed

• 17) Colombetti S, Levy F, Chapattee L: IL-7 adjuvant treatment enhances long-term tumor antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector. Blood 113: 6629-6637, 2009.

• 18) Li Y, Yee C: IL-21-mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111: 229-235, 2008.

• 19) Naylor K, Li G, Vallejo AN, et al: The influence of age on T cell generation and TCR diversity. J Immunol 174: 7446-7452, 2005.

• 20) Mackall CL, Fleisher TA, Brown MR, et al: Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332: 143-149, 1995.
  pubmed

• 21) Hakim FT, Memon SA, Cepeda R, et al: Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 115: 930-939, 2005.
  pubmed

• 22) Min B, Yamane H, Hu-Li J, et al: Spontaneous and homeostatic proliferation of CD4 T cells are regulated by different mechanisms. J Immunol 174: 6039-6044, 2005.
  pubmed

• 23) Bourgeois C, Stockinger B: CD25+CD4+ regulatory T cells and memory T cells prevent lymphopenia induced proliferation of naive T cells in transient states of lymphopenia. J Immunol 177: 4558-4566, 2006.
  pubmed

• 24) Surth CD, Sprent J: Homeostatic T cell proliferation: how far can T cells be activated to self-ligands? J Exp Med 192: F9-F14, 2000.

• 25) Wrzesinski C, Restifo NP: Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol 17: 195-201, 2005.
  pubmed

• 26) Ｗu Ｚ, Bensinger SJ, Zhang J, et al: Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 10: 87-92, 2004.
  pubmed

• 27) Lizee G, Radvanyi LG, Overwijk WW, et al: Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 12: 4794-4803, 2006.
  pubmed

• 28) Fang L, Lonsdorf AS, Hwang ST: Immunotherapy for advanced melanoma. J Invest Dermatol 128: 2596-2605, 2008.
  pubmed

• 29) Goldrath AW, Bogatzki LY, Bevan MJ: Native T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 192: 557-564, 2000.

• 30) Cho BK, Rao VP, Ge Q, et al: Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 192: 549-556, 2000.
  pubmed

• 31) Goldrath AW, Luckey CJ, Park R, et al: The molecular program induced in T cells undergoing homeostatic proliferation. Proc Natl Acad Sci USA 101: 16885-16890, 2004.

• 32) Brown IE, Blank C, Kline J, et al: Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol 177: 4521-4529, 2006.
  pubmed

• 33) Hamilton SE, Wolkers MC, Schoenberger SP, et al: The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat Immunol 7: 475-481, 2006.
  pubmed

• 34) Hamilton SE, Jameson SC: The nature of the lymphopenic environment dictates protective function of homeostatic-memory CD8+ T cells. Proc Natl Acad Sci USA 105: 18484-18489, 2008.
  pubmed

• 35) Suzuki T, Ogawa S, Tanabe K, et al: Induction of antitumor immune response by homeostatic proliferation and CD28 signaling. J Immunol 180: 4596-4605, 2008.
  pubmed

• 36) Schuster K, Gadiot J, Andreesen R, et al: Homeostatic proliferation of naive CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN. Eur J Immunol 39: 2981-2990, 2009.
  pubmed

• 37) Powell DJ Jr, Dudley ME, Robbins PF, et al: Transition of late-stage effector T cells to CD27+CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241-250, 2005.
  pubmed

• 38) Wallen H, Thompson JA, Reilly JZ, et al: Fuldarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cell in patients with metastatic melanoma. PLoS OＮE 4: e4749, 2009.
  pubmed

• 39) Hu HM, Poehlein CH, Urba WJ, et al: Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62: 3914-3919, 2002.
  pubmed

• 40) Ma J, Urba WJ, Si L, et al: Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 33: 2123-2132, 2003.
  pubmed

• 41) Asavaroengchai W, Kotera Y, Mule JJ, et al: Tumor lysate-pulsed dendritic cells can elicite an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99: 931-936, 2002.
  pubmed

• 42) Wang LX, Li R, Yang G, et al: Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lympho depleted mice lead to tumor regression and editing. Cancer Res 65: 10569-10577, 2005.

• 43) Kline J, Brown IA, Zha YY, et al: Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 14: 3156-3167, 2008.

• 44) Mirmonsef P, Tan G, Zhou G, et al: Escape from suppression: tumor-specific effector cells out complete regulatory T cells following stem-cell transplantation. Blood 111: 2112-2124, 2008.

• 45) Jing W, Gershan JA, Johnson BD: Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood 113: 4449-4457, 2009.
  pubmed

• 46) King C, Ilic A, Koelsch K, et al: Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117: 265-277, 2004.
  pubmed

• 47) Le Saout C, Mennechet S, Taylor N, et al: Memory-like CD8+ T and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions. Proc Natl Acad Sci USA 1O5: 19414-19419, 2008.

• 48) Shen S, Ding Y, Tadokoro CE, et al: Control of homeostatic proliferation by regulatory T cells. J Clin Invest 115: 3517-3526, 2005.
  pubmed

• 49) Winstead CJ, Fraser JM, Khoruts A: Regulatory CD4+ CD25+ Foxp3+ T cells selectively inhibit the spontaneous form of lymphopenia-induced proliferation of naive T cells. J Immunol 180: 7305-7317, 2008.
  pubmed

• 50) Antony PA, Piccirillo CA, Akpinarli A, et al: CD8+ T cell immunity against a tumor/self-antigen is augmened by CD4+ T helper cells and hindered by naturally occuring T regulatory cells. J Immunol 174: 2591-2601, 2005.

• 51) Wrzesinski C, Paulos CM, Gattinoni L, et al: Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest 117: 492-501, 2007.
  pubmed

• 52) Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonalrepopulation with antitumor lymphocytes. Science 298: 850-854, 2002.
  pubmed

• 53) Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005.
  pubmed

• 54) Gattinoni L, Finkelstein SE, Klebanoff CA, et al: Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202: 907-912, 2005.
  pubmed

• 55) Paulos CM, Wrzesinski C, Kaiser A, et al: Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 117: 2197-2204, 2007.
  pubmed

• 56) Dudley MK, Yang JC, Sherry R, et al: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239, 2008.

• 57) Paulos CM, Kaiser A, Wrzesinski C, et al: Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13: 5280-5289, 2007.
  pubmed

• 58) Salem ML, Diaz-Montero CM, Al-Khami AA, et al: Recovery from cyclophospamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly (I:C). J Immunol 182: 2030-2040, 2009.

• 59) Shvets A, Chakrabarti R, Gonzalez-Quintial R, et al: Impaired negative regulation of homeostatically proliferating T cells. Blood 113: 622-625, 2009.
  pubmed

• 60) Kochenderfer JN, Simpson JL, Chien CD, et al: Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. Blood 110: 450-460, 2007.

• 61) Salem ML, Diaz-Montero CM, EL-Naggar SA, et al: The TLR3 agonist poly (I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice. Vaccine 27: 549-557, 2009.
  pubmed

• 62) Leen AM, Rooney CM, Foster AE: Improving T cell therapy for cancer. Annu Rev Immunol 25: 243-265, 2007.
  pubmed

• 63) Morgan RA, Dudley ME, Wunderlich JR, et al: Cancer regression in patients after transfer of genetically engineered lymhocytes. Science 314: 126-129, 2006.

• 64) Derby MA, Alexander-Miller MA, Tse R, et al: High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 166: 1690-1697, 2001.

• 65) Chames P, Willemsen RA, Rojas G, et al: TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J Immunol 169: 1110-1118, 2002.
  pubmed

• 66) Sebestyen Z, Schooten E, Sals T, et al: Human TCR that incorporate CD3ζ induce highly preferred pairing between TCRα and β chains following gene transfer. J Immunol 180: 7736-7746, 2008.

• 67) Rosenberg SA, Restifo NP, Yang JC, et al: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308, 2008.
  pubmed

• 68) Russo V, Cipponi A, Raccosta L, et al: Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antituomor immunity. J Clin Invest 117: 3087-3096, 2007.
  pubmed

• 69) Fontana R, Bregni M, Cipponi A, et al: Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 113: 1651-1660, 2009.
  pubmed

P.104 掲載の参考文献

• 1) Hayday A, Tigelaar R: Immunoregulation in the tissues by γδ T cells. Nat Rev Immunol 3: 233-242, 2003.

• 2) Hayday AC: γδ T cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18: 975-1026, 2000.

• 3) Martin B, Hirota K, Cua DJ, et al: Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity 31: 321-330, 2009.

• 4) Roark CL, Simonian PL, Fontenot AP, et al: γδ T cells: an important source of IL-17. Curr Opin Immunol 20: 353-357, 2008.

• 5) Kabelitz D, Wesch D, He W: Perspectives of γδ T cells in tumor immunology. Cancer Res 67: 5-8, 2007.

• 6) Liu Z, Eltoum IE, Guo B, et al: Protective immunosurveillace and therapeutic antitumor activity of γδ T cells demonstrated in a mouse model of prostate cancer. J Immunol 180: 6044-6053, 2008.

• 7) Viey E, Fromont G, Escudier B, et al: Phosphostim-activated γδ T cells kill autologous metastatic renal cell Carcinoma. J Immunol 174: 1338-1347, 2005.

• 8) Wrobel P, Shojaei H, Schittek B, et al: Lysis of a broad range of epithelial tumour cells by human γδ T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition. Scand J Immunol 66: 320-328, 2007,

• 9) Bouet-Toussaint F, Cabillic F, Toutirais O, et al: Vγ9 Vδ2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 57: 531-539, 2008.

• 10) Girardi M, Oppenheim DE, Steele CR, et al: Regulation of cutaneous malignancy by γδ T cells. Science 294: 605-609, 2001.

• 11) Gurardi M, Glusac E, Filler RB, et al: The distinct contributions of murine T cell receptor (TCR) γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer. J Exp Med 198: 747-755, 2003.

• 12) Kobayashi H, Tanaka Y, Yagi J, et al: Gamma/delta T cells provide innate immunity against renal cellcarcinoma. Cancer Immunol Immunother 50: 115-124, 2001.

• 13) Murayama M, Tanaka Y, Yagi J, et al: Antitumor activity and some immunological properties of γδ T-cells from patients with gastrointestinal carcinomas. Anticancer Res 28: 2921-2931, 2008.

• 14) Kondo M, Sakuta K, Noguchi A, et al: Zoledronate faciliates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10: 842-856, 2008.

• 15) Dieli F, Vermijlen D, Fulfaro F, et al: Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67: 7450-7457, 2007.

• 16) Takahara M, Miyai M, Tomiyama M, et al: Copulsing tumor antigen-pulsed dendritic cells with zoledronateefficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vγ9γδ T cell activation. J Leukoc Biol 83: 742-754, 2008.

• 17) Fiore F, Castella B, Nuschak B, et al: Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 110: 921-927, 2007.
  pubmed

• 18) Melani C, Sangaletti S, Barazzetta FM, et al: Amino-bisphosphonate-mediated MMP-9 inhibition breaksthe tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 67: 11438-11446, 2007.
  pubmed

• 19) Zou W: Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 6: 295-307, 2006.
  pubmed

• 20) Gong G, Shao L, Wang Y, et al: Phosphoantigen-activated Vγ2 Vδ2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection, Blood 113: 837-845, 2009.

P.107 掲載の参考文献

• 1) Berzofsky JA, Terabe M: NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 180: 3627-3635, 2008.

• 2) Takahashi T, Chiba S, Nieda M, et al: Cutting edge: analysis of human Vα24+CD8+ NKT cells activated by α-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 168: 3140-3144, 2002.

• 3) Kronenberg M, Rudensky A: Regulation of immunity by self-reactive T cells. Nature 435: 598-604, 2005.
  pubmed

• 4) Terabe M, Park JM, Berzofsky JA: Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 53: 79-85, 2004.
  pubmed

• 5) Fuss IJ, Strober W: The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol Suppl 1: S31-S33, 2008.

• 6) Ambrosino E. Terabe M, Halder RC, et al: Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 179: 5126-5136, 2007.

• 7) Terabe M, Matsui S, Park JM, et al: Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198: 1741-1752, 2003.

• 8) Park JM, Terabe M, Donaldson DD, et al: Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother 57: 907-912, 2008.
  pubmed

• 9) Fichtner-Feigl S, Terabe M, Kitani A, et al: Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-α2. Cancer Res 68: 3467-3475, 2008.

• 10) Kawakami K, Terabe M, Kawakami M, et al: Characterization of a novel human tumor antigen interleukin-13 receptor α2 chain. Cancer Res 66: 4434-4442, 2006.

• 11) Renukaradhya GJ, Khan MA, Vieira MA, et al: Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 111: 5637-5645, 2008.

• 12) van der Vliet HJ, Wang R, Yue SC, et al: Circulating myeloid dendritic cells of advanced cancer patients results in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol 180: 7287-7293, 2008.

• 13) van der Vliet HJ, von Blomberg BM, Nishi N, et al: Circulating Vα24+Vβ11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 100: 144-148, 2001.

• 14) Molling JW, Kolgen W, van der Vliet HJ, et al: Peripheral blood IFN-γ-secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116: 87-93, 2005.

• 15) Molling JW, Langius JA, Langendijk JA, et al: Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25: 862-868, 2007.
  pubmed

• 16) Metelitsa LS, Wu HW, Wang H, et al: Natural killer T cells infiltrate neuroblastomas expressing thechemokine CCL2. J Exp Med 199: 1213-1221, 2004.

• 17) Tachibana T, Onodera H, Tsuruyama T, et al: Increased intratumor Vα24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11: 7322-7327, 2005.

• 18) Tahir SM, Cheng O, Shaulov A, et al: Loss of IFN-γ production by invariant NKT cells in advanced cance. J Immunol 167: 4046-4050, 2001.

• 19) van der Vliet HJ, Molling JW, Nishi N, et al: Polarization of Vα24+Vβ11+ natural killer T cells of healthy volunteers and cancer patients using α-galactosylceramide-loaded and enviromentally instructed dendritic cells. Cancer Res 63: 4101-4106, 2003.

• 20) Dhodapkar MV, Geller MD, Chang DH, et al: A reversible defect in natural killer T cell function characterizes the progression of premalignant to maignant multiple myeloma. J Exp Med 197: 1667-1676, 2003.

• 21) Uldrich AP, Crowe NY, Kyparissoudis K, et al: NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 175: 3092-3101, 2005.
  pubmed

• 22) Fujii S, Shimizu K, Kronenberg M, et al: Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nat Immunol 3: 867-874, 2002.

• 23) Parekh VV, Wilson MT, Olivares-Villagomez D, et al: Glycolipid antigen induces long-term natural T cell anergy in mice. J Clin Invest 115: 2572-2583, 2005.
  pubmed

• 24) Yue SC, Shaulov A, Wang R, et al: CD1 ligation on human monocyte directly signals rapid NF-κB activation and production of bioactive IL-12. Proc Natl Acad Sci USA 102: 11811-11816, 2005.

• 25) van der Vliet HJ, Balk SP, Exley MA: Natural killer T cell-based cancer immunotherapy. Clin Cancer Res 12: 5921-5923, 2006.
  pubmed

• 26) Moreno M, Molling JW, von Mensdorff-Pouilly S, et al: IFN-γ-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J Immunol 181: 2446-2454, 2008.

• 27) Toura I, Kawano T, Akutsu Y, et al: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 163: 2387-2391, 1999.

• 28) Motohashi S, Kobayashi S, Ito T, et al: Preserved IFN-α production of circulating Vα24 NKT cells in primary lung cancer patients. Int J Cancer 102: 159-165, 2002.

• 29) Chang DH, Osman K, Connolly J, et al: Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503-1517, 2005.

• 30) Motohashi S, Nagato K Kunii N, et al: A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182: 2492-2501, 2009.

• 31) Chung Y, Kim BS, Kim YJ, et al: CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 66: 6843-6850, 2006.

• 32) Kim YJ, Ko HJ, Kim YS, et al: α-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int J Cancer 122: 2774-2783, 2008.

• 33) Ko, HJ, Lee JM, Kim YJ, et al: Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 182: 1818-1828, 2009.
  pubmed

P.114 掲載の参考文献

• 1) Mosmann TR Cherwinski H, Bond MW, et al: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
  pubmed

• 2) Romagnani S: Human TH1 and TH2 subsets: doubt no more. Immunol Today 12: 256-257, 1991.
  pubmed

• 3) Nakae S, Iwakura Y, Suto H, et al: Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 81: 1258-1268, 2007.
  pubmed

• 4) Romagnani S: Regulation of the T cell response. Clin Exp Allergy 36: 1357-1366, 2006.

• 5) Acosta-Rodriguez EV, Rivino L, Geginat J, et al: Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat immunol 8: 639-646, 2007.
  pubmed

• 6) Singh SP, Zhang HH, Foley JF, et al: Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 180: 214-221, 2008.

• 7) 臼井 崇: CD4+ヘルパーT細胞分化の基礎と臨床. 日臨免疫会誌 30: 419-427, 2007.

• 8) Afzali B, Lombardi G, Lechler RI, et al: The role of helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 148: 32-46, 2007.
  pubmed

• 9) Gocke AR, Cravens PD, Ben LH, et al: T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 178: 1341-1348, 2007.
  pubmed

• 10) Park H, Li Y, Yang XO, et al: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141, 2005.

• 11) Wei J, Duramad O, Perng OA, et al: Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 104: 18169-18174, 2007.
  pubmed

• 12) Ziegler SF, Buckner JH: FOXP3 and the regulation of Treg/Th17 differentiation. Microbes Infect 11: 594-598, 2009.
  pubmed

• 13) Bettelli E, Korn T, Kuchroo VK: Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 19: 652-657, 2007.

• 14) Mangan PR, Harrington LE, O'Quinn DB, et al: Transforming growth factor-β induces development of the TH17 lineage. Nature 441: 231-234, 2006.

• 15) Ivanov II, Mckenzie BS, Zhou L, et al: The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133, 2006.

• 16) Zhou L, Lopes JE, Chong MM, et al: TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature 453: 236-240, 2008.

• 17) Fantini MC, Rizzo A, Fina D, et al: IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 37: 3155-3163, 2007.
  pubmed

• 18) Yang XO, Nurieva R, Martinez GJ, et al: Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29: 44-56, 2008.
  pubmed

• 19) Xu L, Kitani A, Fuss I, et al: Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 178: 6725-6729, 2007.

• 20) Kryczek I, Wei S, Vatan L, et al: Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 179: 1423-1426, 2007.
  pubmed

• 21) Kryczek I, Wei S, Zou L, et al: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-6733, 2007.
  pubmed

• 22) Koenen HJPM, Smeets RL, Vink PM, et al: Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112: 2340-2352, 2008.
  pubmed

• 23) Nurieva R, Yang XO, Martinez G, et al: Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448: 480-483, 2007.
  pubmed

• 24) Ichiyama K, Yoshida H, Wakabayashi Y, et al: Foxp3 inhibits RORγt-mediated IL-17 A mRNA transcription through direct interaction with RORγt. J Biol Chem 283: 17003-17008, 2008.

• 25) Iwakura Y, Ishigame H: The IL-23/IL-17 axis in inflammation. J Clin Invest 116: 1218-1222, 2006.
  pubmed

• 26) Tanaka K, Ichiyama K, Hashimoto M, et al: Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-γon STAT3 and Smads. J Immunol 180: 3746-3756, 2008.

• 27) Murugaiyan G, Saha B: Protumor vs antitumor functions of IL-17. J Immunol 183: 4169-4175, 2009.
  pubmed

• 28) Miyahara Y, Odunsi K, Chen W, et al: Generation and regulation of human CD4+IL-17-producing T cells in ovarian cancer. Proc Natl J Acad Sci USA 105: 15505-15510, 2008.

• 29) Muranski P, Boni A, Antony P, et al: Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373, 2008.
  pubmed

• 30) Kryczek I, Banerjee M, Cheng P, et al: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149, 2009.
  pubmed

• 31) Hinrichs CS, Kaiser A, Paulos CM, et al: Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114: 596-599, 2009.
  pubmed

• 32) Benchetrit F, Ciree A, Vives V, et al: Interleukin-17 inhibits tumor cell growth by means of a T-cell dependent mechanism. Blood 99: 2114-2121, 2002.

• 33) Hirahara N, Nio Y, Sasaki S, et al: Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 61: 79-89, 2001.
  pubmed

• 34) Kryczek I, Wei S, Szeliga W, et al: Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114: 357-359, 2009.
  pubmed

• 35) Sharma MD, Hou DY, Liu Y, et al: Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113: 6102-6111, 2009.
  pubmed

• 36) Numasaki M, Watanabe M, Suzuki T, et al: IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175: 6177-6189, 2005.
  pubmed

• 37) Tartour E, Fossiez F, Joyeux I, et al: Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59: 3698-3704, 1999.

• 38) Wang L, Yi T, Kortylewski M, et al: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206: 1457-1464, 2009.

• 39) Langowski JL, Zhang X, Wu L, et al: IL-23 promotes tumor incidence and growth. Nature 442: 461-465, 2006.

• 40) Hu J, Yuan X, Belladonna ML, et al: Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 66: 8887-8896, 2006.

• 41) Kaiga T, Sato M, Kaneda H, et al: Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in associated with the endogenously expressed IL-12. J Immunol 178: 7571-7580, 2007.
  pubmed

E. Immunogenic chemotherapy

P.123 掲載の参考文献

• 1) 折田薫三, 合地 明, 中村修治・他: 腫瘍の免疫逃避機構. Biotherapy 18: 279-294, 2004.
  Medical*Online

• 2) Emens LA, Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65: 8059-8064, 2005.
  pubmed

• 3) Correale P, Aquino A, Giuliani A, et al: Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A (*) 02.01 restricted, CEA- peptide-specific cytotoxic T cells in vitro. Int J Cancer 104: 437-445, 2003.
  pubmed

• 4) Yang S, Haluska FG: Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme? and Fas-mediated pathways. J Immunol 172: 4599-4608, 2004.
  pubmed

• 5) Nowak AK, Robinson BWS, Lake RA: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63: 4490-4496, 2003.
  pubmed

• 6) Bauer C, Bauernfeind F, Sterzik A, et al: Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 56: 1275-1282, 2007.

• 7) Lake RA, van der Most RG: A better way for a cancer cell to die. N Engl J Med 354: 2503-2504, 2006.
  pubmed

• 8) Lohmann C, Muschaweckh A, Kirschnek S, et al: Induction of tumor cell apoptosis or necrosis by conditional expression of cell death proteins: analysis of cell death pathways and in vitro immune stlmulatory potential. J Immunol 182: 4538-4546, 2009.
  pubmed

• 9) Gamrekelashvili J, Kruger C, von Wasielewski R, et al: Necrotic tumor cell death in vivo impairs tumor specific immune responses. J Immunol 178: 1573-1580, 2007.
  pubmed

• 10) van der Most RG, Currie A, Robinson BWS, et al: Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 66: 601-604, 2006.
  pubmed

• 11) Nowak AK, Lake RA, Marzo AL, et al: Induction of tumor cell apoptosis in vivo increases tumor antigencross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170: 4905-4913, 2003.

• 12) Tseng CW, Hung CF, Alvarez RD, et al: Pretreatment with cisplatin enhances E7-specific CD8+ T-cell mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 14: 3185-3192, 2008.
  pubmed

• 13) Tsuda N, Chang DZ, Mine T, et al: Taxol increases the amount and T cell-activating ability of self-immunestimulatory multimolecular complexes found in ovariarl cancer cells. Cancer Res 67: 8378-8387, 2007.

• 14) Byrd-Leifer CA, Block EF, Takeda K, et al: The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 31: 2448-2457, 2001.
  pubmed

• 15) Zimmer, SM, Liu J, Clayton JL, et al: Paclitaxel binding to human and murine MD-2. J Biol Chem 283: 27916-27926, 2008.
  pubmed

• 16) Vicari AP, Luu R, Zhang N, et al: Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 58: 615-628, 2009.

• 17) Williams DB: Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 119: 615-623, 2006.
  pubmed

• 18) Obeid M, Tesniere A, Ghiringhelli F, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61, 2007.
  pubmed

• 19) Obeid M, Panaretakis T, Tesniere A, et al: Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res 67: 7941-7944, 2007.

• 20) Bae SH, Park YJ, Park JB, et al: Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 13: 341-349, 2007.

• 21) Hu DE, Moore AM, Thomsen LL, et al: Uric acid promotes tumor immune rejection. Cancer Res 64: 5059-5062, 2004.
  pubmed

• 22) Melief CJM: Cancer immunotherapy by dendritic cells. Immunity 29: 372-383, 2008.
  pubmed

• 23) Behrens MD, Wagner WM, Krco CJ, et al: The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 111: 1472-1479, 2008.
  pubmed

• 24) Liu G, Zhao, Y: Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+CD25+ T cells. Immunology 122: 149-156, 2007.
  pubmed

• 25) Apetoh L, Ghiringhelli F, Tesniere A, et al: Toll-like receptor 4-dependent contribution of the immunesystem to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059, 2007.

• 26) Curtin JF, Liu N, Candolfi M, et al: HMGBI mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 6: e1000010, 2009.

• 27) Apetoh L, Tesniere A, Ghiringhelli F, et al: Molecular interactions between dying tumor cells and innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 68: 4026-4030, 2008.
  pubmed

• 28) Itescu S, Burke E, Lietz K, et al: Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 105: 1214-1219, 2002.
  pubmed

• 29) Machiels JPH, Reilly RT, Emens LA, et al: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cellvaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-3697, 2001.

• 30) Hermans IF, Chong TW, Palmowski MJ, et al: Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model, Cancer Res 63: 8408-8413, 2003.

• 31) Proietti E, Greco G, Garrone B, et al: Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 101: 429-441, 1998.

• 32) Schiavoni G, Mattei F, Di Pucchio T, et al: Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030, 2000.
  pubmed

• 33) North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155: 1063-1074, 1982.
  pubmed

• 34) Hoover SK, Barrett SK, Turk TMT, et al: Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol Immunother 31: 121-127, 1990.

• 35) Rabinovich GA, Rubinstein N, Matar P, et al: The antimetastatic effect of a single low dose ofcyclophosphamide involves modulation of galectin-1 and Bcl-2 expression. Cancer Immunol Immunother 50: 597-603, 2002.

• 36) Matar P, Rozados VR, Gervasoni SI, et al: Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50: 588-596, 2002.

• 37) Brode S, Cooke A: Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 28: 109-126, 2008.
  pubmed

• 38) Brode S, Raine T, Zaccone P, et al: Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 177: 6603-6612, 2006.
  pubmed

• 39) Lutsiak MEC, Semnani RT, De Pascalis R, et al: Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868, 2005.
  pubmed

• 40) Suzuki E, Kapoor V, Jassar AS, et al: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antituomor immune activity. Clin Cancer Res 11: 6713-6721, 2005.
  pubmed

• 41) Ko HJ, Kim YJ, Kim YS, et al: A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67: 7477-7486, 2007.

• 42) Ercolini AM, Ladle BH, Manning EA, et al: Recruitment of latent pools of high-avidity CD8+ Tcells to the antitumor immune response. J Exp Med 201: 1591-1602, 2005.

• 43) Wada S, Yoshimura K, Hipkiss EL, et al: Cyclophosphamide augments antitumor immunity: studies in anautochthonous prostate cancer model. Cancer Res 69: 4309-4318, 2009.
  pubmed

• 44) Liu JY, Wu Y, Zhang XS, et al: Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 56: 1597-1604, 2007.

• 45) Tong Y, Song W, Crystal RG: Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 61: 7530-7535, 2001.
  pubmed

• 46) Salem ML, Kadima AN, EL-Naggar SA, et al: Defining the ability of cyclophosphamide preconditionig to enhance the antigen-specific CD8+ T-cell respnonse to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30: 40-53, 2007.

• 47) Levy MY, Sidana A, Chowdhury WH, et al: Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J Pharmacol Exp Ther 330: 596-601, 2009.
  pubmed

• 48) Bracci L, Moschella F, Sestili P, et al: Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13: 644-653, 2007.

• 49) Eto M, Kamiryo Y, Takeuchi A, et al: Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. Clin Cancer Res 14: 2833-2840, 2008.
  pubmed

• 50) Berd D, Maguire HC Jr, Mastrangelo MJ: Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46: 2572-2577, 1986.
  pubmed

• 51) Laheru D, Lutz E, Burke J, et al: Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14: 1455-1463, 2008.
  pubmed

• 52) Thomas AM, Santarsiero LM, Lutz ER, et al: Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200: 297-306, 2004.
  pubmed

• 53) Prell RA, Gearin L, Simmons A, et al: The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer Immunol Immunother 55: 1285-1293, 2006.

• 54) Garnett CT, Schlom J, Hodge JW: Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 14: 3536-3544, 2008.
  pubmed

• 55) Zhong H, Han B, Tourkova IL, et al: Low-dose paclitaxel prior to intratumoral dendritic cell vaccinemodulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 13: 5455-5462, 2007.
  pubmed

• 56) Yu B, Kusmartsev S, Cheng F, et al: Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage exprimental breast cancer Clin Cancer Res 9: 285-294, 2003.

• 57) Demaria S, Volm MD, Shapiro RL, et al: Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7: 3025-3030, 2001.
  pubmed

• 58) Rovere-Querini P, Manfredi AA, Sabbadini MG: Environmental adjuvants, apoptosis and the censorship over autoimmunity. Autoimmun Rev 4: 555-560, 2005.
  pubmed

• 59) Carson III WE, Shapiro CL, Crespin TR, et al: Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 10: 3401-3409, 2004.

• 60) Arlen PM, Gulley JL, Parker C, et al: A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12: 1260-1269, 2006.

• 61) Broomfield S, Currie A, van der Most RG, et al: Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 65: 7580-7584, 2005.

• 62) Manegold C, Gravenor D, Woytowitz D, et al: Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3979-3986, 2008.

• 63) Correale P, Cusi MG, Tsang KY, et al: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23: 8950-8958, 2005.
  pubmed

• 64) Correale P, Tagliaferri P, Fioravanti A, et al: Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine＋FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 trial). Clin Cancer Res 14: 4192-4199, 2008.123

• 66) Ghiringhelli F, Menard C, Puig PE, et al: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641-648, 2007.
  pubmed

• 67) Casares N, Pequignot MO, Tesniere A, et al: Caspase-dependent immunogenicity of doxorubicin-inducedtumor cell death. J Exp Med 202: 1691-1701, 2005.

• 68) Correale P, Cusi MG, Del Vecchio MT, et al: Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumoractivity in vitro. J Immunol 175: 820-828, 2005.

• 69) Shurin GV, Tourkova IL, Kaneno R, et al: Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183: 137-141, 2009.

• 70) Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005.
  pubmed

F. 腫瘍免疫関連事項

P.144 掲載の参考文献

• 1) 折田薫三: 癌ワクチン療法におけるCD4+ T細胞の重要性. Biotherapy 21: 19-32, 2007.
  Medical*Online

• 2) Donato I, de la Salle, Hanau D, et al: Association of HLA class I deficiency related to TAP2 gene mutation with familial bronchiectasis. J Pediatr 127: 895-900, 1995.

• 3) Elhasid R, Etzioni A: Major histocompatibility complex class II: a clinical review. Blood Rev 10: 242-248, 1996.
  pubmed

• 4) Nekrep N, Fontes JD, Geyer M, et al: When the lymphocyte loses its clothes. Immunity 18: 453-457, 2003.
  pubmed

• 5) Araki K, Turner AP, Shaffer VO, et al: mTOR regulates memory CD8 T-cell differentiation. Nature 460: 108-112, 2009.
  pubmed

• 6) Keene JA, Forman J: Helper activity is required for the in vivo generation of cytotoxic T lymhocytes. J Exp Med 155: 768-782, 1982.

• 7) Bevan MJ: Helping the CD8+ T-cell response. Nat Rev Immunol 4: 595-602, 2004.
  pubmed

• 8) Sun JC, Bevan MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342, 2003.
  pubmed

• 9) Janssen EM, Lemmens EE, Wolfe T, et al: CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852-856, 2003.
  pubmed

• 10) Sun JC, Williams MA, Bevan MJ: CD4+ Tcells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5: 927-933, 2004.
  pubmed

• 11) Shedlock DJ, Shen H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339, 2003.
  pubmed

• 12) Shedlock DJ, Whitmire JK, Tan J, et al: Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J Immunol 170: 2053-2063, 2003.
  pubmed

• 13) Marzo AL, Vezys V, Klonowski KD, et al: Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol 173: 969-975, 2004.
  pubmed

• 14) Novy P, Quigley M, Huang X, et al: CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol 179: 8243-8251, 2007.
  pubmed

• 15) Shiku H: Importance of CD4+ helper T-cells in antitumor immunity. Int J Hematol 77: 435-438, 2003
  pubmed

• 16) Bennett SRM, Carbone FR, Karamalis F, et al: Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T Cell help. J Exp Med 186: 65-70, 1997.

• 17) Castellino F, Huang AY, Altan-Bonnet G, et al: Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440: 890-895, 2006.
  pubmed

• 18) Xiang J, Huang H, Liu Y: A new dynamic model of CD8+ T effector cell responses via CD4+ T helper antigen-presenting cells. J Immunol 174: 7497-7505, 2005.

• 19) Shi M, Hao S, Chan T, et al: CD4+ T cells stimulate memory CD8+ T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion. J Leukoc Biol 80: 1354-1363, 2006.
  pubmed

• 20) Umeshappa CS, Huang H, Xie Y, et al: CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses. J Immunol 182: 193-206, 2009.
  pubmed

• 21) Kennedy R, Undale AH, Kieper WC et al: Direct cross-priming by the lymphocytes generates memory cytotoxic T cell responses. J Immunol 174: 3967-3977, 2005.
  pubmed

• 22) Hao S, Bai O, Li F, et al: Mature dendritic cells pulsed with exosomes stimulate efficent cytotoxic T lymphocyte responses and antitumor immunity. Immunology 120: 90-102, 2007.

• 23) Hao S, Yuan J, Xiang J: Nonspecific CD4+ T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8+ CTL responses and long-term T cell memory. J Leukoc Biol 82: 829-838, 2007.

• 24) Xia D, Hao S, Xiang J: CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion. J Immunol 177: 2976-2984, 2006.
  pubmed

• 25) Armstrong TD, Clements VK, Ostrand-Rosenberg S: MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol 160: 661-666, 1998.
  pubmed

• 26) Qi L, Rojas JM, Ostrand-Rosenberg S: Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol 165: 5451-5461, 2000.
  pubmed

• 27) Dolan BP, Gibbs Jr KD, Ostrand-Rosenberg S: Tumor-specific CD4+ T cells are activated by "crossdressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol 176: 1447-1455, 2006.

• 28) Thompson JA, Dissanayake SK, Ksander BR, et al: Tumor cells transduced with the MHC class II transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res 66: 1147-1154, 2006.
  pubmed

• 29) Kennedy R, Celis E: T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol 177: 2862-2872, 2006.
  pubmed

• 30) Janssen EM, Droin NM, Lemmens EE, et al: CD4+ T-cell help controls CD8+ T-cell memory via TRAIL mediated activation-induced cell death. Nature 434: 88-93, 2005.
  pubmed

• 31) Williams MA, Holmes BJ, Sun JC et al: Developing and maintaining protective CD8+ memory T cells. Immunol Rev 211: 146-153, 2006.
  pubmed

• 32) Northrop JK, Shen H: CD8+ T-cell memory: only the good ones last. Curr Opin Immunol 16: 451-455, 2004.
  pubmed

• 33) Williams MA, Bevan MJ: Shortening the infectious period does not alter expansion of CD8 T cells but diminishes their capacity to differentiate into memory cells. J Immunol 173: 6694-6702, 2004.
  pubmed

• 34) Kumaraguru U, Suvas S, Biswas PS, et al: Concomitant helper response rescues otherwise low avidity CD8+ memory CTLs to become efficient effectors in vivo. J Immunol 172: 3719-3724, 2004.
  pubmed

• 35) Gao FG, Kammanivong V, Liu WJ, et al: Antigen-specific CD4+ T cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 62: 6438-6441, 2002.

• 36) Hermans IF, Ritchie DS, Yang J, et al: CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 164: 3095-3101, 2000.
  pubmed

• 37) Ludewig B, Bonilla WV, Dumrese T, et al: Perforin-independent regulation of dendritic cell homeostasis by CD8+ T cells in vivo: implications for adaptive immunotherapy. Eur J Immunol 31: 1772-1779, 2001.
  pubmed

• 38) Loyer V, Fontaine P, Pion S, et al: The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-associated epitopes. J Immunol 163: 6462-6467, 1999.

• 39) Mueller SN, Jones CM, Stock AT, et al: CD4+ T cells can protect APC from CTL-mediated elimination. J Immunol 176: 7379-7384, 2006.
  pubmed

• 40) Medema JP, Schuurhuis DH, Rea D, et al: Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 194: 657-667, 2001.

• 41) Nakamura Y, Watchmaker P, Urban J, et al: Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res 67: 10012-10018, 2007.
  pubmed

• 42) Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146, 2003.
  pubmed

• 43) Watchmaker PB, Urban JA, Berk E, et al: Memory CD8+ T cells protect dendritic cells from CTL killing. J Immunol 180: 3857-3865, 2008.
  pubmed

• 44) Andrew KA, Simkins HMA, Witzel S, et al: Dendritic cells treated with lipopolysaccharide up-regulate serine protease inhibitor 6 and remain sensitive to killing by cytotoxic T lymphocytes in vivo. J Immunol 181: 8356-8362, 2008.
  pubmed

• 45) Abdullah Z, Saric T, Kashkar H, et al: Serpin-6 expression protects embryonic stem cells from lysis by antigen-specific CTL. J Immunol 178: 3390-3399, 2007.
  pubmed

• 46) Curtsinger JM, Schmidt CS, Mondino A, et al: Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 162: 3256-3262, 1999.
  pubmed

• 47) Curtsinger JM, Valenzuela LO, Agarwal P, et al: Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174: 4465-4469, 2005.

• 48) van Stipdonk MJ, Lemmens EE, Schoenberger SP: Naive CTLs require a signal brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2: 423-429, 2001.
  pubmed

• 49) Curtsinger JM, Johnson CM, Mescher MF: CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol 171: 5165-5171, 2003.
  pubmed

• 50) Xiao Z, Casey KA, Jameson SC, et al: Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol 182: 2786-2794, 2009.
  pubmed

• 51) Bennet SRM, Carbone FR, Karamalis F, et al: Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 393: 478-480, 1998.

• 52) Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be temporal bridge between a CD4+ T helper and a T-killer cell. Nature 393: 474-478, 1998.

• 53) Schoenberger SP, Toes REM, van der Voort EIH, et al: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483, 1998.

• 54) Hochrein H, Shortman K, Vremec D, et al: Differential production of IL-12, IFN-α, and IFN-γ by mouse dendritic cell subsets. J Immunol 166: 5448-5455, 2001.

• 55) Williams MA, Tyznik AJ, Bevan MJ: Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441: 890-893, 2006.
  pubmed

• 56) Araki Y, Fann M, Wersto R, et al: Histon acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B). J Immunol 180: 8102-8108, 2008.
  pubmed

• 57) Agarwal P, Raghavan A, Nandiwada SL, et al: Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol 183: 1695-1704, 2009.

• 58) Cella M, Scheidegger D, Palmer-Lehmann K, et al: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184: 747-752, 1996.

• 59) Hernandez MGH, Shen L, Rock KL: CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD8+ T cell help. J Immunol 178: 2844-2852, 2007.
  pubmed

• 60) Hernandez MGH, Shen L, Rock KL: CD40 on APCs is needed for optimal programming, maintenance, and recall of CD8+ T cell memory even in the absence of CD4+ T cell help. J Immunol 180:　4382-4390, 2008.
  pubmed

• 61) Bourgeois C, Rocha B, Tanchot C: A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297: 2060-2063, 2002.
  pubmed

• 62) Sun JG, Bevan MJ: Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells. J Immunol 172: 3385-3389, 2004.

• 63) Montfort MJ, Bouwer HG, Wagner CR, et al: The development of functional CD8 T cell memory after Listeria monocytogenes infection is not dependent on CD40. J Immunol 173: 4084-4090, 2004.

• 64) Bachmann MF, Schwarz K, Wolint P, et al: Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells. J Immunol 173: 2217-2221, 2004.

• 65) Agnellini P, Wiesel M, Schwarz K, et al: Kinetic and mechanistic requirements for helping CD8 T cells. J Immunol 180: 1517-1525, 2008.
  pubmed

• 66) Hendriks J, Xiao Y, Rossen JWA, et al: During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J Immunol 175: 1665-1676, 2005.
  pubmed

• 67) Croft M: Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3: 609-620, 2003.
  pubmed

• 68) Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23-68, 2005.
  pubmed

• 69) Redmond WL, Weinberg AD: Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 27: 415-436, 2007.
  pubmed

• 70) Soroosh P, Ine S, Sugamura K, et al: OX-40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. J Immunol 176: 5975-5987, 2006.

• 71) Soroosh P, Ine S, Sugamura K, et al: Differential requirements for OX40 signals on generation of effector and central memory CD4+ T cells. J Immunol 179: 5014-5023, 2007.
  pubmed

• 72) Mousavi SF, Soroosh P, Takahashi T, et al: OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells. J Immunol 181: 5990-6001, 2008.
  pubmed

• 73) Jenkins SJ, Perona-Wright G, Worsley AGF, et al: Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarizing, signal for optimal Th2 priming and memory induction in vivo. J Immunol 179: 3515-3523, 2007.

• 74) Mendel I, Shevach EM: Activated T cells express the OX40 ligand: requirements for induction and costimulatory function. Immunology 117: 196-204, 2006.
  pubmed

• 75) Borst J, Hendriks J, Xiao Y: CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 17: 275-281, 2005.

• 76) Sanchez PJ, McWilliams JA, Haluszczak C, et al: Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo.J Immunol 178: 1564-1572, 2007.
  pubmed

• 77) Hendriks J, Gravestein LA, Tesselaar K, et al: CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 1: 433-440, 2000.
  pubmed

• 78) Rowley TF, Al-Shamkhani A: Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J Immunol 172: 6039-6046, 2004.
  pubmed

• 79) Yamada A, Salama AD, Sho M, et al: CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo.J Immunol 174: 1357-1364, 2005.
  pubmed

• 80) Hendriks J, Xiao Y, Borst J: CD27 promotes the survival of activated T cells and complements CD28 in genration and establishment of the effector T cell pool. J Exp Med 198: 1369-1380, 2003.

• 81) Arens R, Schepers K, Nolte MA, et al: Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med 199: 1595-1605, 2004.
  pubmed

• 82) Matter MS, Claus C, Ochsenbein AF: CD4+ T cell help improves CD8+ T cell memory by retained CD27 expression. Eur J Immunol 38: 1847-1856, 2008.
  pubmed

• 83) Xiao Y, Peperzak V, Keller AM, et al: CD27 instructs CD4+ T cells to provide help for the memory CD8+ T cell response after protein immunization. J Immunol 181: 1071-1082, 2008.
  pubmed

• 84) Bullock TNJ, Yagita H: Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J Immunol 174: 710-717, 2005.
  pubmed

• 85) Keller AM, Xiao Y, Peperzak V, et al: Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting. Blood 113: 5167-5175, 2009.

• 86) Hermans IF, Silk JD, Gileadi U, et al: NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171: 5140-5147, 2003.
  pubmed

• 87) Fujii S, Liu K, Smith C, et al: The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation.J Exp Med 199: 1607-1618, 2004.
  pubmed

• 88) Taraban VY, Martin S, Attfield KE, et al: Invariant NKT cells promote CD8+ T cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J Immunol 180: 4615-4620, 2008.
  pubmed

• 89) Yi KH, Nechushtan H, Bowers WJ, et al: Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Res 67: 10027-10037, 2007.
  pubmed

• 90) Zhang H, Snyder KM, Suhoski MM, et al: 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 179: 4910-4918, 2007.
  pubmed

• 91) Habib-Agahi M, Phan TT, Searle PF: Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol 19: 1383-1394, 2007.

• 92) Hernandez J, Aung S, Marquardt K, et al: Uncoupling of proliferative potential and gain of effector function by CD8+ T cells responding to self-antigens. J Exp Med 196: 323-333, 2002.
  pubmed

• 93) Curtsinger JM, Lins DC, Mescher MF: Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197: 1141-1151, 2003.
  pubmed

• 94) Kolumam GA, Thomas S, Thompson LJ, et al: Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in responses to viral infection. J Exp Med 202: 637-650, 2005.

• 95) Sharfe N, Dadi HK, Shahar M, et al: Human immune disorder arising from mutation of the α-chin of the interleukin-2 receptor. Proc Natl Acad Sci USA 94: 3168-3171, 1997.

• 96) O'Gorman WE, Dooms H, Thorne SH, et al: The initial phase of an immune response functions to activate regulatory T cells. J Immunol 183: 332-339, 2009.
  pubmed

• 97) Wilson EB, Livingstone AM: Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses. J Immunol 181: 7445-7448, 2008.
  pubmed

• 98) Blachere NE, Morris HK, Braun D, et al: IL-2 is required for the activation of memory CD8+ T cells via antigen cross-presentation. J Immunol 176: 7288-7300, 2006.
  pubmed

• 99) Fuse S, Zhang W, Usherwood EJ: Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J Immunol 180: 1148-1157, 2008.
  pubmed

• 100) Boyman O, Kovar M, Rubinstein MP, et al: Selective stimulation of cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927, 2006.
  pubmed

• 101) Mostbock S, Lutsiak MEC, Milenic DE, et al: IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells. J Immunol 180: 5118-5129, 2008.
  pubmed

• 102) Molloy MJ, Zhang W, Usherwood EJ: Cutting edge: IL-2 immune complexes as a therapy for persistent virus infection. J Immunol 182: 4512-4515, 2009.
  pubmed

• 103) Wilson MS, Pesce JT, Ramalingam TR, et al: Suppression of murine allergic airway disease by IL-2: anti-IL-2-monoclonal antibody-induced regulatory T cells. J Immunol 181: 6942-6954, 2008.
  pubmed

• 104) Curtsinger JM, Gerner MY, Lins DC, et al: Signal 3 availability limits the CD8 T cell response to a solid tumor.J Immunol 178: 6752-6760, 2007.
  pubmed

• 105) Pearce EL, Shen H: Generation of CD8 T cell memory is regulated by IL-12. J Immunol 179: 2074-2081, 2007.
  pubmed

• 106) Takemoto N, Intlekofer AM, Northrup JT, et al: Cutting edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J Immunol 177: 7515-7519, 2006.
  pubmed

• 107) Henry CJ, Ornelles DA, Mitchell LM: IL-12 produced by dendritic cell augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol 181: 8576-8584, 2008.
  pubmed

• 108) Havenar-Daughton C, Kolumam GA, Murali-Krishna K: Cutting edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 176: 3315-3319, 2006.

• 109) Aichele P, Unsoeld H, Koschella M, et al: CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J Immunol 176: 4525-4529, 2006.
  pubmed

• 110) Luft T, Pang KC, Thomas E, et al: Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161: 1947-1953, 1998.
  pubmed

• 111) Le Bon A, Etchart N, Rossmann C, et al: Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4: 1009-1015, 2003.
  pubmed

• 112) Tough DF, Borrow P, Sprent J: Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272: 1947-1950, 1996.
  pubmed

• 113) Mattei F, Schiavoni G, Belardelli F, et al: IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation.J Immunol 167: 1179-1187, 2001.
  pubmed

• 114) Sikora AG, Jaffarzad N, Hailemichael Y, et al: IFN-α enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antituomor activity. J Immunol 182: 7398-7407, 2009.

• 115) Di Pucchio T, Pilla L, Capone I, et al: Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors. Caner Res 66: 4943-4951, 2006.

• 116) Critchley-Thorne RJ, Simons DL, Yan N, et al: Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 106: 9010-9015, 2009.
  pubmed

• 117) Gogas H, Ioannovich J Daftin U, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709-718, 2006.

• 118) Bottomley A, Coens C, Suciu S, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 27: 2916-2923, 2009.

• 119) Bouwhuis MG, Suciu S, Collette S, et al: Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 101: 869-877, 2009.
  pubmed

• 120) Ramos HJ, Davis AM, Cole AG, et al: Reciprocal responsiveness to interleukin-12 and interferon-α specifies human CD8+effector versus central memory T-cell fates. Blood 113: 5516-5525, 2009.

• 121) Prlic M, Lefrancois L, Jameson SC: Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin IL-15. J Exp Med 195: F49-52, 2002.
  pubmed

• 122) Seder RA, Ahmed R: Similarities and differences in CD4+and CD8+effector and memory T cell generation. Nat Immunol 4: 835-842, 2003.
  pubmed

• 123) Schluns KS, Lefrancois L: Cytokine control of memory T-cell development and survival. Nat Rev Immunopl 3: 269-279, 2003.
  pubmed

• 124) Becker TC, Wherry EJ, Boone D, et al: Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 195: 1541-1548, 2002.
  pubmed

• 125) Goldrath AW, Sivakumar PV, Glaccum M, et al: Cytokine requirements for acute and basal homeostatic proliferation Of naive and memory CD8+ T cells. J EXp Med 195: 1515-1522, 2002.
  pubmed

• 126) Schluns KS, Klonowski KD, Lefrancois L: Transregulation of memory CD8 T-cell proliferation by IL-15Rα+bone marrow-derived cells. Blood 103: 988-994, 2004.

• 127) Berard M, Brandt K, Bulfoner-Paus S, et al: IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol 170: 5018-5026, 2003.

• 128) Surh CD, Boyman O, Purton JF, et al: Homeostasis of memory T cells. Immunol Res 211: 154-163, 2006.

• 129) Ma A, Koka R, Burkett P: Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 24: 657-679, 2006.
  pubmed

• 130) Schluns KS, Stoklasek T, Lefrancois L: The role of interleukin-15 receptor alpha: trans-presentation, receptor component, or both? Int J Biochem Cell Biol 37: 1567-1571, 2005.
  pubmed

• 131) Kokaji AI, Hockley DL, Kane KP: IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells. J Immunol 180: 4391-4401, 2008.
  pubmed

• 132) Stonier SW, Ma LJ, Castillo EF, et al: Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation. Blood 112: 4546-4554, 2008.
  pubmed

• 133) Oh S, Perera LP, Terabe M, et al: IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci USA 105: 5201-5206, 2008.
  pubmed

• 134) Morandi B, Mortara L, Carrega P, et al: NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. Int Immunol 21: 599-606. 2009.
  pubmed

• 135) Mortier E, Woo T, Advincula R, et al: IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 205: 1213-1225, 2008.

• 136) Zhang M, Yao Z, Dubois S, et al: Interleukin-15 combined with an anti-CD40 antibocy provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci USA 106: 7513-7518, 2009.

• 137) Stoklasek TA, Schluns KS, Lefrancois L: Combined IL-15/1L-15Rα immunotherapy maximizes IL-15 activity in vivo. J Immunol 177: 6072-6080, 2006.

• 138) Rubinstein MP, Kovar M, Purton JF, et al: Converting IL-15 to superagonist by binding to soluble IL-15Rα. Proc Natl Acad Sci USA 103: 9166-9171, 2006.

• 139) Epardaud M, Elpek KG, Rubinstein MP, et al: Interleukin-15/interleukin-15Rα complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 68: 2972-2983, 2008.

• 140) Fry TJ, Mackall CL: The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 174: 6571-6576, 2005.
  pubmed

• 141) Kaech SM, Tan MJ, Wherry JT, et al: Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4: 1191-1198, 2003.

• 142) Bachmann MF, Wolint P, Schwarz K, et al: Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor α and CD62L. J Immunol 175: 4686-4696, 2005.

• 143) Huster KM, Busch V, Schiemann M, et al: Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci USA 101: 5610-5615, 2004.
  pubmed

• 144) Yang Y, An J, Weng NP: Telomerase is involved in IL-7-mediated differential survival of naive and memory CD4+ T cells. J Immunol 180: 3775-3781, 2008.

• 145) Colpitts SL, Dalton NM, Scott P: IL-7 receptor expression provides the potential for long-term survival of both CD62Lhigh central memory T cells and Th1 effector cells during Leishmania major infection. J Immunol 182: 5702-5711, 2009.
  pubmed

• 146) Rosenberg SA, Sportes C, Ahmadzadeh M, et al: IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 29: 313-319, 2006.

• 147) Andersson A, Yang SC, Huang M, et al: IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 182: 6951-6958, 2009.
  pubmed

• 148) Boyman O, Ramsey C, Kim DM, et al: IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J Immunol 180: 7265-7275, 2008.
  pubmed

• 149) Casey KA, Mescher MF: IL-21 promotes differentiation of naive CD8 cells to a unique effector phenotype. J Immunol 178: 7640-7648, 2007.
  pubmed

• 150) Thedrez A, Harly C, Morice A, et al: IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human Vγ9 Vδ2 T cells for adoptive immunotherapy. J Immunol 182: 3423-3431, 2009.

• 151) Thompson JA, Curti BD, Redman BG, et al: Phase I study of recombinant inerleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 26: 2034-2039, 2008.

• 152) Davis ID, Brady B, Kefford RF, et al: Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase II a trial. Clin Cancer Res 15: 2123-2129, 2009.

• 153) Johnson LD, Jameson SC: Immunology: A chronic need for IL-21. Science 324: 1525-1526, 2009.
  pubmed

• 154) de Goer de Herve MG, Cariou A, Simonetta F, et al: Heterospecific CD4 help to rescue CD8 T cell killers. J Immunol 181: 5974-5980, 2008.
  pubmed

• 155) Casares N, Lasarte JJ, de Cerio AL, et al: Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicites protective CTL immunity. Eur J Immunol 31: 1780-1789, 2001.

• 156) Kikuchi T, Uehara S, Ariga H, et al: Augmented induction of CD8+ cytotoxic T-cell response and antitumor resistance by T helper type I-induced peptide. Immunology 117: 47-58, 2006.

• 157) Hosoi A, Takeda Y, Furuichi Y, et al: Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization. Cancer Res 68: 3941-3949, 2008.
  pubmed

• 158) Castellino F, Germain RN: Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 24: 519-540, 2006.
  pubmed

• 159) Behrens G, Li M, Smith CM, et al: Helper T cells, dendritic cells, and CTL immunity. Immmunol Cell Biol 82: 84-90, 2004.
  pubmed

• 160) Wong SBJ, Bos R, Sherman LA: Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ cells. J Immunol 180: 3122-3131, 2008.
  pubmed

• 161) Marzo AL, Kinnear BF, Lake RA, et al: Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 165: 6047-6055, 2000.

• 162) Kumaraguru U, Banerjee K, Rouse BT: In vivo rescue of defective memory CD8+ T cells by cognate helper T cells. J Leukoc Biol 78: 879-887, 2005.
  pubmed

• 163) Wang L, Miyahara Y, Kato T, et al: Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine. Cancer Immun 3: 16-28, 2003.
  pubmed

• 164) Hwang ML, Lukens JR, Bullock TNJ: Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control. J Immunol 179: 5829-5838, 2007.
  pubmed

• 165) Perez-Diez A, Joncker NT, Choi K, et al: CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354, 2007.
  pubmed

• 166) Melero I: Antitumor T-cell wars: do CD4s outwit CD8s? Blood 109: 5070-5071, 2007.

• 167) Liu Z, Noh HS, Chen J, et al: Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol 181: 4363-4370, 2008.
  pubmed

• 168) Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-I. N Engl J Med 358: 2698-2703, 2008.

• 169) Melief CJ, Van Der Burg SH, Toes RE, et al: Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188: 177-182, 2002.
  pubmed

• 170) Germeau C, Ma W, Schiavetti F, et al: High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201: 241-248, 2005.
  pubmed

• 171) Van Epps HL: Jump-starting tumor-specific T cells. J Exp Med 201: 163, 2005.

• 172) Carrasco J, Van Pel A, Neyns B, et al: Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.J Immunol 180: 3585-3593, 2008.

• 173) Lehmann PV, Forsthuber T, Miller A, et al: Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358: 155-157, 1992.
  pubmed

• 174) Neville KL, Dal Canto MC, Bluestone JA, et al: CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease. J Virol 74: 8349-8357, 2000.

• 175) Vignard V, Lemercier B, Lim A, et al: Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol 175: 4797-4805, 2005.
  pubmed

• 176) Phan V, Disis ML: Tumor-specific Th1 lymphocytes: modulation of the tumor microenvironment to enhance cross-priming. Am ASSOC Cancer Res (AACR) Educ Book 2009: 199-202, 2009.

• 177) Rapetti L, Meunnier S, Pontoux C, et al: CD4 help regulates expression of crucial genes involved in CD8 T cell memory and sensitivity to regulatory elements. J Immunol 181: 299-308, 2008.

• 178) Badovinac VP, Messingham KA, Griffith TS, et al: TRAIL deficiency delays, but does not prevent, erosion in the quality of "helpless" memory CD8 T cells. J Immunol 177: 999-1006, 2006.

• 179) Sacks JA, Bevan MJ: TRAIL deficiency does not rescue impaired CD8+ T cell memory generated in the absence of CD4+ T cell help. J Immunol 180: 4570-4576, 2008.

• 180) Fuse S, Tsai CY, Molloy MJ, et al: Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1. J Immunol 182: 4244-4254, 2009.
  pubmed

• 181) Chikuma S, Terawaki S, Hayashi T, et al: PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol 182: 6682-6689, 2009.
  pubmed

• 182) Barber D, Wherry EJ, Masopust D, et al: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687, 2006.
  pubmed

• 183) Bucks CM, Norton JA, Boesteanu AC, et al: Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol 182: 6697-6708, 2009.
  pubmed

• 184) Intlekofer AM, Takemoto N, Kao C, et al: Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. J Exp Med 204: 2015-2021, 2007.

• 185) Kilinc MO, Aulakh KS, Nair RE, et al: Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 177: 6962-6973, 2006.
  pubmed

• 186) Kilinc MO, Gu T, Harden JL, et al: Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J immunol 182: 4217-4225, 2009.
  pubmed

P.155 掲載の参考文献

• 1) Joly E, Hudrisier D: What is trogocytosis and what is its purpose? Nat Immunol 4: 815, 2003.
  pubmed

• 2) Hudrisier D, Bongrand P: Intercellular transfer of antigen-presenting cell determinants onto T cells: molecular mechanisms and biological significance. FASEB J 16: 477-486, 2002.
  pubmed

• 3) LeMaoult J, Caumartin J, Carosella ED: Exchanges of membrane patches (trogocytosis) split theoretical and actual functions of immune cells. Hum Immunol 68: 240-243, 2007.
  pubmed

• 4) Brown K, Sacks SH, Wong W: Extensive and bidirectional transfer of major histocompatibility complex class II molecules between donor and recipient cells in vivo following solid organ transplantation. FASEB J 22: 3776-3784, 2008.
  pubmed

• 5) LeMaoult J, Caumartin J, Daouya M, et al: Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 109: 2040-2048, 2007.
  pubmed

• 6) Wiendl H: Fast track to becoming a regulatory T cell: "trogocytosis" of immune-tolerogenic HLA-G. Blood 109: 1796-1797, 2007.

• 7) Hudrisier D, Aucher A, Puaux AL, et al: Capture of target cell membrane components via trogocytosis is triggered by a selected set of surface molecules on T or B cells. J Immunol 178: 3637-3647, 2007.
  pubmed

• 8) Busch A, Quast T, Keller S, et al: Transfer of T cell surface molecules to dendritic cells upon CD4+ T cell priming involves two distinct mechanisms. J Immunol 181: 3965-3973, 2008.
  pubmed

• 9) Harshyne L, Zimmer MI, Watkins SC, et al: A role for class A scavenger receptor in dendritic cell nibbling from live cells. J Immunol 170: 2302-2309, 2003.

• 10) Dolan BP, Gibbs Jr KD, Ostrand-Rosenberg S: Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol 177: 6018-6024, 2006.

• 11) Roda-Navarro P, Reyburn HT: Intercellular protein transfer at the NK cell immune synapse: mechanisms and physiological significance. FASEB J 21: 1636-1646, 2007.
  pubmed

• 12) Vanherberghen B, Andresson K, Carlin LM, et al: Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. Proc Natl Acad Sci USA 101: 16873-16878, 2004.

• 13) Tabiasco J, Espinosa E, Hudrisier D, et al: Active trans-synaptic capture of membrane fragments by natural killer cells. Eur J Immunol 32: 1502-1508, 2002.
  pubmed

• 14) Roda-Navarro P, Vales-Gomez M, Chisholm SE, et al: Trasfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc Natl Acad Sci USA 103: 11258-11263, 2006.

• 15) McCann FE, Eissmann P, Onfelt B, et al: The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences. J Immunol 178: 3418-3426, 2007.

• 16) Espinosa E, Tabiasco J, Hudrisier D, et al: Synaptic transfer by humanγδ T cells stimulated with soluble or cellular antigens. J Immunol 168: 6336-6343, 2002.

• 17) Pardigon N, Takeda K, Saunier B, et al: CD8αα-mediated intraepithelial lymphocyte snatching of thymic leukemia MHC class I b molecules in vitro and in vivo. J Immunol 177: 1590-1598, 2006.

• 18) Fischer K, Voelkl S, Heymann J, et al: Isolation and characterization of human antigen-specific TCRαβ+CD4-CD8- double-negative regulatory T cells. Blood 105: 2828-2835, 2005.

• 19) Ford McIntyre MS, Young KJ, Gao J, et al: Cutting edge: In vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression. J Immunol 181: 2271-2275, 2008.
  pubmed

• 20) Zhou J, Tagaya Y, Tolouei-Semnani R, et al: Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs. Blood 105: 3238-3246, 2005.
  pubmed

• 21) Xiang J, Huang H, Liu Y: A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J Immunol 174: 7497-7505, 2005.

• 22) Wetzel SA, Parker D: MHC transfer from APC to T cells following antigen recognition. Crit Rev Immunol 26: 1-21, 2006.

• 23) Kennedy R, Undale AH, Kieper WC, et al: Direct cross-priming by Th lymphocytes generates memory cytotoxic T cell responses. J Immunol 174: 3967-3977, 2005.
  pubmed

• 24) Shi M, Hao S, Chan T, et al: CD4+ T cells stimulate memory CD8+ T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 secretion. J Leukoc Biol 80: 1354-1363, 2006.
  pubmed

• 25) Helft J, Jacquet A, Joncker NT, et al: Antigen-specific T-T interactions regulate CD4 T-cell expansion. Blood 112: 1249-1258, 2008.

• 26) Huang JF, Yang Y, Sepulveda H, et al: TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science 286: 952-954, 1999.

• 27) Cox JH, McMichael AJ, Screaton GR, et al: CTLs target Th cells that acquire bystander MHC class I-peptide complex from APCs. J Immunol 179: 830-836, 2007.
  pubmed

• 28) Xia D, Hao S, Xiang J: CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion. J Immunol 177: 2976-2984, 2006.
  pubmed

• 29) Urosevic M, Dummer R: Human leukocyte antigen-G and cancer immunoediting. Cancer Res 68: 627-630, 2008.
  pubmed

• 30) Caumartin J, Favier B, Daouya M, et al: Trogocytosis-based generation of suppressive NK cells. EMBO J 26: 1423-1433, 2007.
  pubmed

P.169 掲載の参考文献

• 1) Matzinger P: The danger model: a renewed sense of self. Science 296: 301-305, 2002.

• 2) 折田薫三, 合地 明, 中村修治・他: Danger signal, Toll-like receptor と癌免疫療法. Biotherapy 16: 204- 210, 2002.

• 3) Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145, 2001.
  pubmed

• 4) Kapsenberg ML: Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 3: 984-993, 2003.
  pubmed

• 5) Kaczorowski DJ, Mollen KP, Edmonds R, et al: Early events in the recognition of danger signals after tissue injury. J Leukoc Biol 83: 546-552, 2008.
  pubmed

• 6) Liu G, Zhao Y: Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+CD25+ T cells. Immunology 122: 149-156, 2007.
  pubmed

• 7) Kadowaki N, Ho S, Antonenko S, et al: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194: 863-869, 2001.
  pubmed

• 8) Jarrossay D, Napolitani G, Colonna M, et al: Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31: 3388-3393, 2001.
  pubmed

• 9) Smits EL, Ponsaerts P, Berneman ZN, et al: The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13: 859-875, 2008.
  pubmed

• 10) Schon MP, Schon M: TLR7 and TLR8 as targets in cancer therapy. Oncogene 27: 190-199, 2008.
  pubmed

• 11) Kawai T, Akira S: TLR signaling. Semin Immunol 19: 24-32, 2007.

• 12) Gelman AE, Zhang J, Choi Y, et al: Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172: 6065-6073, 2004.
  pubmed

• 13) Mercier BC, Cottalorda A, Coupet CA, et al: TLR2 engagement on CD8 T cells enables generation of functionl memory cells in response to a suboptimal TCR signal. J Immunol 182: 1860-1867, 2009.

• 14) Xu D, Liu H, Komai-Koma M: Direct and indirect role of Toll-like receptors in T cell mediated immunity. Cell Mol immunol 1: 239-246, 2004.

• 15) Peng G, Guo Z, Kiniwa Y, et al: Toll-like receptor 8-mdiated reversal of CD4+ regulatory T cell function. Science 309: 1380-1384, 2005.

• 16) Kiniwa Y, Miyahara Y, Wang HY, et al: CD8+Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13: 6947-6958, 2007.
  pubmed

• 17) Datta SK, RedeckeV, Prilliman KR, et al: A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 170: 4102-4110, 2003.
  pubmed

• 18) Cho HJ, Hayashi T, Datta SK, et al: IFN-αβpromote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol 168: 4907-4913, 2002.

• 19) Salio M, Palmowski MJ, Atzberger A, et al: CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T-cell responses to endogenous but not exogenous antigens. J Exp Med 199: 567-579, 2004.

• 20) Mourios J, Moron G, Schlecht G, et al: Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112: 3713-3722, 2008.

• 21) Zietara N, Lyszkiewicz M, Gekara N, et al: Absence of IFN-βimpairs antigen presentation capacity of splenic dendritic cells via down-regulation of heat shock protein 70. J Immunol 183: 1099-1109, 2009.

• 22) Huang B, Zhao J, Li H, et al: Toll-like receptors on tumor cells facilitate evasion of immune surveillance.Cancer Res 65: 5009-5014, 2005.

• 23) Szczepanski MJ, Czystowska M, Szajinik M, et al: Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69: 3105-3113, 2009.

• 24) Kelly MG, Alvero AB, Chen R, et al: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66: 3859-3868, 2006.
  pubmed

• 25) Bunt SK, Clements VK, Hanson EM, et al: Inflammation enhances myeloid-derived suppressor cell crosstalk by signaling through Toll-like receptor 4. J Leuhoc Biol 85: 996-1004, 2009.
  pubmed

• 26) Andreani V, Gatti G, Simonella L, et al: Activation of Tol-like receptor 4 on tumor cells in vitro inhibits subsequent growth in vivo. Cancer Res 67: 10519-10527, 2007.

• 27) Chan T, Chen Z, Hao S, et al: Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis. Cancer Gene Ther 14: 409-420, 2007.

• 28) Koido S, Hara E, Homma S, et al: Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J Immunol 179: 4874-4883, 2007.

• 29) Shackleton M, Davis ID, Hopkins W, et al: The impact of imiquimod, a Toll-like receptor-7ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 4: 9, 2004.
  pubmed

• 30) Adams S, O'Neill DW, Nonaka D, et al: Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181: 776-784, 2008.

• 31) Horkheimer I, Quigley M, Zhu J, et al: Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation. Blood 113: 5330-5339, 2009.
  pubmed

• 32) Haining WN, Davies J, Kanzler H, et al: CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res 14: 5626-5634, 2008.
  pubmed

• 33) McBride S, Hoebe K, Georgel P, et al: Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J Immunol 177: 6122-6128, 2006.
  pubmed

• 34) Ngoi SM, Tovey MG, Vella AT: Targeting poly (I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-α/β. J Immunol 181: 7670-7680, 2008.

• 35) Pulko V, Liu X, Krco CJ, et al: TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol 183: 3634-3641, 2009.
  pubmed

• 36) Osterloh A, Kalinke U, Weiss S, et al: Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide. J Biol Chem 282: 4669-4680, 2007.
  pubmed

• 37) Akazawa T, Masuda H, Saeki Y, et al: Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 64: 757-764, 2004.
  pubmed

• 38) Yang Y, Huang CT, Huang X, et al: Persistent toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5: 508-515, 2004.

• 39) Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484, 2006.
  pubmed

• 40) Krieg AM, Efler SM, Wittpoth M, et al: Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 27: 460-471, 2004.

• 41) Sparwasser T, Vabulas RM, Villmow B, et al: Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 30: 3591-3697, 2000.
  pubmed

• 42) Pashenkov M, Goess G, Wagner C, et al: Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24: 5716-5724, 2006.
  pubmed

• 43) Manegold C, Gravenor D, Woytowitz D, et al: Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3979-3986, 2008.

• 44) Curri AJ, van der Most RG, Broomfield SA, et al: Targeting the effector site with IFN-αβ-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol 180: 1535-1544, 2008.

• 45) Dumond FJ, Coker LZ: Interferon α/β enhances the expression of Ly-6 antigens on T cells in vivo and in vitro. Eur J Immunol 16: 735-740, 1986.

• 46) Grauer OM, Molling JW, Bennink E, et al: TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 181: 6720-6729, 2008.
  pubmed

• 47) Sharma S, Dominguez AL, Manrique SZ, et al: Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neu T tolerant mice. Cancer Res 68: 7530-7540, 2008.

• 48) Molenkamp BG, van Leeuwen PA, Meijer S, et al: Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13: 2961-2969, 2007.
  pubmed

• 49) Molenkamp BG, Sluijter BJR, van Leeuwen PAM, et al: Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 14: 4532-4542, 2008.

• 50) Hofmann MA, Kors C, Audring H, et al: Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31: 520-527, 2008.
  pubmed

• 51) Gotoh K, Gouchi A, Akura Y, et al: Augmentation of cytotoxicity of tumor-infltrating lymphocytes by biological response modifiers. Int J Immunopharmacol 13: 485-492, 1991.

• 52) 小林元壮: OK-432 腫瘍内注入による胃癌所属リンパ節リンパ球の抗腫瘍能の増強. 日外会誌 91: 68-75, 1990.

• 53) Gouchi A, Orita K, Fuchimoto S, et al: The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 84: 443-451, 2001.

• 54) Itoh T, Ueda Y, Okugawa K, et al: Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother 52: 207-214, 2003.
  pubmed

• 55) Okamoto M, Oshikawa T, Tano T, et al: Involvement of toll-like receptor 4 signaling in interferon-γproduction and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 95: 316-326, 2003.

• 56) Okamoto M, Furuichi S, Nishioka Y, et al:Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64: 5461-5470, 2004,
  pubmed

• 57) Hill KS, Errington F, Steele LP, et al: OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. J Immunol 181: 3108-3115, 2008.
  pubmed

• 58) Saito K, Yajima T, Nishimura H, et al: Soluble branchedβ-(1,4) glucans from Acetobacter species show strong activities to induce interleukin-12 in vitro and inhibit T-helper 2 cellular response with immunoglobulin E production in vivo. J Biol Chem 278: 38571-38578, 2003.

• 59) Gautier G, Humbert M, Deauvieau F, et al: A type I interferon autocrine-paracrine loop is involved in tolllike receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 201: 1435-1446, 2005.
  pubmed

• 60) Kilinc MO, Gu T, Harden JL, et al: Central role of tumor-associated CD8+ Teffector/memory cells in restoring systemic antitumor immunity. J Immunol 182: 4217-4225, 2009.

• 61) Mazzolini G, Alfaro C, Sangro B, et al: Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 23: 999-1010, 2005.
  pubmed

• 62) Hervas-Stubbs S, Olivier A, Boisgerault F, et al: TLR 3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood 109: 5318-5326, 2007.
  pubmed

• 63) Ahonen CL, Doxsee CL, McGurran SM, et al: Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199: 775-784, 2004.
  pubmed

• 64) Ahonen CL, Wasiuk A, Fuse S, et al: Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 111: 3116-3125, 2008.
  pubmed

• 65) Assudani D, Cho HI, DeVito N, et al: In vivo expansion, persistence, and function of peptide vaccineinduced CD8 T cells occur independently of CD4 T cells. Cancer Res 68: 9892-9899, 2008.
  pubmed

• 66) Kajino K, Nakamura I, Bamba H, et al: Involvement of IL-10 in exhaustion of myeloid dendritic cells and rescue by CD40 stimulaton. Immunology 120: 28-37, 2007.

• 67) Broomfield SA, van der Most RG, Prosser AG, et al: Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.J Immunol 182: 5217-5224, 2009.

G. 免疫抑制T細胞

P.172 掲載の参考文献

• 1) Gershon RK, Kondo K: Infectious immunological tolerance. Immunology 21: 903-914, 1971.
  pubmed

• 2) Sakaguchi S, Takahashi T, Nishizuka Y: Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. J Exp Med 156: 1577-1586, 1982.

• 3)Sakaguchi S, Sakaguchi N, Asano M, et al: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164, 1995.
  pubmed

• 4) Sakaguchi S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352, 2005.
  pubmed

• 5) Wickelgren I: Policing the immune system. Science 306: 5696-5699, 2004.
  pubmed

• 6) Beyer M, Schultze JL: Regulatory T cells in cancer. Blood 108: 804-811, 2006.
  pubmed

• 7) Lopez M, Aguilera R, Perez C, et al: The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines. Immunobiology 211: 127-136, 2006.
  pubmed

P.187 掲載の参考文献

• 1) Takahashi T, Kuniyasu Y, Toda M, et al: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int mmunol 10: 1969-1980, 1998.
  pubmed

• 2) Zhao DM, Thornton AM, DiPaolo RJ, et al: Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107: 3925-3932, 2006.

• 3) Ghiringhelli F, Menard C, Terme M, et al: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 202: 1075-1085, 2005.

• 4) Veldhoen M, Moncrieffe H, Hocking RJ, et al: Modulation of dendritic cell function by naive and regulatory CD4+ T cells. J Immunol 176: 6202-6210, 2006.
  pubmed

• 5) Watanabe N, Wang Y-H, Lee HK, et al: Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 436: 1181-1185, 2005.

• 6) 新田 剛, 高浜洋介: 中枢性トレランスと自己免疫疾患. Jpn J Clin Immunol 29: 8-15, 2006.

• 7) Tai X, Cowan M, Feigenbaum L, et al: CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 6: 152-162, 2005.
  pubmed

• 8) Andersson J, Stefanova I, Stephens GL, et al: CD4+CD25+ regulatory T cells are activated in vivo by recognition of self. Int Immunol 19: 557-566, 2007.

• 9) Cupedo T, Nagasawa M, Weijer K, et al: Development and activation of regulatory T cells in the human fetus. Eur J Immunol 35: 383-390, 2005
  pubmed

• 10) Fujimaki W, Takahashi N, Ohnuma K, et al: Comparative study of regulatory T cell function of human CD25+CD4+ T cells from thymocytes, cord blood, and adult peripheral blood. Clin Dev Immunol 2008: 305859, 2008.
  pubmed

• 11) Miyara M, Yoshioka Y, Kitoh A, et al: Functional delination and differentiation dynamics of human CD4+ T cells expressing the Foxp3 transcription factor. Immunity 30: 899-911, 2009.

• 12) Frizsching B, Oberle N, Eberhardt N, et al: Cutting edge: in contrast to effector T cells, CD4+CD25+ Fopxp3+ regulatory T cells are highly susceptible to CD95 ligand-but not to TCR-mediated cell death. J Immunol 175: 32-36, 2005.

• 13) Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061, 2003.

• 14) Tang Q, Henriksen KJ, Bi M, et al: In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199: 1455-1465, 2004.
  pubmed

• 15) Suzuki H, Kundig TM, Furlonger C, et al: Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268: 1472-1476, 1995.
  pubmed

• 16) Malek TR, Yu A, Vincek V, et al: CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Immunity 17: 167-178, 2002.

• 17) Malek TR, Bayer AL: Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4: 665-674, 2004.

• 18) Godfrey WR, Ge YG, Spoden DJ, et al: In vitro-expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104: 453-461, 2004.
  pubmed

• 19) Earle KE, Tang Q, Zhou X, et al: In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol 115: 3-9, 2005.
  pubmed

• 20) Elpek KG, Yolcu ES, Franke DDH, et al: Ex vivo expansion of CD4+CD25+Foxp3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 179: 7295-7304, 2007.
  pubmed

• 21) Suntharalingam G, Perry MR, Ward S, et al: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028, 2006.

• 22) Battaglia M, Stabilini A, Roncarolo M-G: Rapamycin selectively expands CD4+CD25+Foxp3+ regulatory T cells. Blood 105: 4743-4748, 2005.
  pubmed

• 23) Strauss L, Whiteside TL, Knights A, et al: Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 178: 320-329, 2007.
  pubmed

• 24) Bensinger SJ, Walsh PT, Zhang J, et al: Distinct IL-2 receptor signaling Pattern in CD4+CD25+regulatory T cells. J Immunol 172: 5287-5296, 2004.
  pubmed

• 25) Caramalho I, Lopes-Carvalho T, Ostler D, et al: Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med 197: 403-411, 2003.
  pubmed

• 26) Pasare C, Medzhitov R: Toll pathwy-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036, 2003.
  pubmed

• 27) Toda A, Piccirillo CA: Development and function of naturally occurring CD4+CD25+ regulatory T cells. J. Leikol Biol 80: 458-470, 2006.
  pubmed

• 28) Carson BD, Lopes JE, Soper DM, et al: Insights into transcriptionl regulation by FOXP3. Front Biosci 11: 1607-1619, 2006.

• 29) Sakaguchi S, Ono M, Setoguchi R, et al: Foxp3+CD25+CD4+natural regulatory T cells in dominant selftolerance and autoimmune disease. Immunol Rev 212:8-27, 2006.
  pubmed

• 30) Khattri R, Cox T, Yasayko S-A, et al: An essential role for Sucrifin in CD4+CD25+ T regulatory cells. Nat Immunol 4:337-342, 2003.

• 31) Jain J, Loh C, Rao A: Transcriptional regulation of the IL-2 gene. Curr Opin Immunol 7:333-342, 1995.
  pubmed

• 32) Serfling E, Avots A, Neumann M: The architecture of the interleukin-2 promoter: a refiection of T lymphocyte activation. Biochem Biophys Acta 1263:181-200, 1995.
  pubmed

• 33) Chen C, Rowell EA, Thomas RM, et al: Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histon acetylation. J Biol Chem 281:36828-36834, 2006.
  pubmed

• 34) Zheng Y, Josefowicz SZ, Kas A, et al: Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445:936-940, 2007.
  pubmed

• 35) Wu Y, Borde M, Heissmeyer V, et al: Foxp3 controls regulatory T cell function through cooperation with NAFT. Cell 126:375-387, 2006.

• 36) Marson A, Kretschmer K, Frampton GM, et al: Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445:931-935, 2007.

• 37) Lee SM, Gao B, Fang D: Foxp3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood 111:3599-3606, 2008.
  pubmed

• 38) Ono M, Yaguchi H, Ohkura N, et al: Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446:685-689, 2007.
  pubmed

• 39) Murawski MR, Litherland SA, Clare-Salzler MJ, et al: Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci 1O79:198-204, 2006.

• 40) Pallandre JR. Brillard E. Crehange G, et al: Role of STAT3 in CD4+CD5+Foco3 regulatory lymphocyte generation: implications in graft-versus-host disease ang antitumor immunity. J Immunol 179:7593-7604, 2007.

• 41) Kinjyi I, Inoue H, Hamano S, et al: Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factorβ1. J Exp Med 203:1021-1031, 2006.

• 42) Tone Y, Furuuchi K, Kojima Y, et al: Smad3 and NAFT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 9:194-202, 2008.

• 43) Allan SE, Crome SQ, Crellin NK, et al: Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345-354, 2007.

• 44) Allan SE, Passerini L, Bacchetta, R, et al: The role of FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 115:3276-3284, 2005.
  pubmed

• 45) Gavin MA, Torgerson TR, Houston E, et al: Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 1O3:6659-6664, 2006.

• 46) Baratelli F, Lin Y, Zhu L, et al: Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175:1483-1490, 2005.

• 47) Shimizu J, Yamazaki S, Takahashi T, et al :Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135-142, 2002.
  pubmed

• 48) Balz KM, Krusch M, Bringmann A, et al: Cancer immunoediting by GITR (glucocorticoid-induced TNFrelated protein) ligand in humans: NK cell/tumor cell interaction. FASEB/21:2442-2454, 2007.

• 49) Ji HB, Liao G, Faubion WA, et al: Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates T cell suppression. J Immunol 172:5823-5827, 2004.
  pubmed

• 50) Stephens GL, McHugh RS, Whitters MJ, et al: Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 173:5008-5020, 2004.
  pubmed

• 51) Tuyaerts S, Van Meirvenne S, Bonehill A, et al: Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+regulatory T cells. J Leukoc Biol 82:93-105, 2007.

• 52) Iida T, Ohno H, Nakaseko C, et al: Regulation of cell surface expression of CTLA-4 by secretion of CTLA-4-containing lysosomes upon activation of CD4+ T cells. J Immunol 165:5062-5068, 2000.
  pubmed

• 53) Li J, Hu P, Khawli LA, et al: Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25+ T-cell depletion. Cancer Res 63:8384-8392, 2003.

• 54) Zheng SG, Wang JH, Stohl W, et al: TGF-βrequires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+regulatory cells. J immunol 176:3321-3329, 2006.

• 55) Wing K, Onishi Y, Prieto-Martin P, et al: CTLA-4 control over Foxp3+regulatory T cell function. Science 322:271-275, 2008.
  pubmed

• 56) Li R, Perez N, Karumuthil-Melethil S, et al: Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+and CD4+CD25-TGF-β1+adaptive regulatory T cells. J Immmunol 179:5191-5203, 2007.

• 57) Huang CT, Workman CJ, Flies D, et al: Role of LAG-3 in regulatory T cells. Immunity 21:503-513, 2004.
  pubmed

• 58) Workman CJ, Vignali DA: Negative regulation of T cell homeostasis by lymphocyte activation gene-3(CD223). J Immunol 174:688-695, 2005.
  pubmed

• 59) Anandasabapathy N, Ford GS, Bloom D, et al: GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ Tcells. Immunity 18:535-547, 2003.

• 60) MacKenzie DA, Schartner J, Lin J, et al: GRAIL is up-regulated in CD4+CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem 282:9696-9702, 2007.
  pubmed

• 61) Kostianovsky AM, Maier LM, Baecher-Allan C, et al: Up-regulation of gene related to anergy in lymphocytes is associated with Notch-mediated human T cell suppression. J Immunol 178:6158-6163, 2007.

• 62) Vu MD, Xiao X, Gao W, et al: OX40 costimulation turns off Foxp3+ Tregs. Blood 110:2501-2510, 2007.
  pubmed

• 63) So T, Croft M: Cutting edge: OX40 inhibits TGF-β-and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J Immunol 179:1427-1430, 2007.

• 64) Sugamura K, Ishii N, Weinberg AD: Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4:420-431, 2004.
  pubmed

• 65) Sharma R, Zheng L, Deshmukh US, et al: Cutting edge: a regulatory T cell-dependent novel function of CD25 (IL-2Rα) controlling memory CD8+ T cell homeostasis. J Immunol 178:1251-1255, 2007.

• 66) Zheng G, Wang B, Chen A: The 4-IBB costimulation augments the proliferation of CD4+CD25+regulatory T cells. J Immunol 173:2428-2434, 2004.

• 67) Valencia X, Stephjens G, Goldbach-Mansky R, et al: TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108:253-261, 2006.

• 68) Lehmann J, Huehn J, de la Rosa M, et al: Expression of the integrin αEβ7 identifies unique subsets of CD25+as well as CD25-regulatory T cells. Proc Natl Acad Sci USA 99:13031-13036, 2002.

• 69) Siegmund K, Feuerer M, Siewert C, et al: Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood 1O6:3097-3104, 2005.

• 70) Banz AS, Peixoto A, Pontoux C, et al: A unique subpopulation of CD4+ regulatory T cells controls wasting disease, IL-10 secretion and T cell homeostasis. Eur J Immunol 33:2419-2428, 2003.

• 71) Huehn J, Siegmund K, Lehmann JC, et al: Developmental stage, phenotype, and migration distinguish naive-and effector/memory-like CD4+ regulatory T cells. J Exp Med 199:303-313, 2004.
  pubmed

• 72) Siewert C, Lauer U, Cording S, et al: Experience-driven development: Effetor/memory-like αE+ Foxp3 regulatory T cells originate from both naive T cells and naturally occurring naive-like regulatory T cells. J Immunol 80:146-155, 2008.

• 73) Bochtler P, Wahl C, Schirmbeck R, et al: Functional adaptive CD4 Foxp3 T cells develop in MHC class II-deficient mice. J Immunol 177:8307-8314, 2006,
  pubmed

• 74) Bruder D, Probst-Kepper M, Westendorf AM, et al: Neuropilin-1: a surface marker of regulatory T cells, Eur J Immunol 34:623-630, 2004.
  pubmed

• 75) Corbel C, Lemarchandel V, Thomas-Vaslin V, et al: Neuropilin 1 and CD25 co-regulation during early thymic differentiation. Dev Comp Immunol 31:1082-1094, 2007.
  pubmed

• 76) Chai JG, Xue SA, Coe D, et al: Regulatory T cells, derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation 79:1310-1316, 2005.
  pubmed

• 77) Kim JY, Kim HJ, Hurt EM, et al: Functional and genomic analyses of FOXP3-transduced Jurkat-T cells as regulatory T (Treg)-like cells. Biochem Biophys Res Commun 362:44-50, 2007.

• 78) Qiao M, Thornton AM, Shevach EM: CD4+CD25+ regulatory T cells render naive CD4+CD25- T cells anergic and suppressive. Immunol 120:447-455, 2007.

• 79) Jonuleit H, Schmitt E, Kakirman H, et al: Infectious tolerance: human CD25+ regulatory T cells convey suppressor activity to conventional CD4+ T helper cells. J Exp Med 196:255-260, 2002.
  pubmed

• 80) Marie JC, Letterio JJ, Gavin M, et al: TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+regulatory T cells. J Exp Med 201:1061-1067, 2005.

• 81) Zheng SG, Wang JH, Gray JD, et al: Natural and induced CD4+CD25+ cells educate CD4+CD25 cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J Immunol 172:5213-5221, 2004.

• 82) Selvaraj RK, Geiger TL: A kinetic and dynamic analysis of FoxP3 induced in T cells by TGF-β. J Immunol 178:7667-7677, 2007.

• 83) Kim HP, Leonard WJ: CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med 204:1543-1551, 2007.
  pubmed

• 84) Pyzik M, Piccirillo CA: TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol 82:335-346, 2007.

• 85) Gorelik L, Fields PE, Flavell RA: Cutting edge: TGF-βinhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 165:4773-4777, 2000.

• 86) Mantel PY, Kuipers H, Boyman O, et al: GATA3-driven Th2 responses inhibit TGF-β1-induced FOXP3 expression and the formation of regulatory T cells. PloS Biol 5:e329, 2007.

• 87) Ziegler SF, Buckner JH: FOXP3 and the regulation of Treg/Th17 differentiation. Microbes Infect 11:594-598, 2009.
  pubmed

• 88) Skapenko A, Kalden JR, Lipsky PE, et al: The IL-4 receptorα-chain-binding cytokines, IL-4 and IL-13,induce forkhead box P3-expressing CD25+CD4+regulatory T cells from CD25-CD4+precursors. J Immunol 175:6107-6116, 2005.

• 89) Niedbala W, Cai B, Liu H, et al: Nitric oxide induces CD4+CD25+Foxp3-regulatory T cells from CD4+CD25-T cells via p53, IL-2, and OX40. Proc Natl Acad Sci USA 104:15478-15483, 2007.
  pubmed

• 90) Taylor AW, Namba K: In vitro induction of CD25+CD4+regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (α-MSH). Immunol Cell Biol 79:358-367, 2001.

• 91) Namba K, Kitaichi N, Nishida T, et al: Induction of regulatory T cells by the immunomodulating cytokines α-melanocyte-stimulating hormone and transforming growth factor-β2. J Leukoc Biol 72:946-952, 2002.

• 92) Luger TA, Brzoska T:α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis 66(Suppl 3):iii52-iii55, 2007.

• 93) Kreijveld E, Koenen HJPM, Hilbrand LB, et al: The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+CD25- T cells. Blood 1O9:244-252,2007.

• 94) Lopez M, Clarkson MR, Albin M, et al: A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 17:2844-2853, 2006.
  pubmed

• 95) Ruzek MC, Waire JS, Hopkins D, et al: Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo. Blood 111:1726-1734, 2008.
  pubmed

• 96) Tadokoro CE, Shakhar G, Shen S, et al: Regulatory T cells inhibit stable contact between CD4+ T cells and dendritic cells in vivo. J Exp Med 203:505-511, 2006.
  pubmed

• 97) Guiducci C, Valzasina B, Dislich H, et al: CD40/CD40L interaction regulates CD4+CD25+ Treg homeostasis through dendritic cell-produced IL-2. Eur J Immunol 35:557-567, 2005.

• 98) Hanig J, Lutz MB: Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J Immunol 180:1405-1413, 2008.
  pubmed

• 99) DiPaolo RJ, Brinster C, Davidson TS, et al: Autoantigen-specific TGFβ-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 179:4685-4693, 2007.

• 100) Sakaguchi S, Wing K, Onishi Y, et al: Regulatory T cells: how do they suppress immune responses? Int Immunol 21:1105-1111, 2009.
  pubmed

• 101) Tran DQ, Glass DD, Uzel G, et al: Analysis of adhesion molecules, target cells, and role of IL-2 in human Foxp3+ regulatory T cell suppressor function. J Immunol 182:2929-2938, 2009.
  pubmed

• 102) Houot R, Perrot I, Garcia E, et al: Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 176:5293-5298, 2006.

• 103) Chen W: Dendritic cells and CD4+CD25+ T regulatory cells: cross-talk between two professionals in immunity versus tolerance. Front Biosci 11:1360-1370, 2006.

• 104) Hubert P, Jacobs N, Caberg JH, et al: The cross-talk between dendritic and regulatory T cells: good or evil? J Leukoc Biol 82:781-794, 2007.
  pubmed

• 105) Misra N, Bayry J, Lacroix-Desmazes S, et al: Cutting edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676-4680, 2004.
  pubmed

• 106) Oderup C, Cederbom L, Makowska A, et al: Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+CD25+ regulatory T-cell-mediated suppression. Immunology 118:240-249, 2006.
  pubmed

• 107) Munn DH, Sharma MD, Mellor AL: Ligation of B7-1/B7-2 by human CD4+ T ells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172:4100-4110, 2004.

• 108) Mellor AL, Chandler P, Baban B, et al: Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3dioxygenase. Int Immunol 16:1391-1401, 2004.

• 109) Feunou P, Vanwetswinkel S, Gaudray F, et al: Foxp3+CD25+ T regulatory cells stimulate IFN-γ-independent CD152-mediated activation of tryptophan catabolism that provides dendritic cells with immune regulatory activity in mice unresponsive to staphylococcal enterotoxin B.J Immunol 179:910-917, 2007.

• 110) Liang B, Workman C, Lee J, et al: Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180:5916-5926, 2008.
  pubmed

• 111) Bayry J, Triebel F, Kaven SV, et al: Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 178:4184-4193, 2007.

• 112) Mahnke K, Ring S, Johnson TS, et al: Induction of immunosuppressive functions of dendritic cells in vitro by CD4+CD25+ regulatory T cells:role of B7-H3 expression and antigen prsentation. Eur J Immunol 37:2117-2126, 2007.

• 113) Sica GL, Choi IH, Zhu G, et al: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18:849-861, 2003.
  pubmed

• 114) Lewkowich IP, Herman NS, Schleifer KW, et al: CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med 202:1549-1561, 2005.
  pubmed

• 115) Giroux M, Yurchenko E, St-Pierre J, et al: Tregulatory cells control numbers of NK cells and CD8α+ immature dendritic cells in the lymph node paracortex. J Immunol 179:4492-4502, 2007.

• 116) Terme M, Chaput N, Combadiere B, et al: Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol 180:4679-4686, 2008.
  pubmed

• 117) Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat Rev Immunol 8:523-532, 2008.
  pubmed

• 118) Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.J Exp Med 1 88:287-296, 1998.

• 119) Ermann J, Szanya V, Ford GS, et al: CD4+CD25+ T cells facilitate the induction of T cell anergy. J Immunol 167:4271-4275, 2001.
  pubmed

• 120) Duthoit CT, Mekala DJ, Alli RS, et al: Uncoupling of IL-2 signaling from cell cycle progression in naive CD4+ T cells by regulatory CD4+CD25+ T lymphocytes. J Immunol 174:155-163, 2005.
  pubmed

• 121) Kojima H, Kanno Y, Hase H, et al: CD4+CD25+regulatory T cells attenuate the phosphatidylinositol 3-kinase/Akt pathway in antigen-primed immature CD8+ CTLs during functional maturation. J Immunol 174:5959-5967, 2005.
  pubmed

• 122) de la Rosa M, Rutz S, Dorninger H, et al: Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 34:2480-2488, 2004.
  pubmed

• 123) Pandiyan P, Zheng L, lshihara S, et al: CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8:1353-1362, 2007.

• 124) Scheffold A, Huhn J, Hofer T: Regulaton of CD4+CD25+ regulatory T cell activity: it takes(IL-)two to tango. Eur J Immunol 35:1336-1341, 2005.

• 125) Vercoulen Y, Wehrens EJ, van Teijlingen NH, et al: Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells. PloS One 4:e7183, 2009.
  pubmed

• 126) Chen C, Lee WH, Zhong L, et al: Regulatory T cells can mediate their function through the stimulation of APCs to produce immunosuppressive nitric oxide. J Immunol 176:3449-3460, 2006.
  pubmed

• 127) Bergmann C, Strauss L, Zeidler R, et al: Expansion and characteristics of human T regulatory type 11 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother 56:1429-1442, 2007.

• 128) Bergman C, Strauss L, Wang Y, et al: Tregulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14:3706-3715, 2008.

• 129) Strauss L, Bergmann C, Szczepanski M, et al: A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in tumor microenvironment. Clin Cancer Res l3:4345-4354, 2007.

• 130) Kryczek I, Wei S, Zou L, et al: Cutting edge: Induction of B7-H40n APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 177:40-44, 2006.
  pubmed

• 131) Rubtsov YP, Rasmussen JP, Chi EY, et al: Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28:546-558, 2008.
  pubmed

• 132) Oida T, Zhang X, Goto M, et al: CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-β-dependent mechanism.J Immunol 170:2516-2522,2003.

• 133) Nakamura K, Kitani A, Fuss I, et al:TGF-βl plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and nice.J Immunol l72:834-842, 2004.

• 134) Oida T, Xu L, Weiner HL, et al: TGF-β-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling.J Immunol 177:2331-2339, 2006.

• 135) Fahlen L Read S, Gorelik L, et al: T cells that cannot respond to TGF-βescape control by CD4+CD25+ regulatory T cells.J Exp Med 201:737-746, 2005.

• 136) Li MO, Wan YY, Flavell RA: T cell-produced transforming growth factor-β1 controls T cell tolerance andregulates Th1-and Th17-cell differentiation. Immunity 26:579-591, 2007.

• 137) Yvon ES, Vigouroux S, Rousseau RF, et al: Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood 1O2:3815-3821, 2003.

• 138) Kared H, Adle-Biassette H, Fois E, et al: Jagged 2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling. Immunity 25:823-834, 2006.
  pubmed

• 139) Asano N, Watanabe T, Kitani A, et al: Notch1 signaling and regulatory T cell function. J Immunol 180:2796-2804, 2008.
  pubmed

• 140) Chen ML, Yan BS, Bando Y, et al: Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFβ-mediated function and enhanced suppression of experimental autoimmune encephalornyelitis. J Immunol 180:7327-7337, 2008.

• 141) Tran DQ, Andersson J, Hardwick D, et al: Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II(CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 113:5125-5133, 2009.
  pubmed

• 142) Collison LW, Workman CJ, Kuo TT, et al: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566-569, 2007.
  pubmed

• 143) Oberle N, Eberhardt N, Falk CS, et al: Rapid suppression of cytokine transcription in human CD4+CD25- T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-β, and various inhibitors of TCR signaling. J Immunol 179:3578-3587, 2007.

• 144) Gondek DC, Lu LF, Quezada SA, et al: Cutting edge: Contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174:1783-1786, 2005.
  pubmed

• 145) Grossman WJ, Verbsky JW, Barchet W, et al: Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21:589-601, 2004.

• 146) Cao X, Cai SF, Fehniger TA, et al: Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27:635-646, 2007.
  pubmed

• 147) Ralainirina N, Poli A, Michel T, et al: Control of NK cell functions by CD4+CD25+ regulatory T cells. J Leukoc Biol 81:144-153, 2007.
  pubmed

• 148) Strauss L, Bergmann C, Whiteside TL: Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+bUt nOt CD4+responder cells by Fas-mediated apoptosis.J Immunol 182:1469-1480, 2009.
  pubmed

• 149) Garin MI, Chu CC, Golshayan D, et al: Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood lO9:2058-2065, 2007.

• 150) Ohta A, Sitkovsky M: Role of G-protein-coupled adenosine receptors in down regulation of inflammation and protection from tissue damage. Nature 414:916-920, 2001.

• 151) Sitkovsky MV, Ohta A: The 'danger' sensors that STOP the immune response:the A2 adenosine receptors? Trends Immunol 26:299-304, 2005.
  pubmed

• 152) Chouker A, Thiel M, Lukashev D, et al: Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol Med 14:116-123, 2008.
  pubmed

• 153) Ohta A, Gorelik E, Prasad SJ, et al: A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 1O3:13132-13137, 2006.

• 154) Csoka B, Himer L, Selmeczy Z, et al: Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J 22:3491-3499, 2008.

• 155) Wilson JM, Ross WG, Agbai ON, et al: The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol 182:4616-4623, 2009.
  pubmed

• 156) Zarek PE, Huang CT, Lutz ER, et al: A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111:251-259, 2008.
  pubmed

• 157) Kobie JJ, Shah PR, Yang L, et al: T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5"-adenosine monophosphate to adenosine. J Immunol 177:6780-67862006.

• 158) Deaglio S, Dwyer KM, Gao W, et al: Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.J Exp Med 204:1257-1265, 2007.
  pubmed

• 159) Mandapathil M, Lang S, Gorelik E, et al: Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 346:55-63, 2009.
  pubmed

• 160) Ohta A, Ohta A, Madasu M, et al: A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments.J Immunol 183:5487-5493, 2009.
  pubmed

• 161) Bopp T, Becker C, Klein M, et al: Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 204:1303-1310, 2007.
  pubmed

• 162) Bashyam H: cAMP crosses junctions. J Exp Med 204:1240b, 2007.

• 163) Sitkovsky MV, Klaergaard J, Lukashev D, et al: Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14:5947-5952, 2008.

• 164) Mandapathil M, Szczepanski M, Szajnik M, et al: Increased ectonucleotidase expression activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 15:6348-6357, 2009.
  pubmed

• 165) Mahic M, Yaqub S, Johansson CC, et al: Foxp3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism.J Immunol 177:246-254,2006.
  pubmed

P.206 掲載の参考文献

• 1) Cosmi L, Liotta F, Lazzeri E, et al: Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+regulatory thymocytes. Blood 1O2: 4107-4114, 2003.

• 2) Bienvenu B, Martin B, Auffray C, et al: Peripheral CD8+CD25+ T lymphocytes from MHC class II deficient mice exhibit regulatory activity. J Immunol 175: 246-253, 2005.
  pubmed

• 3) Xystrakis E, Dejean AS, Bernard I, et al: Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood 1O4: 3294-3301, 2004.

• 4) Menager-Marcq I, Pomie C, Romagnoli P, et al: CD8+CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice. Gastroenterology 131: 1775-1785, 2006.
  pubmed

• 5) Jiang H, Zhang SI, Pernis B: Role of CD8+ T cells in murine experimental allergic encephalomyelitis. Science 256: 1213-1215, 1992.
  pubmed

• 6) Koh DR, Fung-Leung WP, Ho A, et al: Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/-mice. Science 256: 1210-1213, 1992.
  pubmed

• 7) Najafian N, Chitnis T, Salama AD, et al: Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest 112: 1037-1048, 2003.

• 8) Vigouroux S, Yvon E, Biagi E, et al: Antigen-induced regulatory T cells. Blood 1O4: 26-33, 2004.

• 9) Peng Y, Sbao H, Ke Y, et al: Minimally activated CD8 autoreactive T cells specific for IRBP express a high level of Foxp3 and are functionally suppressive. Invest Ophthalmol Vis Sci 48: 2178-2184, 2007.

• 10) Shao H, Peng Y, Liao T, et al: A shared epitope of the interphotoreceptor retinoid-binding protein recognized by the CD4+ and CD8+ autoreactive T cells. J Immunol 175: 1851-1857, 2005.

• 11) Maile R, Wang B, Schooler W, et al: Antigen-specific modulation of an Immune response by in vivo administration of soluble MHC class I tetramers. J Immunol 167: 3708-3714, 2001,
  pubmed

• 12) Maile R, Siler CA, Kerry SE, et al: Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J Immumol 174: 619-627, 2005.
  pubmed

• 13) Maile R, Pop SM, Tisch R, et al: Low-avidity CD8lo cells induced by incomplete antigen stimulation in vivo regulate naive higher avidity CD8hi T cell responses to the same antigen. Eur J Immunol 36: 397-410, 2006.

• 14) Kienzle N, Olver S, Buttigieg K, et al: Progressive differentiation and commitment of CD8+ T cells to a poorly cytolytic CD8low phenotype in the presence of IL-4. J Immunol 174: 2021-2029, 2005.
  pubmed

• 15) Jarvis LB, Matyszak MK, Duggleby RC, et al: Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function. Eur J Immunol 35: 2896-2908, 2005.
  pubmed

• 16) Mahic M, Henjum K, Yaqub S, et al: Generation of highly suppressive adaptive CD8+CD25+Foxp3+regulatory T cells by continuous antigen stimulation. Ear J Immunol. 38: 640-646, 2008.

• 17) Belghith M, Bluestone JA, Barriot S, et al: TGF-β-dependent mechanisms mediate restoration of self tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9: 1202-1208, 2003.

• 18) Bisikirska B, Colgan J, Luban J, et al: TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 115: 2904-2913, 2005.
  pubmed

• 19) Ciubotariu R, Colovai AI, Pennesi G, et al: Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells. J Immunol 161: 5193-5202, 1998.
  pubmed

• 20) Suciu-Foca N, Manavalan JS, Scotto L, et al: Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol 5: 7-11, 2005.
  pubmed

• 21) Vlad G, Cortesini R, Suciu-Foca N: License to heal: bidirectional interaction of antiger1-specific regulatory T cells and tolerogenic APC. J Immunol 174: 5907-5914, 2005.
  pubmed

• 22) Scotto, L, Naiyer AJ, Galluzzo S, et al: Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells. Hum Immunol 65: 1297-1306, 2004.
  pubmed

• 23) Liu Z, Tugulea S, Cortesini R, et al: Specific suppression of T helper alloreactivity by allo-MHC class I restricted CD8+CD28- T cells. Int Immunol 1O: 775-783, 1998.

• 24) Jiang S, Tugulea S, Pennesi G, et al: Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro. Hum Immunol 59: 690-699, 1998.
  pubmed

• 25) Ciubotariu R, Li J, Colovai AI, et al: Human xenospecific T suppressor cells inhibit T helper cell proliferation to porcine aortic endothelial cells, and NF-κB activity in porcine APC. Hum Immunol 62: 470-478, 2001.

• 26) Fu S, Yopp AC, Mao X, et al: CD4+CD25+CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 4: 65-78, 2004
  pubmed

• 27) Ermann J, Hoffmann P, Edinger M, et al: Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 1O5: 2220-2226, 2005.

• 28) Hahn BH, Singh RP, La Cava A, et al: Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFβ-secreting CD8+ T cell suppressors. J Immunol 175: 7728-7737, 2005.

• 29) Singh RP, La Cava A, Wong M, et al: CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced Immune tolerance depends on Foxp3 expression. J Immunol 178: 7649-7657, 2007.

• 30) Sharabi A, Mozes E: The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells. J Immunol 181: 3243-3251, 2008.
  pubmed

• 31) Manavalan JS, Kim-Schulze S, Scotto L, et al: Alloantigen specific CD8+CD28-Foxp3+ T suppressor cells induce ILT3+ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 16: 1055-1068, 2004.
  pubmed

• 32) Sindhi R, Manavalan JS, Magill A, et al: Reduced Immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28-T-suppressor cells. Hum Immunol 66: 252-257, 2005.
  pubmed

• 33) Colovai AI, Mirza M, Vlad G, et al: Regulatory CD8+CD28-Tcells in heart transplant recipients. Hum Immunol 64: 31-37, 2003.
  pubmed

• 34) Liu J, Liu Z, Witkowski P, et al: Rat CD8+Foxp3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transplant Immunol 113: 239-247, 2004.

• 35) Grewal IS, Flavell RA: The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 153: 85-106, 1996.

• 36) Guillonneau C, Hill M, Hubert FX, et al: CD401g treatment results in allograft acceptance mediated by CD8+CD45Rclow T cells, IFN-γ, and indoleamine 2, 3-dioxygenase. J Clin Invest 117: 1096-1106, 2007.

• 37) Guillonneau C, Seveno C, Dugast AS, et al: Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 179: 8164-8171, 2007.
  pubmed

• 38) Vacchio MS, Hodes RJ: CD28 costimulation is required for in vivo induction of peripheral tolerance in CD8 T cells. J Exp Med 197: 19-26, 2003.

• 39) Kinter AL, Hennessey M, Bell A, et al: CD25+CD4+ regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4+ and CD8+ HIV-specific T cell Immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 200: 331-343, 2004.
  pubmed

• 40) Weiss L, Donkova-Petrini V, Caccavelli L, et al: Human Immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 1O4: 3249-3256, 2004.

• 41) Elrefaei M, Barugahare B, Ssali F, et al: HIV-specific IL-10-positive CD8+ T cells are increased in advanced disease and are associated with decreased HIV-specific cytolysis. J Immunol 176: 1274-1280, 2006.
  pubmed

• 42) Elrefaei M, Ventura FL, Baker CAR, et al: HIV-specific IL-10-positive CD8+ T cells suppress cytolysis and IL-2 production by CD8+ T cells. J Immunol 178: 3265-3271, 2007.
  pubmed

• 43) Tulunay A, Yavuz S, Direskeneli H, et al: CD8+CD28-, suppressive T cells in systemic lupus erythematosus. Lupus l7: 630-637, 2008.

• 44) Suzuki H, Kundig TM, Furlonger C, et al: Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268: 1472-1476, 1995.
  pubmed

• 45) Suzuki H, Hayakawa A, Bouchard D, et al: Normal thymic selection, superantigen-induced deletion and Fas-mediaed apoptosis of T cells in IL-2 receptor beta chain-deficient mice. Int Immunol 9: 1367-1374, 1997.

• 46) Rifai IM, Kawamoto Y, Nakashima I, et al: Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 200: 1123-1134, 2004.

• 47) Endharti AT, Rifa IM, Shi Z, et al: Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-γ production and proliferation of CD8+ T cells. J Immunol 175: 7093-7097, 2005.

• 48) Wahl C, Bochtler P, Schirmbeck R, et al: Type I IFN-producing CD4 Va14i NKT cells facilitate priming of IL-10-producing CD8 T cells by hepatocytes. J Immunol 178: 2083-2093, 2007.
  pubmed

• 49) Filaci G, Rizzi M, Setti M, et al: Non-antigen-specific CD8+ T suppressor lymphocytes in diseases characterized by chronic Immune responses and inflammation. Ann N Y Acad Sci 1050: 115-123, 2005.
  pubmed

• 50) Filaci G, Bacilieri S, Fravega M, et al: Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 166: 6452-6457, 2001.
  pubmed

• 51) Filaci G, Fravega M, Negrini S, et al: Nonantigen specific CD8+ T suppressor lymphocytes originate fromCD8+CD28-T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol 65: 142-156, 2004.

• 52) Filaci G, Fravega M, Fenoglio D, et al: Non-antigen specific CD8+ T suppressor lymphocytes. Clin Exp Med 4.86-92, 2004.
  pubmed

• 53) Balashov KE, Khoury SJ, Hafler DA, et al: Inhibition of T cell responses by activated human CD8+ T cellsis mediated by interferon-γ and is defective in chronic progressive multiple sclerosis. J Clin Invest 95: 2711-2719, 1995.

• 54) Uss E, Rowshani AT, Hooibrink B, et al: CD103 is a marker for alloantigen-induced regulatory CD8+ T cells. J Immunol 177: 2775-2783, 2006,
  pubmed

• 55) Keino H, Masli S, Sasaki S, et al: CD8+ T regulatory cells use a novel genetic program that includes CD103 to suppress Th1 Immunity in eye-derived tolerance. Invest Ophthalmol Vis Sci 47: 1533-1542, 2006.
  pubmed

• 56) Uss E, Yong SL, Hooibrink B, et al: Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro. Transplantation 83: 1098-1106, 2007.
  pubmed

• 57) Webster WS, Thompson RH, Harris KJ, et al: Targeting molecular and cellular inhibitory mechanisms for Improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol 179: 2860-2869, 2007.
  pubmed

• 58) Myers L, Takahashi C, Mittler RS, et al: Effector CD8 T cells possess suppressor function after 4-IBB and Toll-like receptor triggering. Proc Natl Acad Sci USA, 100: 5348-5353, 2003.

• 59) Myers L, Croft M, Kwon BS, et al: Peptide-specific CD8 T regulatory cells use IFN-γ to elaborate TGF-β-based suppression. J Immunol 174: 7625-7632, 2005.

• 60) Ho J, Kurtz CC, Naganuma M, et al: ACD8+/CD103high T cell subset regulates TNF-mediated chronic murine ileitis. J Immunol 180: 2573-2580, 2008.

• 61) Noble A, Giorgini A, Leggat JA: Cytokine-induced IL-10 secreting CD8 T cells represent a phenotypically distinct suppressor T-cell lineage. Blood 107: 4475-4483, 2006.
  pubmed

• 62) Gilliet M, Liu YJ: Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195: 695-704, 2002.
  pubmed

• 63) Accapezzato D, Francavilla V, Paroli M, et al: Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection. J Clin Invest 113: 963-972, 2004.
  pubmed

• 64) Nordstrom I, Nurkkala M, Collins LV, et al: CD8+ T-cells suppress antigen-specific and allogeneic CD4+ T-cell responses to herpes simplex virus type 2-infected human dendritic cells. Viral Immunol 18: 616-626, 2005.
  pubmed

• 65) Garba ML, Pilcher CD, Bingham AL, et al: HIV antigens can induce TGF-β1-producng ImmunoregulatoryCD8+ T cells. J Immunol 168: 2247-2254, 2002.

• 66) Alatrakchi N, Graham CS, van der Vliet HJJ, et al: Hepatitis C virus(HCV)-specific CD8+ cells producetransforming growth factor β that can suppress HCV-specific T-cell responses. J Virol 81: 5882-5892, 2007.

• 67) Viglietta V, Baecher-Allan C, Weiner HL, et al: Loss of functional suppression by CD4+CD25+regulatory T cells in patients with multiple sclerosis. J Exp Med 199:971-979, 2004.
  pubmed

• 68) Hong J, Li N, Zhang X, et al: Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 1O2: 6449-6454, 2005.

• 69) Araki M, Kondou T, Gumperz JF, et al: Th2 bias of CD4+NKT cells derived from multiple sclerosis in remission. Int Immunol 15: 279-288, 2003.

• 70) Furlan R, Bergami A, Cantarella D, et al: Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-γ. Eur J Immunol 33: 1830-1838, 2003.

• 71) Chun T, Aldrich CJ, Baldeon ME, et al: Constitutive and regulated expression of the class I B molecule Qa-1 in pancreatic beta cells. Immunology 94: 64-71, 1998.

• 72) Sarantopoulos S, Lu L, Cantor H: Qa-1 restriction of CD8+ suppressor T cells. J Clin Invest 114: 1218-1221, 2004.
  pubmed

• 73) Tutaj M, Szczepanik M: Mechanisms involved in the regulation of Immune response in experimental autoimmune encephalomyelitis in mice. Postepy Hig Med Dosw 60: 571-583, 2006.
  pubmed

• 74) Jiang H, Chess L: An integrated view of suppressor T cell subsets in immunoregulation.J Clin Invest 114: 1198-1208, 2004.
  pubmed

• 75) Jiang H, Chess L: Regulation of Immune responses by T cells. N Engl J Med 354: 1166-1176, 2006.

• 76) Tang X, Maricic I, Purohit N, et al: Regulation of Immunity by a novel population of Qa-1-restricted CD8αα+TCRαβ+ T cells. J Immunol 177: 7645-7655, 2006.

• 77) Karandikar NJ, Crawford MP, Yan X, et al: Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis. J Clin Invest 109: 641-649, 2002.
  pubmed

• 78) Tennakoon DK, Mehta RS, Ortega SB, et al: Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 176: 7119-7129, 2006.
  pubmed

• 79) Jiang H, Wu Y, Liang B, et al: An affinity/avidity model of peripheral T cell regulation. J Clin Invest 115: 302-312, 2005.

• 80) Shao L, Allez M, Park M-S, et al: Immunomodulatory roles of the carcinoembryonic antigen family of glycoproteins. Ann N Y Acad Sci 1072: 194-209, 2006.
  pubmed

• 81) Shao L, Jacobs AR, Johnson VV, et al: Activation of CD8+ regulatory T cells by human placental trophoblasts. J Immunol 174: 7539-7547, 2005.
  pubmed

• 82) Hang CC, Ciubotariu R, Manavalan JS, et al: Tolerization of dendritic cells by Ts cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3: 237-243, 2002.

• 83) Manavalan JS, Rossi PC, Vlad G, et al: High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 11: 245-258, 2003.
  pubmed

• 84) Danese S, Dejana E, Fiocchi C: Immune regulation by microvascular endothelial cells: directing innate and adaptive Immunity, coagulation, and inflammation. J Immunol 178: 6017-6022, 2007.

• 85) Suciu-Foca N, Cortesini R: Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 248: 59-67, 2007.

• 86) Jonuleit H, Schmitt E, Kakirman H, et al: Infectious tolerance: human CD25+ regulatory T cells convey suppressor activity to conventionl CD4+ T helper cells. J Exp Med 196: 255-260, 2002.

• 87) Selvaraj RK, Geiger TL: Mitigation of experimental allergic encephalomyelitis by TGF-β induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. J Immunol 180: 2830-2838, 2008.

• 88) Nam KH, Akari H, Terao K, et al: Peripheral blood extrathymic CD4+CD8+ T cells with high cytotoxic activity are from the same lineage as CD4+CD8-T cells in cynomolgus monkeys. int Immunol 12: 1095-1103, 2000.

• 89) Zuckermann FA: Extrathymic CD4/CD8 double positive T cells. Vet Immunol Immunopathol 72: 55-66, 1999.
  pubmed

• 90) Akari H, Terao K, Murayama Y, et al: Peripheral blood CD4+CD8+ lymphocytes in cynomolgus monkeys are of resting memory T lineage. Int Immunol 9: 591-597, 1997.
  pubmed

• 91) Ghia P, Prato G, Stella S, et al: Age-dependent accumulation of monoclonal CD4+CD8+ double positive T lymphocytes in the peripheral blood of the elderly. Br J Haematol 139: 780-790, 2007.
  pubmed

• 92) Kenny E, Mason D, Pombo A, et al: Phenotypic analysis of peripheral CD4+CD8+ T cells in the rat. Immunology 101: 178-184, 2000.
  pubmed

• 93) Antica M, Scollay R: Development of lymphocytes at extrathymic sites. J Immunol 163: 206-211, 1999.

• 94) Nakamura S, Suzuki M, Sugimoto A, et al: IL-2-independent generation of FOXP3+CD4+CD8+CD25+cytotoxic regulatory T cell lines from human umbilical cord blood. Exp Hematol 35: 287-296, 2007.
  pubmed

• 95) 中村修司: 新しいタイプのヒト制御性T細胞 (HOZOT) の発見と臨床応用. Jpn J Clin Immunol 32: 223- 230, 2009.

• 96) Harashima A, Toraya T, Okochi A, et al: Interleukin-8 and RANTES are signature cytokines made by HOZOT, a new type of regulatory T cells. Mol Immunol 46: 3310-3319, 2009.
  pubmed

• 97) Suzuki M, Sugimoto A, Harashima A, et al: Novel mechanisms of suppressor activity exhibited by cytotoxic regulatory T cell lines, HOZOT. Exp Hematol 37: 92-100, 2009.
  pubmed

• 98) Tsuji-Takaysma K, Suzuki M, Yamamoto M, et al: IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT. Exp Hematol 36: 181-192, 2008.

• 99) Sadelain MW, Qin HY, Lauzon J, et al: Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39: 583-589, 1990.
  pubmed

• 100) Qin HY Mukherjee R, Lee-Chan E, et al: A novel mechanism of regulatory T cell-mediated down-regulation of autoimmunity. Int Immunol 18: 1001-1015, 2006.
  pubmed

• 101) Ford MS, Zhang ZX, Chen W, et al: Double-negative T regulatory cell can develop outside the thymus and do not mature from CD8+ T cell precursors. J Immunol 177: 2803-2809, 2006.

• 102) Zhang D, Yang W, Degauque N, et al: New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of Immune responses. Blood 109: 4071-4079, 2007.

• 103) Ford McIntyre MS, Young KJ, Gao J, et al: Cutting edge: in vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression. J Immunol 181: 2271-2275, 2008.
  pubmed

• 104) Chen W, Ford MS, Young KJ, et al: The role and mechanisms of double negative regulatory T cells in the suppression of immune responses. Cell Mol Immunol 1: 328-335, 2004.
  pubmed

• 105) Fischer K, Voelkl S, Heymann J, et al: Isolation and characterization of human antigen-specific TCR αβ+CD4-CD8-double-negative regulatory T cells. Blood 1O5: 2828-2835, 2005.

• 106) Cowley SC, Hamilton E, Frelinger JA, et al: CD4-CD8-T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med 202: 309-319, 2005.
  pubmed

P.227 掲載の参考文献

• 1) Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998.
  pubmed

• 2) Vlad G, Cortesini R, Suciu-Foca N: License to heal: bi-directional interaction of antigen-specific regulatory Tcells and tolerogenic APC. J Immunol 174: 5907-5914, 2005.

• 3) Tamura T, Tailor P, Yamaoka K, et al: IFN regulatory factor-4 and-8 govern dendritic cell subset development and their functional diversity. J Immunol 174: 2573-2581, 2005.
  pubmed

• 4) Gabriele L, Fragale A, Borghi P, et al: IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J Leukoc Biol 80: 1500-1511, 2006.
  pubmed

• 5) den Haan JM, Lehar SM, Bevan MJ: CD8 (+) but not CD8 (-) dendritic cells cross-prime cytotoxic T cells in vino. J Exp Med l92: 1685-1696, 2000.
  pubmed

• 6) Mouries J, Moron G, Schlecht G, et al: Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112: 3713-3722, 2008.
  pubmed

• 7) Palucka AK, Ueno H, Fay J, et al: Role of dendritic cells in cancer immunootherapy. PPO Focus, Cancer Innunol 1 (1), 2007.

• 8) Hubert P, Jacobs N, Caberg JH, et al: The cross-talk between dendritic and regulatory T cells: good or evil? J Lueukoc Biol 82: 781-794, 2007.
  pubmed

• 9) Kryczek I, Wei S, Zou L, et al: Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 177: 40-44, 2006.
  pubmed

• 10) Ou D, Wang X, Metzger DL, et al: Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway. Cell Transplant 15: 399-410, 2006.

• 11) Lau AWT, Biester S, Cornall RJ, et al: Lipopolysaccharide-activated IL-10-secreting dendritic cells suppress experimental autoimmune uveoretinitis by MHC II-dependent activation of CD62L-exprssing regulatory T cells. J Immunol 180: 3889-3899, 2008.

• 12) Torisu M, Murakmi H, Akabar F, et al: Protective role of interleukin-10-producing regulatory dendritic cells against murine autoimmune gastritis. J Gastroenterol 43: 100-107, 2008.

• 13) Asadullah K, Sterry W, Volk HD: Interleukin-10 therapy-Review of a new approach. Pharmacol Rev 55: 241-269, 2003.
  pubmed

• 14) Chhabra A, Chakraborty NG, Mukherji B: Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35. Clin Immunol 126: 251-259, 2008.

• 15) Matsumura Y, Kobayashi T, Ichiyama K, et al: Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J Immunol 179: 2170-2179, 2007.
  pubmed

• 16) Chang CC, Ciubotariu R, Manavalan JS, et al: Tolerization of dendritic cells by T (S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immununol 3: 237-243, 2002.

• 17) Manavalan JS, Rossi PC, Vlad G, et al: High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 11: 245-258, 2003.
  pubmed

• 18) LeMaoult J, Zafaranloo K, Le Danff C, et al: HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19: 662-664, 2005.

• 19) Munn DH, Sharman MD, Baban B, et al: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 22: 633-642, 2005.

• 20) Munn DH, Mellor AL: Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154, 2007.
  pubmed

• 21) Frumento G, Rotondo R, Tonetti M, et al: Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med l96: 459-468, 2002.

• 22) Della Chiesa M, Carlomagno S, Frumento G, et al: The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108: 4118-4125, 2006.
  pubmed

• 23) Schepers K, Schumacher TNM: Tumors hijack fetal enzyme, escape killer T cells. Nat Med 9: 1253-1254, 2003.
  pubmed

• 24) Fallarino F, Asselin-Paturel C, Vacca C, et al: Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 173: 3748-3754, 2004.
  pubmed

• 25) Barton BE: STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance. Expert Opin Ther Targets 10: 459-470, 2006.
  pubmed

• 26) Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited.Annu Rev Immunol 23: 515-548, 2005.
  pubmed

• 27) Petroff MG, Kharatyan E, Torry DS, et al: The immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placenta. Am J Pathol 167: 465-473, 2005.
  pubmed

• 28) Kier ME, Liang SC, Guleria I, et al: Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203: 883-895, 2006.

• 29) Yoshida T, Jiang F, Honjo T, et al: PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-297 for diabetes in NOD mice. Proc Natl Acad Sci USA 105: 3533-3538, 2008.

• 30) Okazaki T, Honjo T: The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27: 195-201, 2006.
  pubmed

• 31) Carter LL, Carreno BM: Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation. Immunol Res 28: 49-59, 2003.
  pubmed

• 32) Nishimura H, Honjo T: PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends immunol 22: 265-268, 2001.
  pubmed

• 33) Yang J, Popoola J, Khandwala S, et al: Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 117: 660-669, 2008.
  pubmed

• 34) Lukens JR, Cruise MW, Lassen MG, et al: Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus murine model. J Immunol 180: 4875-4884, 2008.

• 35) Wong SC, Oh E, Ng CH, et al: Impaired germinal center formation and recall T-cell-dependent immune responses in mice lacking the costimulatory ligand B7-H2. Blood 102: 1381-1388, 2003.
  pubmed

• 36) Qian X, Agematsu K, Freeman GJ, et al: The ICOS-ligand B7-H2, expressed on human type II alveolar epithelial cells, plays a role in the pulmonary host defense system. Eur J Immunol 36: 906-918, 2006.

• 37) Mahnke K, Ring S, Johnson TS, et al: Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: Role of B7-H3 expression and antigen presentation. Eur J Imnunol 37: 2117-2126, 2007.
  pubmed

• 38) Lepenies B, Pfeffer K, Hurchla MA, et al: Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria. J Immunol 179: 4093-4100, 2007.

• 39) Steinman RM, Nussenzweig MC: Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99: 351-358, 2002.
  pubmed

• 40) Park SJ, Nakagawa T, Kitamura H, et al: IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173: 3844-3854, 2004.
  pubmed

• 41) Kim S, Elkon KB, Ma X: Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity 21: 643-653, 2004.
  pubmed

• 42) Vigouroux S, Yvon E, Biagi E, et al: Antigen-induced regulatory T cells. Blood 104: 26-33, 2004.
  pubmed

• 43) Battaglia M, Gregori S, Bacchetta R, et al: Trl cells: from discovery to their clinical application. Semin Immunol 18: 120-127, 2006.

• 44) Kabelitz D, Wesch D, Oberg HH: Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol 26: 291-305, 2006.
  pubmed

• 45) Gandhi R, Anderson DE, Weiner HL: Cutting edge: immature human dendritic cells express latencyassociated peptide and inhibit T cell activation in a TGF-β-dependent manner. J Immunol 178: 4017-4021, 2007.

• 46) Lutz MB, Schuler G: Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity. Trends Immunol 23: 445-449, 2002.
  pubmed

• 47) Kleindienst P, Wiethe C, Lutz MB, et al: Simultaneous induction of CD4 T cell tolerance and CD8 T cell immunity by semimature dendritic cells. J Immunol 174: 3941-3947, 2005.
  pubmed

• 48) Lui G, Manches O, Angel J, et al: Plasmacytoid dendritic cells capture and cross-present viral antigens from infiuenza-virus exposed cells. Plos One 4: e7111, 2009.
  pubmed

• 49) Kuwana M: Induction of anergic and regulatory T cell by plasmacytoid dendritic cells and other dendritic cell subsets. Hum Immunol 63: 1156-1163, 2002.
  pubmed

• 50) Ito T, Amakawa R, Inaba M, et al: Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol 172: 4253-4259, 2004.
  pubmed

• 51) Ito T, Yang M, Wang YH, et al: Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 204: 105-115, 2007.
  pubmed

• 52) Gilliet M, Liu YJ: Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195: 695-704, 2002.
  pubmed

• 53) Kang HK, Liu M, Datta SK: Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 178: 7849-7858, 2007.
  pubmed

• 54) Bendriss-Vermare N, Burg S, Kanzler H, et al: Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-gamma and Th1 chemokine production. J Leukoc Biol 78: 954-966, 2005.
  pubmed

• 55) Moseman EA, Liang X, Dawson AJ, et al: Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4 + CD25 + regulatory T cells. J Immunol 173: 4433-4442, 2004.

• 56) Chen W, Liang X, Peterson AJ, et al: The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. Immunol 181: 5396-5404, 2008.

• 57) Ouabed A, Hubert FX, Chabannes D, et al: Differential control of regulatory cell proliferation and suppressive activity by mature plasmacytoid versus conventional spleen dendritic cells. J Immunol 180: 5862-5870, 2008.

• 58) Akbari O, DeKruyff RH, Umetsu DT: Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2: 725-731, 2001.

• 59) Smits HH, de Jong EC, Wierenga EA, et al: Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol 26: 123-129, 2005.

• 60) Shao L, Allez M, Park MS, et al: Immunomodulatory roles of the carcinoembryonic antigen family of glycoproteins. Ann N Y Acad Sci 1072: 194-209, 2006.

• 61) Abreu MT, Vora P, Faure E, et al: Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 167: 1609-1616, 2001.

• 62) Allez M, Brimnes J, Shao L, et al: Activation of a unique population of CD8+ T cells by intestinal epithelial cells. Ann N Y Acad Sci 1029: 22-35, 2004.

• 63) Menager-Marcq I, Pomie C, Romagnoli P, et al: CD8+ CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice. Gastroenterology 131: 1775-1785, 2006.

• 64) Stagg AJ, Kamm MA, Knight SC: Intestinal dendritic cells increase T cell expression of α4β7 integrin. Eur J Immunol 32: 1445-1454, 2002.

• 65) Johansson-Lindbom B, Svensson M, Wurbel MA: Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 198: 963-969, 2003.

• 66) Siewert C, Menning A, Dudda J, et al: Induction of organ-selective CD4+ regulatory T cell homing. Eur J Immunol 37: 978-989, 2007.

• 67) Mora JR, Bono MR, Manjunath N, et al: Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424: 88-93, 2003.

• 68) Iwasaki A, Kelsall BL: Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of helper T type 2 cells. J Exp Med 190: 229-240, 1999.

• 69) Mowat AM, Parker LA, Beacock-Sharp H, et al: Oral tolerance: overview and historical perspectives. Ann N Y Acad Sci 1029: 1-8, 2004.

• 70) Min SY, Park KS, Cho ML, et al: Antigen-induced, tolerogenic CD11c+, CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type H collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum 54: 887-898, 2006.

• 71) Park MJ, Min SY, Park KS, et al: Indoleamine 2, 3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis Res Ther 10: R11, 2008.

• 72) Bilsborough J, George TC, Norment A, et al: Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 108: 481-492, 2003.

• 73) Chirdo FG, Millington OR, Beacock-Sharp H, et al: Immunomodulatory dendritic cells in intestinal lamina propria. Eur J Immunol 35: 1831-1840, 2005.

• 74) Sun C-M, Hall JA, Blank RB, et al: Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 Treg cells via retinoic acid. J Exp Med 204: 1775-1785, 2007.

• 75) Kang SG, Lim HW, Andrisani OM, et al: Vitamin A metabolites induce gut-homing Foxp3+ regulatory T cells. J Immunol 179: 3724-3733, 2007.

• 76) Jang MH, Sougawa N, Tanaka T, et al: CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J Immunol 176: 803-810, 2006.

• 77) Benson ML, Pino-Lagos K, Rosemblatt M, et al: All-trans retinoic acid mediates enhanced Treg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 204: 1765-1774, 2007.

• 78) Chung Y, Chang JH, Kim BS, et al: Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens. Eur J Immunol 37: 1453-1462, 2007.

• 79) Chung Y, Chang JH, Kweon MN, et al: CD8α-CD11b+ dendritic cells but not CD8α+ dendritic cells mediate cross-tolerance toward intestinal antigens. Blood 106: 201-206, 2005.

• 80) Bynoe MS, Evans JT, Viret C, et al: Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity 19: 317-328, 2003.

• 81) Tutaj M, Szczepanik M: Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRαβ+ CD4+ CD8+ double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE). J Autoimmun 28: 208-215, 2007.

• 82) Szczepanik M, Bryniarski K, Tutaj M, et al: Epicutaneous immunization induces αβ T-cell receptor CD4 CD8 double-positive non-specific suppressor T cells that inhibit contact sensitivity via transforming growth factor-β. Immunology 115: 42-54, 2005.

• 83) Szczepanik M, Tutaj M, Bryniarski K, et al: Epicutaneously induced TGF-β-dependent tolerance inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol 164: 105-114, 2005.

• 84) Ptak W, Bryniarski K, Ptak M, et al: Toll-like receptor ligands reverse suppression of contact hypersensitivity reactions induced by epicutaneous immunization with protein antigen. Int Arch. Allergy Immunol 139: 188-200, 2006.

• 85) He R, Oyoshi MK, Jin H, et al: Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge. Proc Natl Acad Sci USA 104: 15817-15822, 2007.

• 86) van der Marel AP, Samsom JN, Greuter M, et al: Blockade of IDO inhibits nasal tolerance induction. J Immunol 179: 894-900, 2007.

• 87) Kim J, Myers AC, Chen L, et al: Constitutive and inducible expression of B7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol 33: 280-289, 2005.

• 88) Li M, Zhang X, Zheng X, et al: Immune modulation and tolerance induction by ReIB-silenced dendritic cell through RNA interference. J Immunol 178: 5480-5487, 2007.

• 89) Rutella S, Danese S, Leone G: Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108: 1435-1440, 2006.
  pubmed

• 90) Wakkach A, Fournier N, Brun V, et al: Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18: 605-617, 2003.

• 91) Allavena P, Piemonti L, Longoni D, et al: IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 28: 359-369, 1998.

• 92) Perona-Wright G, Anderton SM, Howie SE, et al: IL-10 permits transient activation of dendritic cells to tolerize T cells and protect from central nervous system autoimmune disease. Int Immunol 19: 1123-1134, 2007.

• 93) Ito M, Minamiya Y, Kawai H, et al: Tumor-derived TGFβ-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 176: 5637-5643, 2006.

• 94) Ishinaga H, Jono H, Lim JH, et al: TGF-β induces p65 acetylation to enhance bacteria-induced NF-κB activation. EMBO J 26: 1150-1162, 2007.

• 95) Faunce DE, Terajewicz A, Stein-Streilein J: Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J Immunol 172: 1991-1995, 2004.

• 96) Zhang-Hoover J, Stein-Streilein J: Tolerogenic APC generate CD8+ T regulatory cells that modulate pulmonary interstitial fibrosis. J Immunol 172: 178-185, 2004.

• 97) Kosiewicz MM, Alard P, Liang S, et al: Mechanisms of tolerance induced by transforming growth factor-β-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand. Int Immunol 16: 697-706, 2004.

• 98) Gangi E, Vasu C, Cheatem D, et al: IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol 174: 7006-7013, 2005.

• 99) Sheng JR, Li L, Ganesh BB, et al: Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of Foxp3+ regulatory T cells. J Immunol 177: 5296-5306, 2006.

• 100) Gaudreau S, Guindi C, Menard M, et al: Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J Immunol 179: 3638-3647, 2007.

• 101) Li G, Kim YJ, Broxmeyer HE: Macrophage colony-stimulating factor drives cord blood monocyte differentiation into IL-10highIL-12absent dendritic cells with tolerogenic potential. J Immunol 174: 4706-4717, 2005.

• 102) Talarn C, Urbano-Ispizua A, Martino R, et al: G-CSF increases the number of peripheral blood dendritic cells CD16+ and modifies the expression of the costimulatory molecule CD86+. Bone Marrow Transplant 37: 873-879, 2006.

• 103) Rutella S, Bonanno G, Pierelli L, et al: Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-α. Eur J Immunol 34: 1291-1302,2004.

• 104) Kared H, Masson A, Adle-Biassette H, et al: Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4+ CD25+ regulatory T-cells. Diabetes 54: 78-84, 2005.

• 105) Brandt K, Bulfone-Paus S, Foster D, et al: Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102: 4090-4098, 2003.

• 106) Brandt K, Bulfone-Paus S, Jenckel A, et al: Intrleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J Invest Dermatol 121: 1379-1382, 2003.

• 107) Strengell M, Lehtonen A, Matikainen S, et al: IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. J Leukoc Biol 79: 1279-1285, 2006.

• 108) Bella SD, Nicpla S, Timofeeva I, et al: Are interleukin-16 and thrombopoietin new tools for the in vitr generation of dendritic cells? Blood 104: 4020-4028, 2004.

• 109) Ank N, Iversen MB, Bartholdy C, et al: An important role for type III Interferon (IFN-λ/IL-28) in TLR-induced antiviral activity. J Immunol 180: 2474-2485, 2008.

• 110) Mennechet FJ, Uze G: Interferon-λ-treated dendritic cells specifically induce proliferation of Foxp3-expressing suppressor T cells. Blood 107: 4417-4423, 2006.

• 111) Gonzalez-Rey E, Chorny A, Fernandez-Martin A, et al: Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107: 3632-3638, 2006.

• 112) Chorny A, Gonzalez-Rey E, Fernandez-Martin A, et al: Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 107: 3787-3794, 2006.

• 113) Fabricius D, O'Dorisio MS, Blackwell S, et al: Human plasmacytoid dendritic cell function: inhibition of IFN-α secretion and modulation of immune phenotype by vasoactive intestinal peptide. J Immunol 177: 5920-5927, 2006.

• 114) Wang Y, Mei Y, Bao S, et al: Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses. Clin Exp Immunol 148: 178-187, 2007.

• 115) Rutella S, Bonanno G, Procoli A, et al: Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 108: 218-227, 2006.

• 116) Okunishi K, Dohi M, Fujio K, et al: Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice. J Immunol 179: 5504-5513, 2007.

• 117) D'Adamio F, Zollo O, Moraca R, et al: A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 7: 803-812, 1997.

• 118) Hamdi H, Godot V, Maillot MC, et al: Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood 110: 211-219,2007.

• 119) Ayroldi E, Zollo O, Bastianelli A, et al: GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest 117: 1605-1615, 2007.

• 120) Bianchi R, Adami C Giambanco I, et al: S100B binding RAGE in microglia stimulates COX-2 expression. J Leukoc Biol 81: 108-118, 2007.
  pubmed

• 121) Iruretagoyena MI, Sepulveda SE, Lezana JP, et al: Inhibition of nuclear factor-κB enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 318: 59-67, 2006.

• 122) Cong Y, Konrad A, Iqbal N, et al: Generation of antigen-specific. Foxp3-expressing CD4+ regulatory T cells by inhibition of APC proteosome function. J Immunol 174: 2787-2795, 2005.

• 123) Wang Q, Liu Y, Wang J, et al: Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor. J Immunol 177: 2175-2185, 2006.

• 124) Buckland M, Jago C, Fazekesova, H, et al: Aspirin modified dendritic cells are potent inducers of allo-specific regulatory T-cells. Int Immunopharmacol 6: 1895-1901, 2006.

• 125) Bruckland M, Jago CB, FazekasovaH, et al: Aspirin-treated human DCs up-regulated ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Am Transplant 6: 2046-2059, 2006.

• 126) Mahic M, Yaqub S, Johansson CC, et al: Foxp3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 177: 246-254, 2006.

• 127) von Bergwelt-Baildon MS, Popov A, Saric T, et al: CD25 and indoleamine 2, 3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108: 228-237, 2006.

• 128) Mandrekar P, Catalano D, Dolganiuc A, et al: Inhibition of myeloid dendritic cell accessory cell function and induction of T cell anergy by alcohol correlates with decreased IL-12 production. J Immunol 173: 3398-3407, 2004.

• 129) Lau AH, Abe M, Thomson AW: Ethanol affects the generation, cosignaling molecule expression, and function of plasmacytoid and myeloid dendritic cell subsets in vitro and in vivo. J Leukoc Biol 79: 941-953, 2006.

• 130) Norkina O, Dolganiuc A, Shapiro T, et al: Acute alcohol activates STAT3. AP-1, and Sp-1 transcription factors via the family of Src kinases to promote IL-10 production in human monocytes. J Leukoc Biol 82: 752-762, 2007.

• 131) Penna G, Amuchastegui S, Giarratana N, et al: 1, 25-dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178: 145-153, 2007.

• 132) Turnquist HR, Raimondi G, Zahorchak AF, et al: Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 178: 7018-7031, 2007.

• 133) Noris M, Casiraghi F, Todeschini M, et al: Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 18: 1007-1018, 2007.

• 134) Hackstein H, Taner T, Zahorchak AF, et al: Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101: 4457-4463, 2003.

• 135) Taner T, Hackstein H, Wang Z, et al: Rapamycin-treated alloantigen-pulsed dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am J Trasplant 5: 228-236, 2005.

• 136) Lee YH, Lee YR, Im SA, et al: Calcineurin inhibitors block MHC-restricted antigen presentation in vivo. J Immunol 179: 5711-5716, 2007.

• 137) lwata M, Hirakiyama A, Eshima Y, et al: Retinoic acid imprints gut-homing specificity on T cells. Immunity 21: 527-538, 2004.

• 138) Saurer L, McCullough KC, Summerfield A: In vitro induction of mucosa-type dendritic cells by all-transretinoic acid. J Immunol 179: 3504-3514, 2007.

• 139) Tan PH, Sagoo P, Chan C, et al: Inhibition of NF-κB and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol 174: 7633-7644, 2005.

• 140) Polanczyk MJ, Hopke C, Vandenbark AA, et al: Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol 19: 337-343, 2007.

• 141) Pettersson A, Ciumas C, Chirsky V, et al: Dendritic cells exposed to estrogen in vitro exhibit therapeutic effects in ongoing experimental allergic encephalomyelitis. J Neuroimmunol 156: 58-65, 2004.

• 142) Vassallo R, Tamada K, Lau JS, et al: Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol 175: 2684-2691, 2005.

• 143) Schneider-Schaulies S, Dittmer U: Silencing T cells or T-cell silencing: concepts in virus-induced immunosuppression. J Cen Virol 87: 1423-1438, 2006.

• 144) Wu L, KewalRaman VN: Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immmunol 6: 859-868, 2006.

• 145) Boasso A, Herbeuval JP, Hardy AW, et al: HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells. Blood 109: 3351-3359, 2007.
  pubmed

• 146) Billerbeck E, Blum HE, Thimme R: Parallel expansion of human virus-specific FoxP3- effector memory and de novo-generated FoxP3+ regulatory CD8+ T cells upon antigen recognition in vitro. J Immunol 179: 1039-1048, 2007.
  pubmed

• 147) Gelderblom HC, Nijhuis LE, de Jong EC, et al: Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile. Liver Int 27: 944-953, 2007.

• 148) Saito K, Ait-Goughoulte M, Truscott SM, et al: Hepatitis C virus inhibits cell surface expression of HLa-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol 82: 3320-3328, 2008.
  pubmed

• 149) Kawamura K, Kadowaki N, Kitawaki T, et al: Virus-stimulated plasmacytoid dendritic cells induce CD4+ cytotoxic regulatory T cells. Blood 107: 1031-1038, 2006.
  pubmed

• 150) Kummer M, Turza NM, Muhl-Zurbes P, et al: Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteosome. J Virol 81: 6326-6338, 2007.
  pubmed

• 151) Nordstrom I, Nurkkala M, Collins LV, et al: CD8+ T-cells suppress antigen-specific and allogeneic CD4+ T-cell responses to herpes simplex virus type 2-infected human dendritic cells. Viral Immunol 18: 616-626, 2005.
  pubmed

• 152) Suffia IJ, Reckling SK, Piccirillo CA, et al: Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 203: 777-788, 2006.
  pubmed

• 153) Secco M, Zucconi E, Vieira NM, et al: Multipotent stem cells from umbilical cord: cord is richer than blood! Stem Cells 26: 146-150, 2008.
  pubmed

• 154) Chamberlain G, Fox J, Ashton B, et al: Concise review: Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cell 25: 2739-2749, 2007.
  pubmed

• 155) Selmani Z, Naji A, Zidi I, et al: Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells 26: 212-222, 2008.
  pubmed

• 156) Spaggiari GM, Capobianco A, Abdelrazik H, et al: Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 111: 1327-1333, 2008.
  pubmed

• 157) Prevosto C, Zancolli M, Canevali P, et al: Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92: 881-888, 2007.
  pubmed

• 158) Li YP, Paczesny S, Lauret E, et al: Human mesenchymal stem cells license adult CD34+ hematopoietic progenitor cellS to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 180: 1598-1608, 2008.
  pubmed

• 159) Liotta F, Angeli R, Cosmi L, et al: Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cell 26: 279-289, 2008.
  pubmed

• 160) Haniffa MA, Wang XN, Holtick U, et al: Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 179: 1595-1604, 2007.
  pubmed

• 161) Chomarat P, Banchereau J, Davoust J, et al: IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1: 510-514, 2000.
  pubmed

• 162) Gleissner CA, Zastrow A, Klingenberg R, et al: IL-10 inhibits endothelium-dependent T cell costimulation by up-regulation of ILT3/4 in human vascular endothelial cells. Eur J Immunol 37: 177-192, 2007.
  pubmed

• 163) Suciu-Foca N, Manavalan JS, Scotto L, et al: Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol 5: 7-11, 2005.
  pubmed

• 164) Suciu-Foca N, Cortesini R: Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 248: 59-67, 2007.

• 165) Manavalan JS, Kim-Schulze S, Scotto L, et al: Alloantigen specific CD8+CD28-FOXP3+ T suppressor cells induce ILT3+ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol l6: 1055-1068, 2004.

• 166) Zhang M, Tang H, Guo Z, et al: Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol 5: 1124-1133, 2004.
  pubmed

• 167) Tang H, Guo Z, Zhang M, et al: Endothelial stroma programs hematopoietic stem cells to differentiate into regulatory dendritic cells through IL-10. Blood 108: 1189-1197, 2006.

• 168) Watanabe T, Kudo M, Chiba T, et al: Molecular mechanisms of portal vein tolerance. Hepatol Res 38: 441-449, 2008.
  pubmed

• 169) Schildberg FA, Hegenbarth SI, Schumak B, et al: Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells. Eur J Immunol 38: 957-967, 2008.
  pubmed

• 170) Diehl L, Schurich A, Grochtmann R, et al: Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. Hepatology 47: 296-305, 2008.
  pubmed